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Colophon
This report is published under the acronym NethMap by 
the SWAB, the Dutch Foundation of the Working Party 
on Antibiotic Policy, in collaboration with the Centre 
for Infectious disease control (CIb) of the RIVM, the 
National Institute for Public Health and the Environment 
of the Netherlands. SWAB is fully supported by a 
structural grant from CIb, on behalf of the Ministry 
of Health, Welfare and Sports of the Netherlands. The 
information presented in NethMap is based on data from 
ongoing surveillance systems on the use of antimicrobial 
agents in human medicine and on the prevalence of 
resistance to relevant antimicrobial agents among 
medically important bacteria isolated from healthy 
individuals and patients in the community and from 
hospitalized patients. The document was produced on 
behalf of the SWAB by the Studio of the RIVM.
NethMap can be ordered from the SWAB secretariat, c/o  
Secretariaat SWAB p/a Universitair Medisch Centrum  
St Radboud Medische Microbiologie, Huispost 574, route 
574 Postbus 9101 6500 HB Nijmegen, Telefoon: (024) 36 
19041/14356.
NethMap 2012 and earlier versions are also available 
from the website of the SWAB: www.swab.nl. Contents 
may be reproduced in publications (book chapters, papers, 
reviews, and slide reviews etcetera) without permission 
with a maximum limit of four figures and/or tables per 
publication and full credit (reference) to the original 
publication. 
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1. Preface
This is NethMap 2012, the tenth SWAB/RIVM report on 
the use of antibiotics and trends in antimicrobial resistance 
in The Netherlands in 2011 and previous years. NethMap 
is a cooperative effort by members of The Netherlands 
Society for Infectious Diseases, The Netherlands Society 
of Hospital Pharmacists, The Netherlands Society for 
Medical Microbiology and the Centre for Infectious 
Disease Control Netherlands (CIb) at the National Institute 
for Public Health and the Environment (RIVM). In 1996, 
the Dutch Working Group on Antibiotic Policy was 
created, better known as SWAB (Stichting Werkgroep 
Antibiotica Beleid). Its mission is to manage, limit and 
prevent the emergence of resistance to antimicrobial 
agents among medically important species of micro-
organisms in The Netherlands, thereby contributing to the 
quality of care in The Netherlands. For this effort SWAB 
received in 2008 an award from Prof Stuart Levy on 
behalf of the Alliance for the Prudent Use of Antibiotics 
(APUA) during the 48th Interscience Conference on 
Antimicrobial Agents and Chemotherapy (ICAAC) in 
Washington DC.
Because of the multidisciplinary composition of SWAB, 
this working group can be considered the Dutch equivalent 
of the Intersectoral Coordinating Mechanisms (ICM’s),  
as recommended by the European Union (2001), to control 
emerging antimicrobial resistance and promote rational 
antibiotic use.
SWAB has started several major initiatives to achieve its 
goals. Among these are training programmes on rational 
prescribing of antimicrobial drugs, development of 
evidence-based prescription guidelines, implementation of 
tailor-made hospital guides for antibiotic
prophylaxis and therapy and an integrated nationwide 
surveillance system for antibiotic use and resistance. 
CIb has set up an Infectious Disease Surveillance 
Information System on Antibiotic Resistance (ISIS-
AR) in collaboration with the medical microbiological 
laboratories, which was renewed in 2008. These 
surveillance data, together with surveillance data 
obtained in specific studies such as SERIN (Surveillance 
of Extramural Resistance in The Netherlands) and 
SIRIN (Surveillance of Intramural Resistance in The 
Netherlands), form the basis of resistance trends reported 
in NethMap. The initiatives correspond well with the 
recommendations by The Netherlands Council of Health 
Research (2001). In line with these recommendations, 
SWAB is fully funded by a structural grant from CIb, on 
behalf of the Ministry of Health, Welfare and Sports.
NethMap 2012 extends and updates the information 
of the annual reports since 2003. NethMap parallels 
the monitoring system of antimicrobial resistance and 
antibiotic usage in animals in The Netherlands, entitled 
MARAN – Monitoring of Antimicrobial Resistance 
and Antibiotic Usage in Animals in The Netherlands, 
published annually by the Veterinary Antibiotic Usage and 
Resistance Surveillance Working Group (VANTURES, see 
www.cvi.wur.nl). This year, for the first time, NethMap 
and MARAN are published together in one back-to-
back report. Jointly, NethMap and MARAN provide a 
comprehensive overview of antibiotic usage and resistance 
trends in The Netherlands in humans and in animal 
husbandry and therefore offer insight into the ecological 
pressure associated with emerging resistance. Because of 
the new format chosen, the size of NethMap was reduced 
significantly. The editors have tried to find a balance 
between sufficient detail for the interested professional, 
without losing too much of its content. Some chapters  
are now available electronically only (www.swab.nl, 
www.maran.wur.nl), such as the list of SWAB publications 
and detailed description of methods used for collecting 
data and part of the antibiotic usage data in animals. This 
trend will continue during the next years.  
The interaction between the human and animal areas of 
antibiotic use and resistance is explored in a working 
group started in 2003 by both Ministries of health, Welfare 
and Sport and of Agriculture, Nature and Food Quality. 
Both SWAB and VANTURES are represented in this 
interdepartmental working group in which the evolution 
of antibiotic use and resistance in The Netherlands is 
discussed on the basis of surveillance data as provided by 
SWAB and MARAN.
NethMap thus provides extensive and detailed insight 
in the Dutch state of medically important antimicrobial 
resistance, and compares well with the data of the 
European Antimicrobial Resistance Surveillance System 
(EARSS, see http://www.rivm.nl/earss/). EARSS collects 
resistance data of a limited number of invasive bacterial 
species for the majority of European countries. In 2010, 
EARSS moved from CIb-RIVM to the European Centre 
for Disease Prevention and Control (ECDC) and has been 
renamed EARS-net.
We believe NethMap continues to contribute to our 
knowledge and awareness regarding the use of antibiotics 
and the resistance problems which may arise. We thank all 
who are contributing to the surveillance efforts of SWAB, 
and express our hope that they are willing to continue their 
important clinical and scientific support to SWAB.
The editors:
Prof Dr Mieke Hoogkamp-Korstanje 
Prof Dr Johan W Mouton
Dr Akke van der Bij
Dr AJ de Neeling
Prof Dr Dik J Mevius
Drs Miriam Koene
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2. Summary
NethMap is the annual report of SWAB, in collaboration 
with the Centre for Infectious Disease Control Netherlands 
(CIb) on the use of and resistance to antimicrobial 
agents among common human pathogens isolated in the 
Netherlands, including resistance trends of antimycotic 
and antiviral drugs, the latter with focus on resistance in 
influenza virus.
NethMap’s information on antimicrobial drug use 
and trends in antimicrobial resistance is based on 
systematically collected and analysed data over a period 
from 1996 until the present.
Use of antimicrobial agents
The use of antimicrobial agents in primary health 
care remained below 10 defined daily dosages (DDD) 
per 1000 inhabitants per day until 2005 and increased 
gradually since then to 11 DDD/1000 inhabitant days in 
2008 that stabilised thereafter. The use in the Netherlands 
is still low in comparison with other European countries. 
The distribution of antibiotic usage over the different 
drug groups varies per patient population. Tetracyclines 
represented 23% of the antibiotics used in general 
practice, whereas these drugs are seldom prescribed in 
hospitals. Extramural nitrofurantoin use has been on the 
rise in recent years towards 1.31 DDD/1000 inhabitant-
days in 2011, most probably because of the increased 
resistance to trimethoprim in Escherichia coli in urinary 
tract infection and the subsequent changes in treatment 
guidelines. Trimethoprim is nowadays a second choice 
antibiotic for treatment of urinary tract infections. Extra- 
and intramural fluoroquinolone use increased further 
during the last years with some minor changes within 
the class. NethMap 2012 reports a further substitution of 
amoxicillin by co-amoxiclav and an increase in macrolide 
use. The latter is caused by increased azithromycin use 
in primary health care and hospitals, whereas the use of 
other macrolides stabilized in primary health care or even 
decreased in hospitals. 
The hospital use of the different subclasses of antibiotics, 
measured in DDD per 100 patient-days, remained 
relatively stable, except for combinations of penicillin, 
beta-lactamase resistant penicillins, cephalosporins, 
fluoroquinolones, glycopeptides, carbapenems and 
aminoglycosides, which showed a significant increase. 
However, in 2011 use of these classes of antibiotics 
stabilized. When use was expressed in DDD per 100 
admissions no increase was observed. Different trends 
within the given groups of antibiotics are recognisable 
when usage per bed day, usage per admission and types 
of hospitals are compared. Penicillins, cephalosporins 
and quinolones still account for 72% of the antibiotics 
used in Dutch hospitals.  The use of carbapenems 
and glycopeptides  in university hospitals is higher in 
comparison to general hospitals whereas the latter showed 
a higher consumption of co-amoxiclav. 
The use of systemic antimycotic drugs in university 
medical centres and general hospitals decreased; the use 
in university hospitals is almost four times higher than 
in general hospitals, which underlines the difference in 
patient populations between these two types of hospitals, 
the former harbouring a large group of severely immune 
compromised patients.
NethMap 2012 again shows an almost five times higher 
use of antiviral drugs in the university hospitals compared 
with general hospitals. The use of systemic antivirals in 
2010 has been divided in use of antivirals for acute and 
for chronic infections. Overall use of antivirals for chronic 
infections was slightly higher than for acute infections. 
However, the use of antivirals for chronic and acute 
infections was higher in university hospitals compared to 
general hospitals.
Surveillance of resistance
NethMap 2012 presents data on antimicrobial resistance 
in the community and in hospitals. SWAB resistance 
surveillance data are derived from ISIS-AR (Infectious 
Disease Information System for Antibiotic Resistance) 
system, the inpatient SIRIN and the outpatient and 
community SERIN (Surveillance of Intra-/Extramural 
Resistance In the Netherlands) studies. In NethMap 2012 
data derived from these three initiatives are compared and 
discussed taking into account the different methods used 
to collect and to study these data from different patient 
populations. Resistance data are presented for Escherichia 
coli, Klebsiella species, Enterobacter species, Proteus 
mirabilis and Pseudomonas aeruginosa, staphylococci, 
enterococci and respiratory pathogens and the results 
for patients visiting the general practitioner, patients 
in nursing homes,  outpatient departments and hospital 
departments. In addition, data are presented in bacterial 
species associated with public health related infections e.g. 
meningococci, gonococci and Mycobacterium tuberculosis. 
Resistance in the community was studied in E. coli, 
derived from uncomplicated urinary tract infections in 
general practice in men and women, collected through 
the NIVEL Sentinel Stations Network in 2009/2010, and 
compared with the results in men and women in 2004. 
Overall, the resistant rates for most antibiotics stabilized 
and decreased slightly for trimethoprim. Resistance rates 
were 32% for amoxicillin, 14% for co-amoxiclav, 19% 
for co-trimoxazole, 1% for nitrofurantoin and 5% for 
quinolones, respectively.  The resistance rates in selected 
patients from general practice as reported from the 
ISIS-AR database are all higher. However, these include 
complicated urinary tract infections as well and patients 
that have been treated before. Resistance to amoxicillin 
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was 43%, to co-amoxiclav 16%, to co-trimoxazole 24% 
and to quinolones 10%. 
Resistance against ciprofloxacin of N. gonorrhoeae 
decreased further to 37% in 2011 (52 % in 2009). In 2011 
the development of resistance against third generation 
cephalosporins decreased to 5% (was 9% in 2010), more 
often found in men who have sex with men (8%) than in 
heterosexual men and women (3%). Resistance in 
M. tuberculosis strains is slowly increasing with a level of 
multiresistance in 2011 at 1.5%. 
Resistance in nursing homes was determined for 
E. coli and Staphylococcus aureus. Resistance levels 
in E. coli from urine in 308 residents without infection 
of six nursing homes appeared higher than in both GP 
populations, with 23% resistance to co-amoxiclav and 
16% resistance to ciprofloxacin. Carriership and resistance 
of Staphylococcus aureus were studied in 2010 and 
compared with a similar study in 2007.  Resistance levels 
did not change significantly over time and were similar to 
resistance patterns in hospitals, except for ciprofloxacin 
which was 23% in nursing homes vs 10% in hospitals. 
Resistance in hospitals continues to increase steadily for 
many antimicrobials. Ciprofloxacin resistance among 
E. coli from Unselected Hospital Departments is now 
over 13%, and resistance to co-amoxiclav 21%.  In 
general increasing resistance was found in all study 
populations for co-amoxiclav, cephalosporins, quinolones 
and co-trimoxazole. In intensive care units E. coli 
multiresistance was not yet reported before 1998 but 
increased to 18% in 2010 as reported by SIRIN. Similar 
trends were observed for the Klebsiella spp, Enterobacter 
spp and Proteus mirabilis strains studied. Carbapenems 
and the (toxic) colistin are then often the only remaining 
drugs to treat infections with such strains. Although 
carbapenem resistance is still low (< 1%), around 2% of 
Enterobacteriaceae strains now have an MIC just below 
the breakpoint for resistance (1-8 mg/l). Likewise, the 
MIC distributions over time identified significant “MIC 
creeps” (shifts within the susceptible populations) towards 
for cephalosporins (K. pneumoniae), meropenem  
(P. aeruginosa), quinolones (K. pneumoniae,  
P. aeruginosa) and aminoglycosides (K. pneumoniae, 
E. cloacae) which predict upcoming resistance in the 
following years. These strains are often not recognized 
in routine susceptibility testing but may already pose 
a problem for difficult to treat infections. Ceftazidime 
resistance increased further to 12% for P. aeruginosa.
The national surveillance of carbapenamase producing 
enterobacteriaceae was started during 2010. From patient 
samples taken in 2011, 169 strains from 142 patients were 
submitted by 40 hospitals to the National Institute for 
Public Health and the Environment (RIVM). Thirty five 
different CPE were detected. The majority (21) concerned 
OXA-48 producing K. pneumoniae. In 11 of the 35 cases, 
MICs for meropenem were within susceptible range (<= 2 
mg/L) according to EUCAST criteria. As far as information 
was available (n=17), the origin of strains could either be 
traced back to the Rotterdam outbreak or to previous visits 
to endemic countries from North Africa or the Middle East, 
mainly including hospitalisation in these countries.
The resistance rates for S. aureus were not much different 
from previous years, although methicillin resistant  
S. aureus (MRSA) increased slightly and is now 1.8 
% in Unselected Hospital Departments. Resistance to 
vancomycin, still the rescue drug for MRSA infection 
is rarely encountered in the Netherlands. Rifampicin 
resistance was lower than 1%, and mupirocin resistance 
1%.Animal husbandry related MRSA isolates (CC398 
strains) were at approximately the same level over the last 
year, 39% of the total number. 
Data on pneumococci and Haemophilus influenzae were 
collected in hospitals. For the majority of these strains it 
can, by the nature of such public health related species, 
be suggested that these are community related rather 
than hospital acquired. Their resistance profiles may be 
considered a reflection of the situation in the general 
population. Therefore it is of interest that in H. influenzae 
an increase of resistance to amoxicillin to 16 % as well 
as to co-amoxiclav (4%) is observed in unselected 
departments. The increase is clearly not exclusively due 
to a rise in beta lactamase producing strains, therefore 
indicating an increasing prevalence of so called Beta 
Lactamase Negative Amoxicillin Resistant (BLNAR) 
strains. Doxycycline is still a reasonable alternative 
choice to combat infections with BLNAR H. influenzae.
In pneumococci resistance against macrolides is still at 
a critical 10% in unselected hospital departments and 
increasing in pulmonology services to 14%. Tetracycline 
resistance parallels this. Resistance to penicillin, the most 
important antibiotic prescribed for serious pneumococcal 
disease, increased to 2.4 %. 
Studies in Aspergillus spp. indicate that resistance to 
azoles is further increasing. A large retrospective study 
in the Radboud UNMC showed that azole resistance 
emerged in 2000. Since then, resistance has slowly crept 
upwards and now has reached the critical value of 10%. It 
is expected that azole resistance will continue to rise in the 
near future. This will limit treatment options significantly 
and new guidelines for empiric treatment are necessary.
Finally, data from surveillance studies of influenza viruses 
in The Netherlands indicate treatment limitations due to 
emerging resistance against anti -influenza specific drugs 
such as oseltamivir. 
We conclude that the data presented in NethMap 2012 
increases concern with respect to the emergence of 
antibiotic resistance in the Netherlands. The overall rise 
in resistance requires a rethinking of antimicrobial use 
and policy, including restricted use of some classes of 
antibiotics, in particular those that are employed as a 
last line of defence. Diagnostic cultures and in particular 
susceptibility testing are increasingly necessary to guide 
antimicrobial treatment and antimicrobial stewardship.
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3.  Use of antimicrobials
3.1  Primary health care
3.1.1 Use of antibiotics
Data on the use of antibiotics in primary health care 
were obtained from the Foundation for Pharmaceutical 
Statistics (SFK; http://www.sfk.nl) and expressed as 
the number of Defined Daily Doses (DDD) per 1000 
inhabitants per day. 
About 85% of antibiotic use in primary health care is 
prescribed by general practitioners (1) and the remaining 
by dentists and specialists.
From 1998-2004, the total antibiotic use was 10 
DDD/1000 inhabitant-days. Over the past six years, 
use gradually increased to 11 DDD/1000 inhabitant-
days. In 2011, the use of antibiotics remained stable as 
compared to 2010. The distribution of antibiotics per 
class in 2011 is presented in figure 3.1. Tetracyclines 
(mainly doxycycline) represented 23% of total antibiotic 
use in primary health care. Other frequently used 
antibiotics were penicillins with extended spectrum 
(mainly amoxicillin), combinations of penicillins 
with beta-lactamase inhibitors (essentially amoxicillin 
with clavulanic acid) and macrolides/lincosamides, 
each representing 17%, 16% and 13% of the total use, 
respectively.
From 2005 to 2011, the use of amoxicillin remained 
stable at about 1.9 DDD/1000 inhabitant-days. The use 
of amoxicillin/clavulanic acid increased steadily to 1.8 
(table 3.1; figure 3.2).
After a small decrease from 2009 until 2010, the use 
of macrolides increased again to 1.34 DDD/1000 
inhabitant-days in 2011 (table 3.1). In figure 3.2 the use 
of the different macrolides is depicted. Clarithromycin 
is still the most commonly used macrolide, but its use 
continues to decline from 2005-2011 in favour of the use 
of azithromycin. The use of azithromycin almost equals 
the use of clarithromycin now. The use of erythromycin 
declined to 0.09 DDD/1000 inhabitant-days in 2011.
Use of fluoroquinolones remained about stable, except 
for norfloxacin which further declined to 0.17 DDD/1000 
12
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Figure 3.1. Distribution (%) of the use of antibiotics for systemic use (J01) 
in primary health care, 2011 (SFK).
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Figure 3.2. Use of antibiotics for systemic use in primary health care, 1997-2011 (SFK).
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inhabitant-days in favour of ciprofloxacin which slightly 
increased to 0.51 (table 3.1; figure 3.2). 
The use of nitrofurantoin is still increasing to 1.31 
DDD/1000 inhabitant-days in 2011 as compared to 1.23 
DDD/1000 inhabitant-days in 2010. Over the past five 
years, the use of sulphonamides and trimethoprim (J01EA 
and J01EE combined) remained almost stable at 0.54 
DDD/1000 inhabitant-days (table 3.1; figure 3.2).
Discussion
Despite the small increase in antibiotic use from 2005 to 
2011 from 10 to 11.2 DDD/1000 inhabitant-days, use of 
antibiotics in the Netherlands is still low as compared to 
other European countries (2).
The largest increase was found for nitrofurantoin. The 
national guideline of the Dutch College of General 
Practitioners (3) was revised in 2005. According to this 
revision, antibiotic treatment can be considered without 
urine investigation for women recognising symptoms 
from a previous episode. The increases in incidence 
and antibiotic treatment for uncomplicated urinary tract 
infections need attention in the future. 
Subtle shifts in the patterns of use within the various 
classes of antibiotics are observed. The increased use 
of ciprofloxacin seems to be offset by a decrease in 
ofloxacin and norfloxacin. Since its introduction in 2002 
in the Netherlands, the use of moxifloxacin increased to 
0.06 DDD/1000 inhabitant-days in 2007. After warnings 
about serious adverse events of moxifloxacin issued by 
the Dutch Medicines Evaluation Board in 2008, its use 
declined to 0.04 DDD/1000 inhabitant-days and remained 
stable until 2011. Within the class of macrolides, a shift 
is observed from erythromycin to the newer macrolides 
clarithromycin and azithromycin. Especially the use of 
azithromycin continues to increase. These trends may 
be relevant from the perspective of growing rates of 
resistance among common pathogens.
3.2 Hospitals
3.2.1 Use of antibiotics
Data on the use of antibiotics in Dutch hospitals were 
collected by the SWAB by means of a questionnaire 
distributed to all Dutch hospital pharmacists. 
Data on antibiotic use are expressed in DDD per 100 
patient-days, as well as in DDD per 100 admissions, 
because trends over time in these units of measurement do 
not always correlate (tables 3.2 and 3.3) (4).
For the first time in years, the total systemic use of 
antibiotics in our cohort of hospitals slightly decreased 
from 70.9 DDD per 100 patient-days in 2009 to 70.2 in 
2010 (a decrease of 0.92%) (table 3.2). For comparison, in 
2000 the total systemic use of antibiotics was 43.0 DDD 
per 100 patient-days. The total number of DDD per 100 
admissions decreased by 1.6% from 321 DDD in 2009 to 
316 DDD in 2010 (tables 2 and 3). A similar decrease was 
seen for almost all groups of antibiotics. The distribution 
of antibiotics per class in 2010 is depicted in figure 3.3.
Over recent years, the use of the different subclasses 
Table 3.1. 13-years data on the use of antibiotics for systemic use (J01) in primary care (DDD/1000 inhabitant-days), 1999-2011 (Source: SFK).
ATC 
Group*
Therapeutic group 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
J01AA Tetracyclines 2.49 2.48 2.40 2.34 2.24 2.24 2.41 2.37 2.57 2.66 2.67 2.67 2.60
J01CA Penicillins with extended spectrum 2.05 1.88 1.83 1.78 1.78 1.71 1.86 1.87 1.91 1.91 1.89 1.81 1.91
J01CE Beta-lactamase sensitive penicillins 0.52 0.52 0.49 0.46 0.44 0.43 0.44 0.50 0.46 0.42 0.39 0.37 0.35
J01CF Beta-lactamase resistant penicillins 0.23 0.24 0.25 0.25 0.27 0.28 0.29 0.31 0.32 0.36 0.38 0.38 0.39
J01CR Penicillins + beta-lactamase-inhibitors 1.04 1.15 1.25 1.34 1.40 1.39 1.50 1.59 1.66 1.71 1.74 1.80 1.82
J01D Cephalosporins 0.10 0.08 0.07 0.07 0.06 0.05 0.05 0.04 0.05 0.04 0.04 0.04 0.04
J01EA Trimethoprim and derivatives 0.30 0.28 0.28 0.27 0.27 0.26 0.25 0.23 0.22 0.21 0.21 0.20 0.20
J01EC Intermediate-acting sulphonamides 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01EE Sulphonamides + trimethoprim 0.46 0.43 0.42 0.40 0.40 0.39 0.38 0.37 0.36 0.36 0.35 0.35 0.34
J01FA Macrolides 1.17 1.14 1.23 1.24 1.27 1.32 1.42 1.39 1.39 1.36 1.33 1.31 1.34
J01FF Lincosamides 0.04 0.04 0.05 0.06 0.06 0.07 0.08 0.09 0.10 0.11 0.12 0.14 0.15
J01GB Aminoglycosides 0.00 0.00 0.01 0.01 0.02 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03
J01MA Fluoroquinolones 0.85 0.80 0.80 0.78 0.79 0.83 0.84 0.87 0.91 0.89 0.86 0.85 0.82
J01MB Other quinolones 0.04 0.04 0.04 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01
J01XB Polymyxins 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.00 0.00 0.00 0.00 0.00 0.00
J01XE Nitrofuran derivatives 0.64 0.68 0.72 0.74 0.78 0.81 0.90 1.00 1.07 1.13 1.17 1.23 1.31
J01XX05 Methenamine 0.06 0.06 0.06 0.04 0.03 0.02 0.02 0.03 0.03 0.02 0.03 0.04 0.03
J01 Antibiotics for systemic use (total) 10.02 9.86 9.92 9.83 9.86 9.87 10.51 10.73 11.10 11.24 11.21 11.23 11.22
*  From the 2011 edition of the Anatomical Therapeutic Chemical (ATC) classification system
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Figure 3.3. Distribution (%) of the use of antibiotics for systemic use (J01) in hospitals, 2010 (SWAB).
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J01XX other antibacterials
J01XE Nitrofuran derivatives
J01XD Imidazole derivatives
J01XC Steroid antibacterials (fusidic acid)
J01XB Polymyxins
J01XA Glycopeptides
J01MB Other quinolones
J01MA Fluoroquinolones
J01GB Aminoglycosides
J01FF Lincosamides
J01FA Macrolides
J01EE Combinations of sulfonamides and trimethoprim, including derivatives
J01EC Intermediate-acting sulfonamides
J01EA Trimethoprim and derivatives
J01DH Carbapenems
J01DF Monobactams
J01DB -DE Cephalosporins
J01CR Combinations of penicillins, incl. beta-lactamase-inhibitors
J01CF Beta-lactamase resistant penicillins
J01CE Beta-lactamase sensitive penicillins
J01CA Penicillins with extended spectrum
J01AA Tetracyclines
Table 3.2. Use of antibiotics for systemic use (J01) in hospitals (DDD/100 patient-days), 2000-2010 (Source: SWAB).
ATC group* Therapeutic group 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
J01AA Tetracyclines 1.6 1.6 1.7 1.4 1.5 1.6 1.6 1.4 1.4 1.6 1.7
J01CA Penicillins with extended spectrum 5.8 6.0 6.1 6.0 6.0 6.7 7.6 7.3 5.5 7.6 7.3
J01CE Beta-lactamase sensitive penicillins 1.1 1.3 1.2 1.2 1.4 1.4 1.4 1.2 1.1 1.6 1.5
J01CF Beta-lactamase resistant penicillins 4.3 4.3 4.4 5.4 5.7 5.8 5.9 5.6 5.4 6.6 6.8
J01CR Combinations of penicillins. incl. beta-
lactamase-inhibitors
8.9 9.9 12.2 12.1 12.8 13.9 15.1 14.0 13.5 16.5 16.0
J01DB -DE Cephalosporins 5.6 6.1 6.3 6.5 7.0 7.4 8.4 8.4 7.4 10.1 10.2
J01DF Monobactams 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.01 0.0 0.0
J01DH Carbapenems 0.4 0.4 0.5 0.5 0.5 0.6 0.6 0.8 0.85 1.1 1.2
J01EA Trimethoprim and derivatives 0.3 0.5 0.5 0.5 0.4 0.6 0.8 0.5 0.3 0.4 0.5
J01EC Intermediate-acting sulfonamides 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.05 0.0 0.0
J01EE Combinations of sulfonamides and 
trimethoprim. incl. derivatives
2.3 2.3 2.4 2.3 2.1 2.3 2.1 2.3 2.0 2.0 2.0
J01FA Macrolides 2.1 2.3 2.7 2.4 2.3 2.8 2.5 2.7 2.3 2.6 2.7
J01FF Lincosamides 1.2 1.3 1.5 1.6 1.8 1.9 2.0 2.1 1.8 2.4 2.3
J01GB Aminoglycosides 2.1 2.0 2.1 2.5 2.2 2.6 2.5 2.5 3.3 4.2 4.1
J01MA Fluoroquinolones 4.7 5.5 5.7 6.4 6.5 7.3 8.0 7.6 9.6 9.3 9.0
J01MB Other quinolones 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.05 0.1 0.0
J01XA Glycopeptides 0.5 0.5 0.5 0.5 0.6 0.8 0.7 1.0 1.0 1.3 1.3
J01XB Polymyxins 0.3 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.4
J01XC Steroid antibacterials (fusidic acid) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.06 0.1 0.0
J01XD Imidazole derivatives 1.1 1.3 1.5 1.6 1.7 1.5 1.7 1.8 1.4 1.8 1.9
J01XE Nitrofuran derivatives 0.5 0.5 0.5 0.7 0.9 1.0 1.0 1.1 1.0 1.1 1.2
J01XX05 Methenamine 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.02 0.0 0.0
J01XX08 Linezolid 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.05 0.1 0.1
J01 Antibiotics for systemic use (total) 43 46.5 50.2 51.9 53.8 58.3 62.2 60.9 58.1 70.9 70.2
* From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system
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from 2007-2010, the second generation cephalosporins 
showed a slight decrease from 2009-2010, whereas the 
third generation showed an increase in this period. The 
use of these three categories is rising when measured in 
DDD per 100 patient-days (figure 3.4).
Since 2006, a remarkable increase in the use of 
meropenem is seen (figure 3.4).
The patterns of macrolides use vary. Compared with 
last year the use of azithromycin increases while 
erythromycin decreases; this reflects the trend seen over 
the last decade (figure 3.5).
This year we splitted the use of gentamicin in parenteral 
and local use (implants of beads and cement), because of 
the important differences between these ways of usage. 
The parenteral use remains about constant over the past 
years, while local use shows a large increase. However, 
compared with 2009 the local and parenteral use showed 
a small decrease in 2010. Compared with the last year the 
use of tobramycin increased, though the trend over the 
years remains stable (figure 3.5).
After years of increase, the use of ciprofloxacin seems to 
stabilize. The use of the other quinolones is, compared 
with ciprofloxacin, relatively low and stable over the last 
of antibiotics, measured in DDD per 100 patient-
days, remained relatively stable, except for the 
use of combinations of penicillin, beta-lactamase 
resistant penicillins, cephalosporins, fluoroquinolones, 
glycopeptides, carbapenems and aminoglycosides, 
which showed a significant increase. However, in 2011 
use of these classes of antibiotics stabilized (table 3.2). 
When use was expressed in DDD per 100 admissions no 
increase was observed. 
Figure 3.3 shows the relative distribution of antibiotic use 
per class, specified for the different types of hospitals. 
The use of penicillins includes the largest proportion, 
namely 45%. Second are the cephalosporins with 14%, 
followed by the quinolones with 13%. Notable is the high 
use of carbapenems (3.7%) and glycopeptides (4.2%) in 
university hospitals compared with the general hospitals 
(0.8 and 0.7%, respectively). General hospitals showed a 
higher consumption of amoxicillin/clavulanic acid. 
All penicillins showed a slight decrease in use from 
2009-2010, except for flucloxacillin which shows a 
minimal increase (figure 3.4). 
Measured in DDD/100 admissions the total use of first 
generation cephalosporins remained stable compared 
Table 3.3. Use of antibiotics for systemic use (J01) in hospitals (DDD/100 admissions), 2000-2010 (Source: SWAB).
ATC-group* Therapeutic group 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
J01AA Tetracyclines 12.1 11.3 11.2 8.8 8.4 8.8 8.7 7.8 8.5 7.4 7.5
J01CA Penicillins with extended spectrum 44.3 41.5 41.5 38.6 34.3 36.4 41.0 39.9 33.7 34.3 32.6
J01CE Beta-lactamase sensitive penicillins 8.1 9.2 8.2 7.8 7.8 7.5 7.7 6.8 6.6 7.3 6.9
J01CF Beta-lactamase resistant penicillins 32.8 31.7 31.5 34.6 33.0 31.4 31.8 31.2 33.2 30.1 30.6
J01CR Combinations of penicillins, incl. beta-
lactamase-inhibitors
68.1 68.0 81.6 77.7 73.1 75.4 81.7 79.6 83.5 74.8 71.8
J01DB-DE Cephalosporins 42.8 42.3 42.0 42.0 39.4 39.8 45.3 46.0 45.5 45.9 45.8
J01DF Monobactams 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0
J01DH Carbapenems 3.3 2.4 3.2 3.3 2.8 3.2 3.0 4.6 5.1 5.1 5.4
J01EA Trimethoprim and derivatives 2.5 3.6 3.3 3.1 2.3 3.0 4.2 2.7 2.0 1.7 2.4
J01EC Intermediate-acting sulfonamides 0.5 0.1 0.2 0.8 0.3 0.3 0.1 0.4 0.3 0.2 0.2
J01EE Combinations of sulfonamides and 
trimethoprim, including derivatives
17.3 15.6 16.0 14.4 12.1 12.2 11.5 12.7 12.2 9.3 9.1
J01FA Macrolides 15.4 15.7 17.3 15.4 13.4 15.1 13.4 15.1 13.9 11.9 12.0
J01FF Lincosamides 9.0 9.2 10.0 10.2 10.2 10.5 10.8 11.4 11.1 10.8 10.5
J01GB Aminoglycosides 16.2 14.0 14.2 15.8 12.5 13.9 13.7 14.5 20.4 18.9 18.3
J01MA Fluoroquinolones 35.9 38.0 38.2 41.0 37.2 39.7 43.3 41.9 45.6 42.2 40.6
J01MB Other quinolones 0.4 0.5 0.5 0.6 0.8 0.5 0.3 0.2 0.3 0.5 0.0
J01XA Glycopeptides 3.8 3.2 3.4 3.4 3.5 4.1 3.9 5.4 5.9 5.7 5.6
J01XB Polymyxins 2.3 0.8 0.4 0.5 0.6 1.1 0.9 0.7 1.2 1.0 1.8
J01XC Steroid antibacterials (fusidic acid) 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.4 0.4 0.1
J01XD Imidazole derivatives 8.5 9.0 9.7 10.1 9.6 7.9 9.0 10.1 8.8 8.3 8.8
J01XE Nitrofuran derivatives 2.8 3.3 3.6 4.7 4.9 5.6 5.2 6.1 6.2 5.0 5.3
J01XX05 Methenamine 0.3 0.1 0.1 0.2 0.4 0.1 0.1 0.1 0.1 0.1 0.2
J01XX08 Linezolid 0.0 0.0 0.1 0.1 0.1 0.2 0.2 0.2 0.3 0.3 0.3
J01 Antibiotics for systemic use (total) 327.1 320.2 336.6 333.2 306.8 316.9 335.9 335.9 344.7 321.3 315.9
*  From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system
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Figure 3.4. Use of beta-lactams in hospitals, expressed as DDD/100 patient-days (A) and DDD/100 admissions (B), 1999-2010 (SWAB).
years (figure 3.5). Vancomycin also stabilized this year 
after years of increasing use, while the use of teicoplanin 
remained stable and low (figure 3.5).
3.2.2 Use of systemic antimycotics
The total use of systemic antimycotics decreased from 
3.65 to 3.49 DDD per 100 patient-days over the last year. 
Seventy-eight percent of the total use comprised triazole 
derivatives. Over the last four years their use remained 
stable when measured in DDD per 100 patient-days. 
Their DDD per 100 admissions is stable as well, except 
for a little decline in the use of fluconazole from 10.7 to 
8.7 DDD per 100 admissions. There is a big difference 
in the total use in general hospitals (1.93 DDD per 100 
patient-days) compared with university hospitals (8.66 
DDD per 100 patient-days) (table 3.4)
3.2.3 Use of systemic antimycobacterials
The total use of systemic antimycobacterials showed a 
slight increase in use; 1.49 DDD per 100 patient-days in 
2010 compared with 1.43 in 2009. The distribution of the 
different groups was more or less similar in university 
hospitals compared with the general hospitals, with the 
largest proportion (59%) represented by the antibiotics 
(mainly rifampicin) (table 3.5).
3.2.4 Use of systemic antivirals
A slight increase was shown in the total use of systemic 
antivirals, from 1.8 DDD per 100 patient-days in 2009 to 
1.9 in 2010 (table 3.6). Over the past 4 years the pattern 
remained stable for the different groups. The largest 
proportion (41%) was represented by the nucleosides 
(without reverse transcriptase inhibitors), both in the 
general and the university hospitals (6).
The group of antivirals can be divided into 2 categories: 
antivirals mainly used for acute infections (J05AB, 
nucleosides without reverse transcriptase inhibitors; 
J05AD, phosphonic acid derivatives; J05AH, 
neuraminidase inhibitors) and antivirals used for chronic 
infections (J05AE, protease inhibitors; J05AF, nucleoside 
reverse transcriptase inhibitors; J05AG, non-nucleoside 
reverse transcriptase inhibitors; J05AR, antivirals for the 
treatment of HIV, combinations; J05AX, other antivirals). 
Overall the use of antivirals for chronic infections was 
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slightly higher than for acute infections, which is shown in 
figure 3.6. This figure also shows a substantial higher use 
of antivirals in university hospitals compared with general 
hospitals. In the last year, there was an increase in use for 
chronic conditions in university hospitals, whereas use for 
acute conditions decreased. Contrarily in general hospitals 
use for chronic conditions slightly decreased, whereas use 
for acute conditions increased to the same level.
Discussion
In 2009, the total antibiotic use increased in reference to 
2008 when expressed in DDD per 100 patient-days, but 
decreased when expressed in DDD per 100 admissions. In 
2010 we see a slight decrease in both. Despite some small 
Figure 3.5. Use of macrolides, aminoglycosides, fluoroquinolones and glycopeptides in hospitals, expressed as DDD/100 patient-days (A) and DDD/100 
admissions (B), 1999-2010 (SWAB).
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increases, there seems to be a stabilisation in use of all 
groups of antibiotics measured in DDD per 100 patient-
days and in DDD per 100 admissions.
The unit in which antibiotic usage is expressed matters, 
especially for the hospital outcomes (4). This is of 
particular importance when hospital resource indicators 
change over a study period. In relation to antibiotic 
resistance development, the measure of antibiotic use 
should reflect the antibiotic selection pressure exerted. At 
the population level the selection pressure is thought to 
depend on the volume of antibiotics used in a particular 
geographical area, the number of individuals exposed and 
the proportion of the population treated with antibiotics 
(5). The denominator should therefore preferably include 
information on all these factors. However, there is a lack 
of studies determining the correlation between different 
measures of antibiotic use and the level of antibiotic 
resistance.
Table 3.4. Use of antimycotics for systemic use (J02) in general hospitals, university hospitals and all hospitals (DDD/100 patient-days), 
2007-2010 (Source: SWAB).
ATC 
group *
Therapeutic group 2007 2008 2009 2010
total
38
general
31
academic
7
total
51
general
43
academic
8
total
63
general
55
academic
8
total
67
general 
59
academic
8
J02AA01 Antibiotics 
(amfotericin B)
1.50 0.12 4.44 0.41 0.13 1.12 0.42 0.14 1.35 0.46 0.10 1.65
J02AB02 Imidazole 
derivatives 
(ketoconazole)
0.04 0.01 0.12 0.05 0.03 0.11 0.05 0.04 0.08 0.06 0.03 0.15
J02AC Triazole derivatives 2.74 1.59 5.18 3.06 1.75 6.36 2.89 1.74 6.72 2.74 1.66 6.31
J02AX Other mycotics for 
systemic use
0.09 0.05 0.19 0.16 0.06 0.40 0.29 0.20 0.61 0.23 0.14 0.56
J02 Antimycotics for 
systemic use (total)
4.34 1.71 9.93 3.67 1.97 7.98 3.65 2.11 8.77 3.49 1.93 8.66
* From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system
Table 3.5. Use of antimycobacterials for systemic use (J04) in general hospitals, university hospitals and all hospitals  
(DDD/100 patient-days), 2007-2010 (Source: SWAB).
ATC 
group *
Therapeutic group 2007 2008 2009 2010
total
37
general
30
academic
7
total
49
general
41
academic
8
total
63
general
55
academic
8
total
67
general 
59
academic
8
J04AA Aminosalicylic acid 
and derivatives
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J04AB Antibiotics (mainly 
rifampicin)
0.83 0.52 1.44 0.92 0.75 1.34 0.86 0.74 1.27  0.89 0.73 1.41
J04AC Hydrazides (mainly 
isoniazide)
0.28 0.22 0.39 0.21 0.18 0.29 0.21 0.14 0.40 0.21 0.16 0.34
J04AD Thiocarbamide 
derivatives
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J04AK Other drugs for treat-
ment of tuberculosis 
(pyrazinamide, 
ethambutol)
0.25 0.18 0.38 0.18 0.13 0.31 0.21 0.17 0.34 0.22 0.17 0.37
J04AM Combinations 
of drugs for 
tuberculosis
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J04BA Drug for treatment of 
leprosy (dapson)
0.27 0.14 0.53 0.15 0.05 0.39 0.15 0.10 0.33 0.17 0.09 0.45
J04 Antimycobacterials 
for systemic use 
(total)
1.63 1.06 2.74 1.46 1.11 2.33 1.43 1.15 2.35 1.49 1.16 2.58
* From the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system
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Since NethMap 2004, data on antibiotic use in Dutch 
hospitals have been expressed in DDD per 100 patient-
days and in DDD per 100 admissions. An increase in both 
outcomes is worrisome. With respect to development of 
resistance, decrease of the outcomes is favourable. When 
a constant use per patient is seen in combination with an 
increase in the number of admissions, selection pressure 
by antibiotics in hospitals increases over the years. An 
intensification of antibiotic therapy per 100 patient-
days may in part be due to an increase in the number of 
admitted patients, and possibly to a shortening of the 
duration of antibiotic treatment. Such shortening might 
lead to less selection of resistant micro-organisms (6).
The total number of admissions has increased, whereas 
the total number of patient-days decreased. This reflects 
the decrease in the duration of hospital stay in the 
Netherlands (from an average of 7.6 days per admission 
in 2000, to 4.5 days per admission this year). The use per 
individual patient has remained constant. Therefore, the 
selection pressure on the hospital ward has increased. 
The question that now arises is whether the development 
of resistance is more relevant in the patient or in the 
surrounding environment?
In university hospitals, the use of systemic antimycotics 
is more than four times higher than in general hospitals. 
This can be explained by the relatively larger patient 
population of haematology- and oncology-patients in 
university hospitals. 
Although university hospitals use almost twice as much 
antimycobacterials, the distribution of the different groups 
is rather similar in both hospital settings. Higher usage 
in university hospitals might be explained by rifampicin 
being used as an adjuvant in certain infections with 
Staphylococci besides its use for tuberculosis. 
In the Netherlands, tuberculosis is treated with a limited 
combination of antimycobacterials; there is not much 
room for variation (7) (except for MDR-TB). The use 
of dapson is explained by its role in the prophylaxis 
and treatment of Pneumocystis carinii and toxoplasmic 
encephalitis.
Use of systemic antivirals is much higher in university 
hospitals than in general hospitals as well, for both 
chronic and acute infections. The largest group of 
antivirals used are the nucleosides (reverse transcriptase 
inhibitors excluded), like (val)acyclovir and (val)
ganciclovir. In the Netherlands, all university hospitals 
and a few general hospitals are specialised in the 
treatment of HIV patients. 
Table 3.6. Use of antivirals for systemic use (J05) in general hospitals, university hospitals and all hospitals (DDD/100 patient-days), 2007-
2010 (Source: SWAB).
ATC 
group *
Therapeutic group 2007 2008 2009 2010
total
36
general
29
academic
7
total
44
general
36
academic
8
total
63
general
55
academic
8
total
67
general 
59
academic
8
J05AB Nucleosides 
excl. Reverse 
transcriptase 
inhibitors 
0.78 0.27 1.72 0.78 0.29 2.00 0.79 0.35 2.22 0.77 0.39 2.02
J05AD Phosphonic acid 
derivatives
0.02 0 0.06 0.03 0.01 0.11 0.03 0.00 0.13 0.03 0.01 0.10
J05AE Protease inhibitors 0.35 0.06 0.7 0.34 0.11 0.92 0.31 0.18 0.75 0.31 0.17 0.78
J05AF Nucleoside reverse 
transcriptase 
inhibitors
0.38 0.14 0.83 0.34 0.18 0.74 0.25 0.13 0.64 0.24 0.11 0.67
J05AG Non-nucleoside 
reverse 
transcriptase 
inhibitors
0.11 0.05 0.2 0.11 0.06 0.25 0.14 0.11 0.23 0.10 0.07 0.22
J05AH Neuraminidase 
inhibitors 
0.01 0 0.02 0.03 0.02 0.05 n.a.# n.a.# n.a.# 0.11 0.07 0.21
J05AR Antivirals for the 
treatment of HIV, 
combinations
0.16 0.07 0.33 0.22 0.10 0.52 0.24 0.15 0.55 0.29 0.14 0.76
J05AX Other antivirals 0 0 0 0.02 0.00 0.06 0.03 0.02 0.06 0.05 0.02 0.15
J05 Antivirals for 
systemic use (total)
1.81 0.59 3.86 1.88 0.78 4.65 1.80 0.95 4.59 1.90 0.99 4.91
* from the 2010 edition of the Anatomical Therapeutic Chemical (ATC) classification system
# Total use not to be assesed because of alternative distribution during the pandemic
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3.3 Results of the PREZIES point-prevalence 
study on antimicrobial use in hospitals
In 2011, for the first time, Dutch hospitals collected 
detailed data on antibiotic usage, (according to the 
methodology proposed by ECDC) combined with the 
PREZIES prevalence study on healthcare associated 
infections. Twenty nine hospitals participated: four 
university-, five large teaching- and 20 general hospitals. 
All patients admitted to the hospital had to be included, 
with the exception of patients on psychiatric wards and 
in the haemodialysis centre. Only systemic antibacterials 
(ATC code J01) were included, with a maximum of three 
concomitant substances per patient. Of 6360 patients, 
2059 patients were on antibiotics with a total of 2683 
prescriptions.
The antibiotics most often prescribed were amoxicillin/
clavulanic acid (22.0%), ciprofloxacin (12.3%), 
flucloxacillin (6.3%), cefuroxime (6.1%) and amoxicillin 
(5.5%). The respective distribution for community-
acquired and nosocomial infections are shown in figure 
3.7.
For surgical as well as medical prophylaxis, a wide 
variety of antibiotics is used. For surgical prophylaxis, 
cefazolin is most often used (33.6%), followed by 
amoxicillin/clavulanic acid (22.5%) and cefuroxime 
(14.3%).
For medical prophylaxis, amoxicillin/clavulanic acid 
is used in 18.0% of cases, followed by ciprofloxacin 
(16.4%), trimethoprim/sulfamethoxazol (11.9%), colistin 
(8.4%) and tobramycin (7.3%). 
Figure 3.6. Distribution of the use of antivirals for chronic (J05 AE-AG, AR, AX) vs acute (J05 AB-AD, AH) infections in hospitals, expressed as DDD/100 
patient-days (A) and DDD/100 admissions (B), 2007-2010 (SWAB).admissions (B), 1999-2010 (SWAB).
Figure 3.7. Distribution (%) of the use of antibiotics for systemic use (J01) for treatment of community acquired infections and of nosocomial infections, 
2011 (PREZIES).
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4.1 Surveillance of resistance in the 
Community 
The studies on resistance levels in the community include 
estimation of antimicrobial resistance in (1) the indigenous 
flora of various populations of healthy persons, (2) 
pathogens from patients visiting their general practitioner 
(GP) and (3) specific pathogens (meningococci, gonococci 
and mycobacteria).
Longitudinal multicentre Surveillance of Extramural 
Resistance in The Netherlands (SERIN) has been 
performed in cooperation with the Department for 
Medical Microbiology, University Hospital Maastricht, 
The Netherlands Institute for Health Services Research 
(NIVEL) and the regional Institutes for Public Health 
Services (GGDs).
Resistance levels among meningococci are recorded by the 
Netherlands Reference Laboratory for Bacterial Meningitis 
since 1993.
Surveillance of resistance of Neisseria gonorrhoeae 
among patients from outpatient-STI centres (Gonococcal 
Resistance to Antimicrobials Surveillance; GRAS) and 
the susceptibility testing and identification of first isolates 
of Mycobacterium tuberculosis of each patient with 
tuberculosis are carried out by the RIVM.
4.1.1 General Practice
Escherichia coli
Antibiotic resistance among bacteria causing community 
acquired urinary tract infections (UTI) was determined 
for strains collected from male patients visiting GPs with 
symptoms indicative for an uncomplicated UTI in the 
absence of fever. The GPs (42) participated in the national 
NIVEL network. A total of 603 men (range 18-97 year) 
were included during 2009-2010, of whom 390 were 
positive; 83% of the isolated pathogens were Gram-
negative bacteria with E. coli as the most common one 
in each age category (48-55%, table 4.1). Quantitative 
susceptibilities of all strains isolated towards indicator 
antibiotics were determined by microbroth dilution using 
the EUCAST breakpoints for resistance; resistance levels 
of all pathogens are presented in table 4.2. 
The results for E. coli were compared with those obtained 
during a comparable study in 2004 and with data obtained 
from comparable studies among women in 2004 and 2009. 
Overall a slight increase of resistance over time was 
observed for all antibiotics tested among E. coli from men, 
except for nitrofurantoin (figure 4.1), but these differences 
were not statistically significant. Resistance levels in 
women were stable for amoxicillin, co-amoxiclav, 
quinolones and nitrofurantoin, whereas the resistance to 
trimethoprim and co-trimoxazole decreased. Gentamicin 
resistance was < 1% in men and women. Resistance levels 
for co-amoxiclav, trimethoprim, co-trimoxazole and 
quinolones among strains from men were higher than those 
found in strains from women (significant for trimethoprim 
and co-trimoxazole, p < 0.05) (figure 4.1). No differences 
in resistance levels were found between the different age 
categories. Only one ESBL producing E. coli (0.3%) was 
isolated.
4.  Resistance among common bacterial pathogens
Table 4.2. Resistance (%) among uropathogens from men with uncomplicated UTI in 2009-2010. 
Species Resistance (%)
amoxicillin co-amoxiclav trimethoprim co-trimoxazole norfloxacin ciprofloxacin nitrofurantoin
Escherichia coli (N=200) 35 16 24 23 6 6 0
Proteus mirabilis (N=18) 18 0 18 12 0 0 59
Klebsiella sp (N=25) 100 14 5 0 0 0 5
other Gramnegative facultative 
bacteria* (N=43)
82 53 16 11 16 8 13
Non-fermenters** (N=39) 62 38 64 62 19 16 47
* Morganella sp., Citrobacter sp., Serratia sp., Providencia sp., Enterobacter sp.and Pasteurella sp.    
** Pseudomonas sp.and Acinetobacter sp.    
Table 4.1. Distribution (%) of isolated uropathogens in men per 
age category in 2009-2010.
Age category (y)
18-50 51-70 > 70 Total
Patients (N) 60 166 164 390
Escherichia coli 55 53 48 51
Proteus mirabilis 3 2 7 5
Klebsiella  pneumoniae 12 6 5 6
Other Gram-negatives* 8 9 14 11
Non-fermenters** 12 8 11 10
Enterococcus sp. 3 5 6 5
Other Gram-positives 7 16 9 11
* Morganella sp., Citrobacter sp., Serratia sp., Providencia sp., 
Enterobacter sp.and Pasteurella sp.   
** Pseudomonas sp. and Acinetobacter sp.   
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Streptococcus haemolyticus
De prevalence of S. haemolyticus in the normal 
nasopharyngeal fl ora was investigated by taking nasal 
swabs from patients visiting the general practitioner with 
non-infectious- and non-throat complaints. A total of 41 
GPs from the NIVEL network participating in this study 
sent swabs from 1925 patients from which 33 strains of 
S. haemolyticus serogroup A were isolated (1.7%). This 
study is still ongoing.
4.1.2 Nursing homes
Escherichia coli
Urine (freshly voided urine or pressed in incontinence 
materials) from 308 residents without infection of six 
nursing homes in the province of Limburg were cultured 
by taking dipslides in 2010-2011 and examined for the 
presence of E. coli. In total 208 strains were obtained; the 
resistance levels are presented in fi gure 4.2. Amoxicillin-, 
co-amoxiclav- and quinolone resistance levels are higher 
(p<0.05), than those found in GP patients (fi gure 4.1), 
the resistance levels of trimethoprim, co-trimoxazole and 
nitrofurantoin are comparable with those found in GP 
patients. Two E. coli strains (1%) were ESBL positive. 
Gentamicin resistance was 6%. This surveillance will 
be continued in 2012 by recruiting more nursing homes 
in other parts of the Netherlands and to determine also 
the prevalence of health care related infections and its 
relationship with antibiotic use.
Staphylococcus aureus
Nasal swabs from 308 residents having somatic 
disabilities without infections, living in six nursing homes 
in the province of Limburg were cultured for carriership 
of S. aureus in the commensal fl ora in 2010. A total of 
99 strains of S. aureus were isolated (32%), of which one 
was an MRSA (1%).  This is somewhat lower than the 
carriership found in 2007 in a comparable population of 
nursing home residents (N= 260, with 40% carriers and 
2.6% MRSA). The resistance to penicillins, macrolides, 
0
5
10
15
20
25
30
35
5
10
15
20
25
30
35
am
ox
ici
llin
co
-a
mo
xic
lav
trim
eth
op
rim
co
-tr
im
ox
az
ole
no
rflo
xa
cin
cip
ro
flo
xa
cin
nit
ro
fur
an
toi
n
am
ox
ici
llin
co
-a
mo
xic
lav
ge
nta
mi
cin
ge
nta
mi
cin
trim
eth
op
rim
co
-tr
im
ox
az
ole
no
rflo
xa
cin
cip
ro
flo
xa
cin
nit
ro
fur
an
toi
n
men women
2004 (left)    2009/2010 (right)
Re
sis
tan
ce
 (%
)
Escherichia coli - GP Patients - SERIN
   
Staphyloccus aureus - Nursing Homes - SERIN
Re
sis
tan
ce
 (%
) 
0
10
20
30
40
50
pe
nic
illi
n
me
thi
cil
lin
er
yth
ro
my
cin
cli
nd
am
yc
in
do
xy
cy
cli
ne
co
-tr
im
ox
az
ole
fus
idi
c a
cid
mu
pir
oc
in
cip
ro
flo
xa
cin
left 2007 (N=105) right 2010 (N=99)
78 72
Escherichia coli - Nursing Homes - SERIN
Re
sis
tan
ce
 (%
) 
0
10
20
30
40
50
am
ox
ici
llin
co
-a
mo
xic
lav
ge
nta
mi
cin
trim
eth
op
rim
co
-tr
im
ox
az
ole
no
rflo
xa
cin
cip
ro
flo
xa
cin
nit
ro
fur
an
toi
n
Figure 4.1. Resistance to antibiotics among Escherichia coli from male patients in 2004 (N=103) and in 2009/2010 (N=200) and female patients in 2004 
(N=1724) and in 2009 (N=489) in the community.
Figure 4.3. Resistance to antibiotics among Staphylococcus aureus from 
Nursing Home residents in 2007 (N=105) and 2010 (N=99).
Figure 4.2. Resistance to antibiotics among Escherichia coli (N=208) from 
Nursing Home residents in 2010.
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doxycycline, co-trimoxazole, fusidic acid, mupirocin and 
ciprofloxacin is presented in figure 4.3 and compared 
with the results found in 2007. No significant changes 
were recorded in resistance patterns. Resistance levels 
are comparable with those found in strains isolated 
from patients in Unselected Hospital Departments and 
Intensive Care Units (see later) except for ciprofloxacin, 
which was 23% in nursing home residents compared with 
10% in hospital patients in 2010 (p< 0.02). 
No resistance to clindamycin, gentamicin, co-trimoxazole, 
vancomycin or linezolid was recorded. Resistance to 
daptomycin was 1% (not shown). 
GP and Nursing Homes - Conclusion 
1. Overall resistance levels among E. coli in UTI 
strains in male GP patients is higher than in 
female GP patients; difference is significant for 
trimethoprim and co-trimoxazole (p<0.05).
2. Slight increase in resistance among E. coli in men 
since 2004; stable resistance in women.
3. Amoxicillin-, co-amoxiclav- and quinolone 
resistance levels among E. coli in nursing home 
residents are higher (p<0.05) than in GP patients.
4. Low prevalence of ESBL producing strains in GP 
patients (0.3%) and in nursing home residents 
(1%).
5. Gentamicin resistance in nursing home residents is 
6% vs. < 1% in the community.
6. Carriership of S. aureus in commensal flora of 
nursing home residents is 32% with 1% MRSA.
7. Resistance levels among S. aureus in nursing 
homes are similar to those found for Unselected 
Hospital Departments and Intensive Care Units, 
except for ciprofloxacin which was significantly 
higher in nursing homes (23%, p< 0.05).
4.1.3 Community
Neisseria meningitidis
From 1994-2011 a total of 4657 strains from cerebrospinal 
fluid (CSF) and 2859 strains from blood were included 
in the surveillance project of The Netherlands Reference 
Laboratory for Bacterial Meningitis of the Academic 
Medical Centre, Amsterdam. The number of strains 
moderately susceptible to penicillin (MIC 0.125-0.25 
mg/l) increased since 2000 from less than 2% to 22% in 
2011 and from 1% to 35% for strains isolated from CSF 
and blood, respectively (figure 4.4). Penicillin resistance 
(MIC >0.5 mg/l) was occasionally found in strains both 
from CSF and blood in some years, the last time in 2006 
(4.4). The MIC distributions of penicillin showed a slow 
movement of the peak to the right from 0.03 to 0.06 mg/l 
from 2008 onwards and broadening of the range, including 
more strains with MICs 0.125-0.25 mg/l in 2011.
Nineteen of the 27 strains isolated in 2011 which were 
moderately susceptible belonged to serogroup B, six 
to serogroup Y, one to serogroup C and one was not 
groupable.
Resistance to rifampicin and ceftriaxone was not found.
Neisseria meningitidis - Conclusion 
1. Penicillin resistance not found since 2006.
2. 22% of strains from blood and 35% from CSF 
were moderately susceptible to penicillin in 2011. 
3. Resistance to ceftriaxone and rifampicin not found.
Neisseria gonorrhoeae
The national project GRAS started in 2006 and collects 
epidemiologic data on gonorrhea and resistance patterns 
of isolated strains from Sexually Transmitted Infections 
(STI) centres. The participating STI centres represent 
83% of the total population of STI centre attendees, but 
exclude GP patients. Diagnosis of gonorrhea is made by 
culture or PCR on patients’ materials, with an obvious 
decrease in number and percentages of cultures over time 
(figure 4.5) (data from the yearly questionnaire sent by the 
RIVM to all laboratories).
Susceptibility testing for 5789 isolates was performed 
by E-test for penicillin, tetracycline, ciprofloxacin 
and cefotaxime (2006-2011); in 2011 ceftriaxone, 
azithromycin and spectinomycin were added to the panel 
for which 1283 isolates were tested. Resistance levels 
were calculated using the EUCAST breakpoints for 
resistance.
Overall penicillin resistance decreased significantly 
until 2010 (p< 0.05) and increased thereafter to 13% in 
2011 (figure 4.6). It is difficult to estimate this increase 
since only 20% of strains was tested for penicillin 2011. 
Tetracycline resistance increased to 60% in 2009 and 
decreased to 47% in 2011 (figure 4.6).
Ciprofloxacin resistance increased to 52% in 2009 and 
decreased to 37% in 2011.
Cefotaxime resistance (MIC > 0.12 mg/l) increased from 
1% in 2006 up to 9% in 2010 and decreased to 5% in 
2011 (figure 4.6). The MIC distribution of cefotaxime 
(figure 4.7) showed a unimodal shape with broadening 
over the range since 2009 and a growing subpopulation 
with MIC 0.12-0.25 mg/l. Cefotaxime resistant strains 
were more common in MSM (8%), than in heterosexual 
men and women (3%).
Ceftriaxone resistance was not found, the MIC 
distribution was also unimodal (figure 4.7). Resistance to 
azithromycin was 7%; one isolate (0.1%) was resistant to 
spectinomycin.
The changing antibiotic resistance pattern among 
gonococci underlines the need for a continuous 
surveillance to detect trends which might necessitate 
modification of treatment guidelines.
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Neisseria gonorrhoeae  - Conclusion 
1. Resistance to tetracycline (47%) and ciprofloxacin 
(37%) decreased.
2. Overall cefotaxime resistance was 5%, highest 
resistance (8%) among isolates in men having sex 
with men. Ceftriaxone resistance was not found.
3. Azithromycin resistance was 7% in 2011.
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Figure 4.4. Trends in penicillin resistance and MIC distributions of penicillin for Neisseria meningitidis from CSF (N= 4.657) and blood (N=2.859). MIC data 
for 2007 were not available.
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Figure 4.6. Trends in antibiotic resistance among Neisseria gonorrhoeae 
(N=5.789).
Figure 4.5. Diagnoses of gonorrhoea in The Netherlands since 2002 
(yearly RIVM questionnaire).
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Mycobacterium tuberculosis
A total of 12,250 strains of M. tuberculosis complex 
were obtained during 1998-2011. In the period of 2001 
till 2006, the number of strains isolated yearly gradually 
decreased, from 1080 in 2001 to 727 in 2006 (33% 
decline), since then this number is stable. In 2011, 
734 strains were sent to the RIVM; susceptibility was 
determined for 546 strains. INH resistance increased since 
2008 to 11.3% in 2011 (figure 4.8).
Rifampicin resistance increased to 3% in 2011. 
Ethambutol is also routinely used as a first line drug in 
TB treatment. Resistance to ethambutol remained low, 
fluctuating between 0.2% and 1.6% and was 1.5% in 
2011.
Figure 4.7. MIC distributions of cefotaxime and ceftriaxone for Neisseria gonorrhoeae.
Figure 4.8. Trends in antibiotic resistance among Mycobacterium 
tuberculosis (N= 12,250).
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Figure 4.9. Trends in combined resistance among Mycobacterium tuberculosis (N= 12,250).
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Streptomycin is not used as a first line drug in the western 
world anymore; resistance to streptomycin decreased 
from 10.2% in 2000 to 4.9% in 2008, but has raised since 
then to 8.7% in 2011.
Combined resistance to more than one drug increased 
from 3.5% in 2010 to 5.6% in 2011 (figure 4.9); co-
resistance to rifampicin and INH was recorded in 2.8% of 
the isolates, whereas resistance to all four antimicrobial 
agents re-increased from 0.4% in 2010 to 1.5% in 2011 
(figure 4.9).
Mycobacterium tuberculosis - Conclusion 
1. Increasing resistance to INH (11%), rifampicin 
(3%) and streptomycin (8%).
2. Varying and low resistance to ethambutol (1.5% in 
2011). 
3. Combined resistance to INH and rifampicin was 
3.5%; multiresistance to the four drugs tested 
increased to 1.5% in 2011.
4.2	 Surveillance	of	resistance	in	specific	
patient populations
ISIS-AR 
Between 2008 and 2011, 22 laboratories continuously 
reported susceptibility data to the Infectious Disease 
Surveillance Information System for Antibiotic Resistance 
(ISIS-AR) including MICs, breakpoint MICs (≤ or >),  
S I R interpretations and disk zone diameters. When 
MICs or breakpoint MICs were available the EUCAST 
breakpoints for resistance (R) were applied to the available 
MICs to determine the annual proportion of resistant 
isolates for E. coli, P. mirabilis, K. pneumoniae, E. 
cloacae, P. aeruginosa, Acinetobacter spp., S. aureus, and 
coagulase-negative staphylococci including S. epidermidis. 
These results may differ from previous interpretations 
(NethMap 2009-2011) where only S I R data as reported by 
the individual laboratories were evaluated. In 2009-2011, 
the S I R interpretations of the laboratories were primarily 
based on CLSI breakpoints of which the I+R proportion 
for most antimicrobial agents corresponds to the proportion 
of resistant (R) isolates when using EUCAST breakpoints. 
In NethMap 2009-2010 I+R values, as reported by the 
laboratories, were therefore used to determine resistance.  
Now the reported S I R interpretations were only used 
when no MICs were available or when < 80% of the MICs 
was available for a specific antimicrobial agent within 
a given species, such as for enterococci, H. influenzae, 
S. pneumoniae and M. catarrhalis. Not all antimicrobial 
agents were tested for all species by all participating 
laboratories; therefore the range of the minimum and 
maximum numbers of isolates tested within each species 
is given. A more detailed overview of the materials and 
methods used can be found at www.swab.nl.
4.2.1 General Practice - ISIS-AR
Data from urinary isolates from GP patients were 
included in this evaluation. General practitioners use to 
send urine samples for culture and susceptibility testing 
in case of complicated UTI or when there is no response 
to antimicrobial therapy (selected GP patients). The 
presented resistance levels are therefore not representative 
for all patients with UTI presenting at the GP.
Escherichia coli
Isolates tested (N): 4089-54,685  
Laboratories participating (N): 13-20.
Trends. Amoxicillin resistance decreased slightly from 
42% in 2008 to 40% in 2011, co-amoxiclav resistance was 
around 15% during the whole period (figure 4.10); both 
levels were higher than the resistance level in GP patients 
with uncomplicated UTI  (figure 4.1) ). Cefuroxime 
resistance remained stable at 6%, resistance to ceftriaxone/
cefotaxime increased slightly (from 2% in 2008 to 3% in 
2011, figure 4.10). Trimethoprim resistance decreased to 
28%, but co-trimoxazole resistance increased from 24% to 
26%. Normally these two drugs follow the same trend. Not 
all participating laboratories tested both trimethoprim and 
co-trimoxazole and when restricting the analysis to those 
laboratories which tested both agents, a significant increase 
in resistance over time for both drugs was observed. 
Differences in methodology used by the participating 
laboratories may also contribute to these discrepancies 
and need further analyses. Gentamicin resistance was 4% 
which is higher than the level found in GP patients with 
uncomplicated UTI in the community (figure 4.1) 
Quinolone resistance was stable at 14-15% for norfloxacin 
and 9% for ciprofloxacin. 
The resistance levels of amoxicilline, co-amoxiclav, 
trimethoprim, co-trimoxazole and the quinolones are all 
significantly higher than the levels found in GP patients 
with uncomplicated UTI (figure 4.1), indicating that the 
selected GP patients were exposed to these drugs before.
Nitrofurantoin resistance was 2% during the whole period, 
fosfomycin resistance was less than 1%, but was only 
reported by 13 laboratories.
Klebsiella pneumoniae 
Isolates tested (N): 1213-5359
Laboratories participating (N): 13-20.
Trends. Co-amoxiclav resistance remained stable at 9% 
(figure 4.10), cefuroxime resistance was around 12%, 
the resistance level of ceftriaxone/cefotaxime (3% in 
2011) and ceftazidime (2%) resembled those for E. coli. 
Trimethoprim resistance decreased with fluctuations to 26% 
in 2011 with a simultaneous increase of co-trimoxazole 
resistance from 15% in 2008 to 18% in 2011 (p< 0.05). 
Ciprofloxacin resistance level remained low (4% in 2011), 
whereas norfloxacin resistance appeared to be 20%. 
Data on fosfomycin resistance were only reported by 13 
laboratories for a limited number of strains from 2009-2011 
(1213-4547); a slight increase in resistance was observed 
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Figure 4.10. Trends in antibiotic resistance (2008-2011) among urinary strains of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and 
Pseudomonas aeruginosa from Selected Patients of General Practice, reported to ISIS-AR.
Table 4.3. Resistance levels among Enterobacteriaceae and Pseudomonas aeruginosa from Selected Patients of General Practice in 2011.
Antibiotic E. coli K. pneumoniae P. mirabilis P. aeruginosa
amoxicilin 40 24
co-amoxiclav 15 9 11
piperacillin 3
cefuroxime 6 12 1
cefotaxime/ceftriaxone 3 3 1
ceftazidime 1 2 1 3
gentamicin 4 2 4
tobramycin 1
trimethoprim 28 26 37
co-trimoxazole 26 18 33
norfloxacin 14 20 10
ciprofloxacin 9 4 7 8
nitrofurantoin 2 41
fosfomycin 1 22 11
increasing since 2008
decreasing since 2008
stable since 2008
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cefotaxime increased slightly (4% in 2011). The 
resistance levels of trimethoprim (31% in 2011) and 
co-trimoxazole (29%) showed the same trends as those 
among selected GP patients, but at a higher level (figure 
4.11). Norfloxacin resistance fluctuated around 23% and 
ciprofloxacin showed a slight increase to 17% in 2011. 
Both levels were significantly higher than those found 
in selected GP patients and are therefore no option for 
empirical therapy. Nitrofurantoin resistance was stable at 
3% and fosfomycin resistance remained 1% during the 
whole study period (figure 4.11). 
Klebsiella pneumoniae
Isolates tested (N): 1689-2512
Laboratories participating (N): 9-21.
Trends. Co-amoxiclav resistance (10%) and cefuroxime 
resistance (12%) remained stable over time and were 
comparable with the levels found in selected GP patients.  
Resistance to ceftriaxone/cefotaxime increased from 2% 
in 2008 to 5% in 2011 (p<0.05); that to ceftazidime from 
1% to 4% (p<0.05). Trimethoprim resistance level was 
stable at 26%, that of co-trimoxazole increased to 18% 
(figure 4.11), both levels being similar to those found in 
selected GP patients. Norfloxacin resistance was high 
(20%), resistance to ciprofloxacin remained around 
7%. Nitrofurantoin resistance levels reported by the 
different laboratories showed the same large variations as 
observed for selected GP patients, and. decreased since 
2008 to 36% in 2011. Data on fosfomycin resistance 
were reported by nine laboratories; resistance increased 
over the years from 14% to 25% (p< 0.05). 
Proteus mirabilis
Isolates tested (N): 1302-1912
Laboratories participating (N): 9-21.
Trends. Amoxicillin resistance was stable and remained 
at 26%, but co-amoxiclav resistance increased from 
7.5% to 13% (figure 4.11), p< 0.05); both levels were 
somewhat higher than those found in selected GP patients. 
Resistance levels to cefuroxime, ceftriaxone/cefotaxime 
and ceftazidime were 2% or less. Trimethoprim and co-
trimoxazole resistance levels were similar to those found 
in selected GP patients that to co-trimoxazole showed 
an increase and was 33% in 2011 (p<0.05). Gentamicin 
resistance was stable at 6%. Norfloxacin resistance 
was 20%, similar to the level in selected GP patients, 
ciprofloxacin resistance increased slightly in 2011 to 11% 
(figure 4.11, not significant). Data on fosfomycin resistance 
were obtained from 887 isolates from nine laboratories; 
resistance fluctuated from 10-16% (figure 4.11). 
Pseudomonas aeruginosa
Isolates tested (N): 863-1112
Laboratories participating (N): 11-21.
Trends. Stable resistance levels were observed for 
piperacillin (6%), ceftazidime (4%), tobramycin (1%) 
and ciprofloxacin (10%).
from 19% in 2009 to 22% in 2011. Data on nitrofurantoin 
resistance varied highly between the different laboratories 
which may be associated with the fact that the EUCAST 
breakpoints fall within the wild type distribution; overall 
41% resistance was reported in 2011 (figure 4.10).
Proteus mirabilis
Isolates tested (N): 3591-5360
Laboratories participating (N): 13-20.
Trends. Amoxicillin resistance decreased to 24% in 2011 
(figure 4.10) with a simultaneous increase in resistance to 
co-amoxiclav (11%, p< 0.05). Cephalosporin resistance 
remained low over time (1%). Also here, a decrease in 
trimethoprim resistance was observed from 39% in 2008 
to 37% in 2011, with a simultaneous increase in resistance 
to co-trimoxazole from 26% to 33%. Norfloxacin 
resistance was around 10%, ciprofloxacin resistance 7%. 
Data on fosfomycin resistance were available from 13 
laboratories; the resistance was stable at 11% over time.
Pseudomonas aeruginosa
Isolates tested (N): 1353-1999 
Laboratories participating (N): 8-20.
Trends. Stable resistance levels over time were found for 
piperacillin (4%), ceftazidime (3%), tobramycin (0.5%) 
and ciprofloxacin (8%) (figure 4.10). 
Selected GP Patients - Conclusion (see also table 4.3) 
1. All resistance levels in selected GP patients were 
significantly higher than in GP patients from the 
community with an uncomplicated UTI.
2. Co-amoxiclav resistance was 9-15% among 
Enterobacteriaceae. Empirical therapy with  
co-amoxiclav should be reconsidered in selected 
GP patients.
3. Cephalosporin resistance remained low, except for 
cefuroxime in K. pneumoniae (12% resistance).
4. Trimethoprim- and co-trimoxazole resistance 
levels are too high for empirical therapy in selected 
GP patients.
5. Quinolone resistance is stable, but high, except for 
ciprofloxacin in K. pneumoniae. 
4.2.2 Outpatient Departments - ISIS-AR
Data from urinary isolates from patients visiting 
Outpatients Departments reported to ISIS-AR were 
included in this evaluation.
Escherichia coli 
Isolates tested (N): 1034-16,372
Laboratories participating (N): 9-21.
Trends. Resistance levels for amoxicillin (45%) and 
co-amoxiclav (19%) were stable over time (figure 4.11) 
and higher than in selected GP patients. Cefuroxime
resistance was around 10%, that of ceftriaxone/
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Figure 4.11. Trends in antibiotic resistance (2008-2011) among urinary strains of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and 
Pseudomonas aeruginosa from patients of Outpatients Departments reported to ISIS-AR.
Table 4.4. Resistance levels among Enterobacteriaceae and P. aeruginosa in Outpatients Departments in 2011.
Antibiotic E. coli K. pneumoniae P. mirabilis P. aeruginosa
amoxicilin 45 26
co-amoxiclav 19 10 13
piperacillin 6
cefuroxime 10 12 2
ceftriaxone/cefotaxime 4 5 2
ceftazidime 2 4 1 4
gentamicin 6 3 6
tobramycin 1
trimethoprim 31 26 37
co-trimoxazole 29 18 33
norfloxacin 23 20 14
ciprofloxacin 17 7 11 10
nitrofurantoin 3 36
fosfomycin 1 25 15
increasing since 2008
decreasing since 2008
stable since 2008
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Outpatient Departments - Conclusion  
(see also table 4.4)
1. Resistance levels among urinary isolates from 
patients visiting Outpatient Departments were 
similar or 1-3% higher than those in selected GP 
patients.
2. The resistance levels of amoxicillin, co-amoxiclav, 
trimethoprim, co-trimoxazole and the quinolones 
are too high for empirical therapy of infections by 
Enterobacteriaceae.
3. Fosfomycin resistance low in E. coli, but 
increasing in K. pneumoniae and P. mirabilis to 
levels which may make the drug unusable for 
empirical therapy.
4. Empirical therapy of urinary infections by 
E. coli (most frequently) is only possible 
with nitrofurantoin or fosfomycin in case of 
uncomplicated UTI or with a 3rd generation 
cephalosporins or gentamicin for complicated UTI. 
5. Empirical therapy of urinary infections by 
pathogens other than E. coli is only possible with 
cephalosporins or gentamicin. 
4.2.3 Unselected Hospital Departments - ISIS-AR
Data from clinical isolates (urine, wound, blood, 
respiratory tract) of patients hospitalized in Unselected 
Hospital Departments excluding Intensive Care Units, 
reported to ISIS-AR were evaluated. Resistance to 
carbapenems among Enterobacteriaceae was only 
evaluated in 2011, since isolates from previous years 
were not confirmed by a second phenotypic antimicrobial 
susceptibility test. For further details see chapter 6. 
Escherichia coli
Isolates tested (N): 12,336-18,427
Laboratories participating (N): 18-21.
Trends. Amoxicillin resistance (figure 4.12) was similar 
to the level found in Outpatient Departments; co-
amoxiclav resistance increased from 19% in 2009 to 21% 
in 2011, piperacillin-tazobactam resistance from 2% to 
5%. A slight increase was observed for all cephalosporins 
tested (figure 4.12).  One of 16.932 isolates in 2011 was 
resistant to the carbapenems. Gentamicin resistance 
was stable at 5% over time, similar to the level found in 
Outpatient Departments and selected GP patients. Co-
trimoxazole resistance was increasing from 21% in 2008 
to 28% in 2011.  Resistance to ciprofloxacin increased 
from 11% to 13%. Nitrofurantoin resistance remained 
stable at 2% (figure 4.12), similar to the level found for E. 
coli in other patient groups. 
Klebsiella pneumoniae
Isolates tested (N): 2644-3373
Laboratories participating (N): 20-21.
Trends. Resistance to co-amoxiclav increased slowly to 
12%, to cefuroxime to 13% and the resistance levels of 
ceftriaxone/cefotaxime and ceftazidime increased to 7% 
and 6% respectively (figure 4.12). One of 2.931 isolates 
tested was resistant to imipenem/meropenem in 2011. 
Co-trimoxazole resistance increased to levels similar 
to those found in selected GP patients and Outpatient 
Departments. Ciprofloxacin resistance remained stable 
around 7%, whereas nitrofurantoin resistance decreased 
to 28%. 
Enterobacter cloacae
Isolates tested (N): 1624-1953
Laboratories participating (N): 18-21.
Trends. Data on susceptibility to the carbapenems, 
gentamicin, co-trimoxazole, ciprofloxacin and 
nitrofurantoin were available for interpretation. One of 
1.796 isolates tested was confirmed to be resistant to 
imipenem/meropenem in 2011. Resistance to gentamicin 
and ciprofloxacin was 5% or less over time (figure 4.12), 
whereas that to co-trimoxazole increased significantly 
from 5% in 2008 to 8% in 2011 (p<0.05). Nitrofurantoin 
resistance fluctuated around 19-20%. 
Proteus mirabilis
Isolates tested (N): 2633-3539
Laboratories participating (N): 18-21.
Trends. Resistance levels to amoxicillin (25%) and co-
amoxiclav (increasing from 8% to 12%, p< 0.05) were 
similar to the levels found in the former patient groups. 
Piperacillin-tazobactam resistance was low (3% in 2011); 
resistance to cephalosporins remained low (1-2%). 
Carbapenem resistance was not recorded. Significantly 
increasing were the resistance levels to co-trimoxazole 
(from 19% to 30%) and to ciprofloxacin (from 5% to 8%).
Pseudomonas aeruginosa
Isolates tested (N): 2976-3928
Laboratories participating (N): 18-21.
Trends. Piperacillin resistance increased slowly from 
8% in 2008 to 10% in 2011 (figure 4.12); piperacillin-
tazobactam resistance, reported for 1.395 isolates from 
14 laboratories in 2011, was also 10%. Carbapenem 
resistance was stable at 2%, ceftazidime resistance 
remained 5%. Resistance to gentamicin increased 
significantly between 2008 (4%) and 2011 (8%), that 
to tobramycin remained 2% over time. Ciprofloxacin 
resistance was stable (8%) and similar to the level in 
selected GP patients and lower than in Outpatients 
Departments.  
Acinetobacter species
Isolates tested (N): 276-433
Laboratories participating (N): 20-21.
Trends. Data on susceptibility to the carbapenems, 
ceftazidime, gentamicin, co-trimoxazole and ciprofloxacin 
were available for interpretation. Resistance levels 
fluctuated considerably over time (figure 4.12). 
Carbapenem resistance was 1-4%, gentamicin 
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resistance ranged from 3-7%, co-trimoxazole 2-8% and 
ciprofloxacin resistance was 6-8%.  
Enterococcus species
Isolates tested (N): E. faecalis 1535-3663; E. faecium 
350-1490
Laboratories participating (N): E. faecalis 12-19; E. 
faecium 12-21. 
Trends. Data on susceptibility to vancomycin and 
teicoplanin were evaluated by taking I+R interpretations 
of the participating laboratories. Vancomycin resistance 
among E. faecalis ranged from 0.2-0.6%, teicoplanin 
resistance was 0.1-0.4%; no significant trend could be 
observed for both glycopeptides. Vancomycin resistance 
among E. faecium isolates fluctuated between 0.1-0.8% 
from 2008-2010 and was 1.5% in 2011. This increase 
was associated with an outbreak of VRE in several 
hospitals in the northern part of the Netherlands. Most of 
these strains were teicoplanin susceptible, as only 0.3% 
resistance to teicoplanin was observed in 2011.
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Figure 4.12. Trends in antibiotic resistance (2008-2011) among clinical strains of Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus 
mirabilis, Pseudomonas aeruginosa and Acinetobacter spp. from patients of Unselected Hospital Departments reported to ISIS-AR.
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Staphylococcus aureus
Isolates tested (N): 8140-8824
Laboratories participating (N): 18-22.
Methicillin resistance increased slowly to 1.8% in 2011. 
In 2011 a total number of 3,246 MRSA isolates were 
forwarded to the National Institute for Public Health and 
the Environment (RIVM) for typing, 16 isolates less than 
in 2010. A total of 1271 strains (39%) appeared to be 
livestock-related CC398 strains (figure 4.13).  
MSSA - Number of isolates available for interpretation: 
4646-6313
Trends. No significant changes were observed for 
resistance levels of erythromycin (9%), clindamycin 
(4%), doxycycline (3-4%), gentamicin (< 1%), co-
trimoxazole (3%) or ciprofloxacin (9%) (figure 4.13). 
Less than 0.5% of the strains were resistant to rifampicin; 
resistance to fusidic acid decreased from 10% in 2008 to 
8% in 2011 (p< 0.05). 
MRSA - Number of isolates available for interpretation: 
55-125
Trends. Resistance levels to all antibiotics tested 
were significantly higher among MRSA compared to 
MSSA (figure 4.13). Resistance rates for clindamycin, 
doxycycline, co-trimoxazole and rifampicin increased 
over time, those of erythromycin, ciprofloxa cin and 
fusidic acid tended to decrease. None of the isolates was 
resistant to linezolid.
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Figure 4.14. Trends in antibiotic resistance (1998-2011) among clinical strains of Haemophilus influenzae and Moraxella catarrhalis from patients of 
Unselected Hospital Departments, reported to ISIS-AR.
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Figure 4.13. Trends in antibiotic resistance (1998-2011) among clinical strains of Staphylococcus aureus from patients of Unselected Hospital Departments, 
reported to ISIS-AR. and the numbers and origin of MRSA strains sent to the RIVM for typing. 
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Coagulase negative staphylococci including 
Staphylococcus epidermidis
Isolates tested (N): 3450-4089
Laboratories participating (N): 16-21.
Trends. Resistance data of linezolid and vancomycin 
were taken for evaluation. Linezolid resistance appeared 
stable around 0.7%; nine strains (0.2%) were vancomycin 
resistant. 
Streptococcus pneumoniae
Isolates tested (N): 1640-2226
Laboratories participating (N): 20-22.
Trends. Data on susceptibility to benzylpenicillin, 
erythromycin and doxycycline were evaluated by using 
the I+R interpretations of the participating laboratories.
Resistance to (benzyl) penicillin (2-3%) and erythromycin 
(9%) were relatively stable over time, resistance to 
doxycycline/tetracycline increased significantly from 7% 
in 2008 to 10% in 2011.
Table 4.5. Resistance levels among Enterobacteriaceae and Non-fermenters in Unselected Hospital Departments in 2011.
Antibiotic E.coli K. pneumoniae E. cloacae P. mirabilis P. aeruginosa Acinetobacter sp.
amoxicilin 46 25
co-amoxiclav 21 12 12
piperacillin 10
piperacillin-tazobactam 5 6 3
carbapenem 0.1 2 3
cefuroxime 11 13 2
ceftriaxone/cefotaxime 5 7 1
ceftazidime 3 6 1 5 49
gentamicin 5 5 4 5 8 7
tobramycin 2
co-trimoxazole 28 17 8 30 8
ciprofloxacin 13 7 5 8 8 7
nitrofurantoin 2 28 20
increasing since 2008
decreasing since 2008
stable since 2008
Table 4.6. Resistance levels among Staphylococcus aureus and respiratory pathogens in Unselected Hospital Departments in 2011.
Antibiotic MSSA MRSA S. pneumoniae H. influenzae M. catarrhalis
penicillin 2
amoxicillin 15 84
co-amoxiclav 4 1
ceftriaxone 0.1 1
erythromycin 9 35 9 11
clindamycin 4 32
doxycycline 3 44 10 2 4
co-trimoxazole 3 27 21 8
gentamicin 1 26
ciprofloxacin 9 35 0 0.5
rifampicin 0.1 8
vancomycin
linezolid
fusidic acid 8 15
increasing since 2008
decreasing since 2008
stable since 2008
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Haemophilus influenzae
Isolates tested (N): 859-3105
Laboratories participating (N): 10-22.
Trends. Data on susceptibility were evaluated by using 
I+R interpretations of the participating laboratories.
Amoxicillin resistance was 15-16% and stable over time 
(figure 4.14), 4% of all strains were also co-amoxiclav 
resistant, indicating that resistance was not exclusively 
caused by production of beta-lactamase. Cefotaxime 
resistance remained low (0.4% or less), doxycycline 
resistance level was 2% during the whole study period. 
Co-trimoxazole resistance increased significantly from 
17% in 2008 to 21% in 2011. Ciprofloxacin resistance 
was rare.  
Moraxella catarrhalis
Isolates tested (N): 220-1124
Laboratories participating (N): 7-22.
Trends. Data on susceptibility were evaluated by using 
the I+R interpretations of the participating laboratories. 
Amoxicillin/ampicillin resistance increased from 79% to 
84% (p<0.05) figure 4.14); resistance to co-amoxiclav 
was observed in 1% of the strains tested. Resistance to 
cefotaxime was 1-2%. Erythromycin resistance increased 
from 6% to 11% (p<0.05) between 2008 and 2011. 
Resistance to doxycycline was 3-4%, that to ciprofloxacin 
1-3%, whereas around 8% of all strains appeared to be 
resistant to co-trimoxazole (figure 4.14)
 
Unselected Hospital Departments - Conclusion 
(see also tables 4.5 and 4.6)
1. Co-amoxiclav resistance is increasing in E. 
coli (21%) and P. mirabilis (12%), and its use 
for empirical therapy should be reconsidered. 
Piperacillin-tazobactam is 3-6%, but increasing.
2. Cefuroxime resistance is increasing in E. coli 
and K. pneumoniae and its use for empirical 
therapy should be reconsidered. Cefotaxime- and 
ceftriaxone resistance is low, but increasing in  
E. coli and K. pneumoniae.
3. Aminoglycoside resistance is stable at 4-5% for 
Enterobacteriaceae. Gentamicin resistance is 
increasing in P. aeruginosa (8%); tobramycin 
resistance was 2%, reflecting its higher intrinsic 
activity towards P. aeruginosa.
4. Trimethoprim- and co-trimoxazole resistance 
is too high for empirical therapy, except for 
Acinetobacter sp. infections.
5. Quinolone resistance is increasing in E. coli and  
P. mirabilis and a matter of concern.
6. Prevalence of MRSA is low (1.8%), but seems 
to increase; resistance to other antibiotics among 
MRSA is significantly higher than among MSSA.
7. Standard antibiotics for respiratory tract infections 
by pneumococci remain first choice (penicillin/
amoxicillin, macrolides, and doxycycline); high 
resistance to amoxicillin and co-trimoxazole 
among H. influenzae necessitates other treatment 
schedules. 
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Figure 4.15. Trends in antibiotic resistance among clinical strains of Escherichia coli from Intensive Care Units.
Figure 4.16. MIC distributions of amoxicillin and co-amoxiclav for Escherichia coli from Intensive Care Units.
SIRIN
Resistance in selected hospital departments was 
recorded by studying susceptibility patterns in 14 large 
referral centres participating in the longitudinal SWAB 
study for Surveillance of Intramural Resistance in the 
Netherlands (SIRIN). Unique unrelated consecutive 
isolates isolated from various clinical materials of 
patients admitted to Intensive Care Units, Urology 
Services and Pulmonology Services were yearly collected 
for quantitative susceptibility testing in one central 
laboratory. MICs were determined by broth micro-dilution 
assays and breakpoints for resistance according to the 
recommendations of EUCAST (January 2012) were used. 
A total of 34.150 strains were collected from 1996-2010. 
4.2.4 Intensive Care Units - SIRIN
Escherichia coli
Isolates tested (N): 2844 
Trends. Amoxicillin resistance increased from 46% 
in 1998 to 60% in 2010 (figure 4.15); the bimodal 
MIC distribution showed a flattening and decrease of 
the susceptible subpopulation and a growing resistant 
subpopulation with MIC > 32 mg/l (figure 4.16). 
Co-amoxiclav resistance increased from 22% in 1998 to 
44% in 2010 (figure 4.15); the unimodal MIC distribution 
showed a growing number of strains with MIC 16-32 
mg/l (figure 4.16).
Piperacillin resistance increased in all Units to 43% 
in 2010 (figure 4.15). The MIC distribution became 
clearly bimodal after 2001 with a growing subpopulation 
of resistant strains (MIC > 16 mg/l). Resistance to 
piperacillin-tazobactam was 2-5% during the whole study 
period with a unimodal MIC distribution; 90% of the 
strains were inhibited by 2 mg/l or less. 
Imipenem- and meropenem resistance was occasionally 
found in 2000 and 2005; MIC90was 0.25 mg/l for 
imipenem and 0.125 mg/l for meropenem. Around 1-2% 
of strains had MIC 1-8 mg/l (table 4.7), which categorizes 
the strains as susceptible, but indicate the emergence of 
non Wild Type (WT) strains. Strains in the higher MIC 
range may form a problem in the treatment of infections 
at the currently recommended dosage schemes. 
Cefuroxime resistance levels rose from 9% to 20%  
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(figure 4.15).The MIC distribution changed to bimodal 
during the years with lowering of the peak at 4 mg/l and an 
increase of the resistant subpopulation with an MIC > 16 
mg/l (figure 4.17). Cefotaxime- and ceftazidime resistance 
increased slowly to 7.7% and 6% in 2010, respectively. 
The MIC distribution of cefotaxime became bimodal, that 
of ceftazidime remained unimodal over a broad range 
(figure 4.17). No highly resistant strains were found. 
Resistance to cefixime increased from 6% in 1998 to 
19% in 2010 like cefuroxime but its intrinsic activity was 
higher with 75% of strains susceptible to 0.1-0.5 mg/l 
cefixime compared to 1-8 mg/l of cefuroxime.
Gentamicin resistance ranged from 1-9% with 6% 
resistance in 2010 (figure 4.15). The fluctuations 
were caused by an unusual high resistance level in 
some centres (up to 15%); resistance was not found 
in all centres (figure 4.18). Therefore the increasing 
trend found does not reflect a real national trend and 
underlines the importance of local surveillance of 
resistance. The bimodal MIC distribution showed a large 
susceptible subpopulation with MIC 0.25-1 mg/l and a 
small subpopulation with MIC > 32 mg/l (figure 4.19). 
Amikacin resistance remained less than 1% over the 
years. The MIC distribution was unimodal over a broad 
range (0.5-8 mg/l). Incidentally strains with MIC > 32 
mg/l were found (figure 4.19). Tobramycin resistance was 
higher (4-9%) with 8% in 2010 (not shown).  
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Figure 4.17. MIC distributions of cephalosporins for Escherichia coli from Intensive Care Units.
Table 4.7. MIC distribution (% of strains) of meropenem for Escherichia coli from Intensive Care Units.
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Figure 4.18. Number of centres with gentamicin-resistant Escherichia 
coli on Intensive Care Units. Each color represents one specific centre.
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The MIC distribution of tobramycin resembled that of 
amikacin (not shown).
Trimethoprim resistance increased with fluctuations 
from 26% in 1998 to 34% in 2010 (figure 4.15). 
Co-trimoxazole resistance followed that trend at a 
somewhat lower level (32% resistance in 2010). The 
MIC distributions for co-trimoxazole (figure 4.20) were 
bimodal with one susceptible (MIC < 0.25 mg/l) and one 
highly resistant subpopulation (MIC > 16 mg/l).
Nitrofurantoin resistance was not found until 2001, 
increased to 4.5% in 2004 and decreased 1% in 2006 and 
remained less than 1 mg/l thereafter (figure 4.15).
Overall quinolone resistance (ciprofloxacin, norfloxacin, 
levofloxacin, moxifloxacin) increased from 1% in 1998 
to 17% in 2010 (figure 4.15). Quinolone resistance was 
found in 11 of 13 centres and the level of resistance varied 
between the centres from 5-53%. This underlines the 
importance of local surveillance. The MIC distributions 
were bimodal with a large susceptible subpopulation 
over a small range (< 0.12 -0.25 mg/l) and a small 
subpopulation of strains with MIC >8 mg/l (figure 4.21, 
only ciprofloxacin is shown). The intrinsic activity of 
ciprofloxacin remained superior: 70% of the isolates 
were susceptible to <0.03 mg/l ciprofloxacin compared to 
46% for levofloxacin, 32% for moxifloxacin and 4% for 
norfloxacin in 2010. 
Multiresistance of Escherichia coli in Intensive  
Care Units 
Resistance to three or more classes of antibiotics 
(multiresistance) was recorded for various combinations 
at increasing levels from 4% in 1998 to 17.7% in 
2010 (figure 4.22). A total of 10.8% was resistant to 
three classes, 4.2% to four and 2.7% to five classes of 
antibiotics. Resistance to the combination co-amoxiclav/
co-trimoxazole with another drug (cefuroxime / 
gentamicin / ciprofloxacin) was prevalent (12.6%). 
Numbers and origin of Intensive Care Units with 
multiresistant strains varied over time, but increased; 10 of 
14 Units had multiresistant strains in 2010 (figure 4.22). 
So multiresistance was a local problem, but becomes more 
and more a problem in most Intensive Care Units.
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Figure 4.19. MIC distributions of aminoglycosides for Escherichia coli from Intensive Care Units..
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Figure 4.20. MIC distributions of co-trimoxazole for Escherichia coli from 
Intensive Care Units.
Figure 4.21. MIC distributions of ciprofloxacin for Escherichia coli from 
Intensive Care Units.
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Klebsiella pneumoniae
Isolates tested (N): 884 
Trends. Resistance to all antibiotics tested increased 
slowly during the last five years of the study period 
(figure 4.23). Co-amoxiclav and piperacillin-tazobactam 
resistance reached levels of 32% and 10% respectively 
in 2010. The MIC distribution of piperacillin-tazobactam 
was clearly bimodal with one susceptible and one 
resistant subpopulation, the bimodality for co-amoxiclav 
was less prominent - the MICs of the strains were 
distributed over a broad range (figure 4.24). 
Carbapenem resistance was rare; MIC90 of meropenem 
was < 0.12 mg/l, but occasionally strains with an MIC 
1-4 mg/l were found in 2007 and 2010 in two centres. 
Resistance to all cephalosporins tested increased very 
rapidly from 2008 on, with levels of resistance of 12.5% 
for ceftazidime, 17% for cefotaxime, 33% for cefuroxime 
and 6-17% for the fourth generation cephalosporins 
(figure 4.23). The MIC distribution of cefuroxime 
(figure 4.25) showed a significant shift to the right in 
the susceptible subpopulation: the MIC50 was 1 mg/l in 
2008 compared to 2-4 mg/l in 2010. This “MIC creep” 
may predict further upcoming resistance in the near 
future. The MIC distributions of cefotaxime, ceftazidime 
and cefixime were similar, but here also a change was 
observed with lowering of the peak at MIC 0.012 
mg/l (80% of strains until 2009 and 60% in 2010) and 
appearance of high resistant strains with MIC > 16 mg/l 
(figure 4.25). 
Trimethoprim resistance increased with fluctuations 
over the years from 13% in 1998 to 33% in 2010. 
The resistance to co-trimoxazole followed this trend 
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Figure 4.22. Trends in multiresistance among Escherichia coli from Intensive Care Units and the number of centres with multiresistance. Each color 
represents one specific centre.
Figure 4.23. Trends in antibiotic resistance among clinical strains of Klebsiella pneumoniae from Intensive Care Units.
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at a lower level and reached 25% in 2010. The MIC 
distribution was bimodal (figure 4.26). 
Quinolone resistance showed an increasing trend from 
less than 1% for the four quinolones in 1998 to 22% 
(norfloxacin), 18% (ciprofloxacin, figure 4.23), 15% for 
levofloxacin and 16% for moxifloxacin (not shown).  
The MIC distributions of all quinolones tested showed 
the same pattern: change from unimodal over broad 
range with a peak at MIC < 0.03 mg/l to a bimodal 
shape with one subpopulation of susceptible strains 
and one with highly resistant strains (MIC > 32 mg/l. 
The appearance of so many strains in the intermediate 
area during the past years warned us for this change to 
bimodality and high resistance (figure 4.27).
Gentamicin-resistant strains were observed continuously 
in two Intensive Care Units from 1999 onward and 
intermittent in nine other Units resulting in large 
fluctuations in gentamicin resistance rates (0-23%) over 
the years of surveillance. Yet the increase that started in 
2009 seems to continue resulting in a mean resistance 
rate of 14% in 2009 and 15.5% in 2010 (figure 4.23). 
These figures are not representative for the individual 
Intensive Care Units and again underline the need for 
local surveillance. Tobramycin resistance followed 
the pattern of gentamicin increasing to 19% in 2010. 
The MIC distributions of gentamicin (figure 4.28) and 
tobramycin (not shown) showed significant changes 
compared to the years before: they became clearly 
bimodal (one subpopulation with MIC 0.12-1 mg/l and 
one with MIC > 32 mg/l) and showed a shift to the 
right with lowering of the peak at MIC 0.5 mg/l (80% 
of strains in 2008 were susceptible to 0.5 mg/l, 67% in 
2009 and 53% in 2010). Amikacin resistance was found 
sporadically in 2003 and 2004, but also here the MIC 
distributions showed a significant change in 2010 with 
lowering of the peak at 0.5 mg/l (70% of strains in 2007 
vs. 53% in 2010) and broadening of the range in the 
area 4-16 mg/l (24% of all strains). Such changes are 
predictable for emerging resistance. 
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Figure 4.24. MIC distributions of co-amoxiclav and piperacillin-tazobactam for Klebsiella pneumoniae from Intensive Care Units.
Figure 4.25. MIC distributions of cephalosporins for Klebsiella pneumoniae from Intensiv  e Care Units.
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Care Units
Multiresistance (resistance to three or more classes 
of antibiotics) was recorded yearly except in 2001 
at varying percentages; 22% of all strains were 
multiresistant in 2010 (figure 4.29). Multiresistance 
was not common in all centres and not found every 
year in a given centre (figure 4.29); it was often related 
to an outbreak or circulation of resistant clones in a 
centre and disappeared after appropriate measures were 
taken. Therefore these figures are not representative 
for the country as a whole, but the overall increasing 
trend is a matter of concern. Resistance to four classes 
of antibiotics was common (17.8%) among which the 
combination with gentamicin was prevalent (15.7%). 
Enterobacter cloacae
Isolates tested (N): 722
Trends.The resistance trends for E. cloacae strains were 
evaluated from 2003 onward; resistance to piperacillin-
tazobactam fluctuated around 15% (figure 4.30). 
Ceftazidime resistance fluctuated around 25% without 
a significant increase, that of cefotaxime increased to 
33% in 2010. Resistance to cefixime and ceftibuten were 
also increasing to high levels (50-70%, not shown); the 
resistance level of cefepime fluctuated between 0% and 
13%. The fluctuations were partly related to existence 
and circulation of resistant clones in some Intensive Care 
Units. Therefore the overall resistance percentage does not 
reflect the general situation in Intensive Care Units and 
does not indicate a trend. Because of the high resistance 
rates and the presence of an inducible chromosomal beta-
lactamase in every Enterobacter spp, cephalosporins and 
penicillins are not recommended as empiric therapy in 
Intensive Cares with circulating E. cloacae strains.
Imipenem- and meropenem resistance was rare (3% in 
2003, 0% thereafter). The intrinsic activity of meropenem 
(MIC90 < 0.06 mg/l) was significantly higher than that of 
imipenem (MIC90= 0.25 mg/l) with less strains in the area 
with MIC 1-8 mg/l.
Co-trimoxazole resistance increased with annual 
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Figure 4.26. MIC distributions of co-trimoxazole for Klebsiella 
pneumoniae from Intensive Care Units.
Figure 4.27. MIC distributions of ciprofloxacin for Klebsiella pneumoniae 
from Intensive Care Units.
St
ra
ins
 (%
) 
Klebsiella pneumoniae - Intensive Care Units - SIRIN
<=0.12 0.25 0.5 1 2 4 8 16 >16
cefuroxime
0
20
40
60
80
100
<=0.120.25 0.5 1 2 4 8 16 >16
0
20
40
60
80
100
cefotaxime
1998 
1999 
2000 
2001 
2002 
2003 
2005 
2006 
2007 
2008 
2009 
2010 
2004 
Minimal Inhibitory Concentration (mg/l)
Figure 4.28. MIC distributions of aminoglycosides for Klebsiella pneumoniae from Intensive Care Units.
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fluctuations from 5% in 2003 to 11% in 2010.  
Ciprofloxacin resistance increased from 7% in 2003 to 
28% in 2008 with a sharp decrease to 14% in 2009 and 
8% in 2010. These fluctuations were due to the existence 
of strains around the breakpoint of 1 mg/l (figure 4.31). 
The MIC distributions of the quinolones showed a 
consistent unimodal shape over a broad range with a large 
subpopulation with MIC < 0.12 mg/l (70-80%) and small 
subpopulations with MIC 1-16 mg/l. Co-resistance with 
gentamicin and tobramycin occurred in 50% or more of 
ciprofloxacin-resistant strains.
Gentamicin resistance was recorded in 10 of 14 centres 
during the study period, but only in 1-5 centres each year 
(figure 4.32); the overall resistance was 5-10% with two 
peaks in 2008 (19%) and 2009 (13%) respectively. There 
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Figure 4.30. Trends in antibiotic resistance (2003-2010) among clinical 
strains of Enterobacter cloacae from Intensive Care Units.
Figure 4.31. MIC distributions of ciprofloxacin for Enterobacter cloacae 
from Intensive Care Units.
Figure 4.29. Trends in multiresistance among Klebsiella pneumoniae and number of centres with multiresistant Klebsiella pneumoniae from Intensive Care 
Units. 
Figure 4.32. Number of centres with gentamicin-resistant Enterobacter 
cloacae on Intensive Care Units. Each color represents one specific 
centre.
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was complete cross resistance with tobramycin, but not 
with amikacin (21% of strains). The MIC distribution for 
gentamicin was bimodal with a susceptible subpopulation 
(MIC < 2 mg/l) and a small resistant one (MIC > 
16mg/l) (figure 4.33). Small subpopulations with MIC 
4- 8 mg/l appeared from 2004 on; the appearance of 
less susceptible strains is a warning signal of emerging 
resistance and underlines the importance of the 
longitudinal evaluation of the MIC distributions. Overall 
amikacin resistance was sporadic. 
Proteus mirabilis 
Isolates tested (N): 549 
Trends.The resistance trends for P. mirabilis strains were 
evaluated from 2003 onward. Amoxicillin resistance 
was stable at 27%; co-amoxiclav resistance was low. 
No resistance to imipenem, meropenem was observed; 
resistance to cefuroxime (3-7%), cefotaxime (2%) or 
ceftazidime (2%) were rather stable over the years 
with some exceptions in some Intensive Care Units. 
Gentamicin and tobramycin resistances fluctuated (0-
9%) and were overall 4% in 2010, amikacin resistance 
was lower (0-2%). The fluctuations were related to 
certain Intensive Care Units and do not reflect a general 
trend. Co-trimoxazole resistance was 26% in 2010 and 
quinolone resistance was 4-5% until 2009, but increased 
to 11% in 2010.
Pseudomonas aeruginosa
Isolates tested (N): 1579 
Trends. Piperacillin resistance among P. aeruginosa was 
not found until 2000, it increased to 15% in 2002 and 
stabilized around 10-15% during the following years 
(figure 4.34). The MIC distributions of piperacillin (and 
piperacillin-tazobactam) became bimodal after 2000 with 
emergence of a small resistant subpopulation (MIC > 64 
mg/l) (figure 4.35). 
Meropenem resistance was less than 2% until 2006, 
increased then to 8% in 2010 (figure 4.34). Resistant 
strains were found in 10 centres throughout the study 
years, but never more than in four centres yearly. 
Meropenem resistance appeared to be a local temporary 
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Figure 4.34. Trends in antibiotic resistance among clinical strains of 
Pseudomonas aeruginosa from Intensive Care Units.
Figure 4.35. MIC distributions of piperacillin for Pseudomonas aeruginosa 
from Intensive Care Units.
Figure 4.33. MIC distributions of aminoglycosides for Enterobacter cloacae from Intensive Care Units.
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problem for most centres and is not representative for The 
Netherlands as a whole. Concern is the increase of strains 
with MIC 1-8 mg/l (table 4.8), which are categorized 
susceptible, but may require higher dosing of meropenem. 
Ceftazidime resistance fluctuated but the trend was 
increasing from 1% in 1998 to 11 % in 2010. Like for 
meropenem, resistance was recorded in a part of the 
centres (N=5-6), so the current resistance levels reflect 
local problems with highly resistant populations rather 
than a general problem. Gentamicin resistance was 
recorded in 13 centres during the whole study period, but 
never more than in six centres per year; this may explain 
the yearly variations in the total resistance level of 4-10% 
(figure 4.34). The same was found for tobramycin; 
amikacin resistance varied from 0-4%. A total 63% of 
gentamicin-resistant strains were tobramycin-resistant 
and 27% were amikacin-resistant; 84% of tobramycin-
resistant strains were gentamicin-resistant and 31% were 
amikacin-resistant. The MIC distributions of gentamicin 
(not shown) and tobramycin were bimodal with one 
subpopulation with MICs over a broad range (0.12-4 
mg/l and a very small resistant subpopulation (MIC > 
16 mg/l, figure 4.36). The MIC distribution of amikacin 
was unimodal over a broad range from 0.5-> 16 mg/l. 
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Figure 4.36. MIC distributions of aminoglycosides for Pseudomonas aeruginosa from Intensive Care Units. 
Minimal Inhibitory Concentration (mg/l)
Year <=0.12 0.25 0.5 1 2 4 8 16 32 >32
'98 10.6 22.4 34.1 18.8 5.9 3.5 3.5 1.2 - - 
'99 6.8 37.8 27.0 16.2 6.8 4.1 1.4 - - - 
'00 25.4 27.0 14.3 15.9 7.9 6.3 1.6 1.6 - - 
'01 27.3 40.3 15.6 6.5 5.2 2.6 1.3 1.3 - - 
'02 35.2 23.1 26.4 5.5 5.5 2.2 2.2 - - - 
'03 47.6 23.8 10.5 7.6 6.7 1.0 1.0 - - 1.9 
'04 59.0 15.6 17.2 0.8 1.6 2.5 0.8 0.8 - 1.6 
'05 50.8 18.5 8.1 5.6 11.3 1.6 2.4 1.6 - - 
'06 58.8 14.7 8.8 4.9 6.9 2.0 2.9 - 1.0 - 
'07 38.5 23.9 17.4 5.5 4.6 2.8 2.8 3.7 0.9 - 
'08 43.0 23.7 14.1 5.2 5.9 2.2 2.2 1.5 - 2.2 
'09 33.7 16.0 15.4 9.5 8.9 1.8 4.1 0.6 4.1 5.9 
'10 40.4 21.3 14.9 5.0 1.4 7.1 2.1 7.1 0.7 - 
Table 4.8. MIC distribution (% of strains) of meropenem for Pseudomonas aeruginosa from Intensive Care Units
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Figure 4.37. MIC distributions of ciprofloxacin for Pseudomonas 
aeruginosa from Intensive Care Units.
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Figure 4.38. Trends in antibiotic resistance among clinical strains of 
Staphylococcus aureus from Intensive Care Units.
Tobramycin had the highest intrinsic activity with MICs 
two-fold lower than those of gentamicin and four-fold 
lower than those of amikacin. 
Quinolone resistance fluctuated strongly (figure 4.34) 
during the study period and stabilized in 2010 at 25% for 
ciprofloxacin (figure 4.34) and 32% for levofloxacin (not 
shown). The MIC distributions (figure 4.37) remained 
unimodal over a broad range of MICs, but the whole 
population moved slowly to higher MICs during the 
study period: 90% of strains were susceptible to 0.5 mg/l 
ciprofloxacin or less in 1998 versus 70% in 2010. These 
figures were 70% and 45%, respectively for levofloxacin. 
Enterococcus faecalis
Isolates tested (N): 1091 
Trends. A total of 19 isolates of E. faecalis appeared 
amoxicillin resistant (2%); these strains were found 
occasionally in six centres during 1-4 years; 18 were also 
resistant to imipenem. two were vancomycin resistant of 
which one was also teicoplanin resistant. The latter strain 
was co-resistant to linezolid, quinupristin/dalfopristin a nd 
chloramphenicol.
Imipenem resistance fluctuated between 1% and 14% 
without a real trend; such strains were incidentally 
found in 11 centres over the years. It is therefore a local 
problem rather than a national phenomenon. 
Vancomycin resistance was found in one centre in 2003 and 
in another in 2007, teicoplanin resistance was not found.
Staphylococcus aureus
Isolates tested (N): 1466 
Trends. MRSA strains were occasionally isolated 
(1.2%). Eight of 17 MRSA strains were co-resistant to 
ciprofloxacin, six also to clarithromycin, and one also to 
gentamicin. 
Table 4.9. Resistance levels among Enterobacteriaceae and Pseudomonas aeruginosa in Intensive Care Units in 2010.
Antibiotic E. coli K. pneumoniae E. cloacae P. mirabilis P. aeruginosa
amoxicillin 60 27
co-amoxiclav 44 32 100 2
piperacillin 43 39 30 6 11
piperacillin-tazobactam 3 10 14 0 12
carbapenem 0 0 0 0 8
cefuroxime 20 33 2
cefotaxime/ceftriaxone 8 17 33 2
ceftazidime 6 13 32 0 11
ceftibuten 13 10 38 2
cefixime 20 17 58 2
cefepime 4 6 2 0
gentamicin 6 16 4 4 4
tobramycin 8 19 4 4 4
amikacin 1 0 0 2 0
trimethoprim 34 33 12 39
co-trimoxazole 32 25 11 26
norfloxacin 19 24 11 15
ciprofloxacin 17 18 8 11 25
levofloxacin 16 15 4 2 32
moxifloxacin 17 16 10 15
nitrofurantoin 1 19 0 61
increasing since 2005
decreasing since 2005
stable since 2005
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Clarithromycin resistance increased from 5% in 1998 
to 12% in 2010 (figure 4.38). Clindamycin resistance 
fluctuated around 2-4% over the years without a shift 
or clear trend, indicating that MLSb resistance is stable, 
and the increase of macrolide resistance is due to efflux 
or other mechanisms. Doxycycline resistance remained 
6-8% during the last years, co-trimoxazole resistance was 
low (2-3%).
Gentamicin resistance remained less than 1% (not 
shown). Ciprofloxacin resistance increased from 4% 
in 1998 to 16% in 2005, decreased to 9% in 2006 and 
remained at that level since (figure 4.38). Moxifloxacin 
resistance followed this trend at a lower level (8% in 
2010). MIC90 was 8 mg/l for ciprofloxacin and 0.5 mg/l 
for moxifloxacin in 2010. 
Resistance rates to rifampicin, linezolid and quinupristin/
dalfopristin were less than 1% (not shown). Vancomycin 
resistance was once recorded in 2006 and 2010, 
teicoplanin resistance once in 2003. 
Staphylococcus epidermidis
Isolates tested (N): 694 
Trends. About 80% of all strains of S. epidermidis 
were methicillin-resistant; 75% of methicillin-resistant 
strains were co-resistant to erythromycin, clarithromycin, 
gentamicin and ciprofloxacin. Mean resistance levels for 
clarithromycin were 77%, clindamycin 60%, gentamicin 
74%, ciprofloxacin 74% and for moxifloxacin 52%. 
Rifampicin resistance fluctuated around 20% (figure 
4.39). Vancomycin-resistance was occasionally found 
in 1-2 centres per year since 2002. Three vancomycin-
resistant strains were also teicoplanin-resistant (MIC 8, 
64, 256 mg/l, respectively). Teicoplanin resistance was 
observed intermittently in nine centres with 10% overall 
resistance in 2010. Linezolid resistance was sporadic.
High resistance levels among S. epidermidis from 
Intensive Care Units are common and reflect the high 
selective pressure in these wards. They belong to specific 
populations circulating in Intensive Care Units and their 
resistance levels may differ from Unit to Unit. Such 
populations may serve as a reservoir for multiresistance 
with the risk of exchange of resistance factors to other 
micro-organisms in the commensal flora of patients and 
health care workers.
Intensive Care Units - Conclusion  
(see also table 4.9)
1. Increasing and/or high resistance to co-
amoxiclav, piperacillin and cephalosporins 
among Enterobacteriaceae except in P. mirabilis.
2. Carbapenem resistance was rare among 
Enterobacteriaceae, but occasionally among  
P. aeruginosa in some centres. Concern for 
strains with MIC 1-8 mg/l, reflecting creeping 
MIC values which often remain unnoticed in 
routine susceptibility testing.
3. Aminoglycoside resistance not in all centres; if 
found: low and stable in E. coli, increasing in  
K. pneumoniae, decreasing in E. cloacae.
4. Co-trimoxazole- and quinolone resistance was 
high, increasing in K. pneumoniae and  
P. mirabilis.
5. Increasing multiresistance among E. coli and  
K. pneumoniae. 
6. Empiric therapy for suspected Gram-negative 
infections in Intensive Care Units requires wide-
spectrum antibiotics in most centres such as 
combination therapy or carbapenems.
7. Amoxicillin resistance among E. faecalis is 
low (2%) and centre-related; vancomycin- en 
teicoplanin resistance not found in 2010. 
8. Resistance among S. aureus low for all antibiotics 
tested, MRSA 1.2%.
9. Resistance among S. epidermidis high for most 
antibiotics. 
10. The MIC distributions over time identified 
significant “MIC creeps” for cephalosporins 
(K. pneumoniae), meropenem (P. aeruginosa), 
quinolones (K. pneumoniae, P.aeruginosa) and 
aminoglycosides (K. pneumoniae, E. cloacae) 
which predict upcoming resistance in the 
following years.
11. High resistance levels to aminoglycosides, 
ceftazidime, meropenem and quinolones 
among Enterobacteriaceae, P. aeruginosa and 
multiresistance are centre-related. This underlines 
the need of both local and national surveillance. 
4.2.5 Urology Services - SIRIN
Escherichia coli
Isolates tested (N): 8149 
Trends. Amoxicillin resistance increased to 47% in 
2010 (figure 4.40); co-amoxiclav resistance was steadily 
increasing from 19% in 1998 to 30% in 2009 en 2010. 
Piperacillin- (40%) and piperacillin-tazobactam (2%) 
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Figure 4.39. Trends in antibiotic resistance among clinical strains of 
Staphylococcus epidermidis from Intensive Care Units.
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Figure 4.40. Trends in antibiotic resistance among clinical strains of Escherichia coli from Urology Services.
Figure 4.42. Trends in multiresistance among Escherichia coli from Urology Services and the number of centres. Each color represents one specific centre. 
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Figure 4.41. Number of centres with gentamicin-resistant Escherichia 
coli on Urology Services. Each color represents one specific centre.
resistances were similar to those found in Intensive Care 
Units. Carbapenem resistance was rare.
Cephalosporin resistance levels were consistently lower 
than those recorded for Intensive Care Units, but slowly 
increasing with resistance to cefuroxime 12%, cefotaxime 
6%, ceftazidime 3%, cefixime 9% and ceftibuten 4%.
Gentamicin- and tobramycin resistance was found in all 
centres since 2003 at low levels (figure 4.40 and 4.41). 
Amikacin resistance remained less than 1%. 
Trimethoprim resistance increased from 31% to 38% in 
2002 and remained around that level, co-trimoxazole 
resistance showed the same trend at a lower level (36% in 
2010), both levels being consistently higher compared to 
those in Intensive Care Units.  
Ciprofloxacin resistance level increased to 25% in 2010. 
The same levels were found for norfloxacin, levofloxacin 
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and moxifloxacin. The MICs showed the same 
distributions as found in strains from Intensive Care Units. 
Nitrofurantoin resistance increased from 0% in 1998 to 
5% in 2002 and stabilized at 3% since 2003 (figure 4.40).
Multiresistance of Escherichia coli in Urology Services
Surprisingly a higher rate of multiresistance was found 
in Urology Services compared to Intensive Care Units 
(figure 4.42), increasing from 6% of all strains in 1998 
to 16.7% in 2010. A total of 696 multiresistant strains 
were isolated during the whole study period (9.8% of 
all). Resistance to three classes increased from 2.9% in 
1998 to 9.4% in 2010, to four classes from 1.9% to 6% 
and to five classes from 0.4% to 1.3%. The combination 
co-amoxiclav/co-trimoxazole/ ciprofloxacin was most 
prominent. Multiresistance was found in almost all 
centres since 2006 (figure 4.42); reflecting a national 
problem.
Klebsiella pneumoniae
Isolates tested (N): 1082 
Trends. Co-amoxiclav resistance increased from 4% in 
1998 to 20% in 2010 (figure 4.43).
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Figure 4.43. Trends in antibiotic resistance among clinical strains of Klebsiella pneumoniae from Urology Services.
Figure 4.45. Trends in multiresistance among Klebsiella pneumoniae and number of centres with multiresistant Klebsiella from Urology Services. 
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Figure 4.44. MIC distributions of trimethoprim for Klebsiella pneumoniae 
from Urology Services.
Piperacillin-tazobactam resistance fluctuated at a low 
level (0-6%) and was only found in a few centres. So the 
piperacillin-tazobactam resistance found did not reflect 
the resistance level for Urology Services as a whole.  
Carbapenem resistance was not found.
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broadening of the susceptible subpopulation (MIC 0.25-8 
mg/l) from 2000 onward, flattening of the peak at 1 mg/l 
and appearance of small and growing subpopulations with 
MIC 8 ->16 mg/, resulting in resistance in the following 
years. Such creeping MICs are predictable for upcoming 
resistance. 
Piperacillin resistance fluctuated at low levels (4% in 
2010); no resistance to piperacillin-tazobactam was 
recorded. Imipenem- and meropenem resistance was not 
found.
Cefuroxime resistance fluctuated from 0-4%; resistance to 
the other cephalosporins was sporadically found. 
Trimethoprim resistance was fluctuating and high 
with 50% of all strains resistant until 2007, thereafter 
a decrease followed to 39% in 2010. Co-trimoxazole 
resistance levels were lower and decreased to 18% in 
2010 (not shown).
Gentamicin resistance increased from 3% in 1998 to 8% 
in 2008 and decreased to 3% in 2010 (figure 4.46). These 
fluctuations were due to emergence of resistant strains 
in 2-6 centres each year, underlining the value of local 
surveillance.
Resistance to cefuroxime increased since 2007 (3.5%) to 
16% in 2010 (figure 4.43). Ceftazidime and cefotaxime 
resistance were slightly increasing to 4% and 7% 
respectively.
Trimethoprim resistance increased slowly from 29% in 
1998 to 34% in 2001 and remained stable with some 
fluctuations, which might be explained by the existence 
of strains with MICs 4-8 mg/l, which is around the 
breakpoint for resistance (figure 4.44). The resistance to 
co-trimoxazole followed the trend of trimethoprim with a 
total increase from 12% in 1998 to 24% in 2010. 
Gentamicin and tobramycin resistance was less than 6% in 
2010 and not common in all Urology Services. Amikacin 
resistance was not found.
Nitrofurantoin was stable at 23-27% throughout the 
years. Quinolone resistance increased slowly to 21% 
for norfloxacin and 9% for ciprofloxacin. The MIC 
distributions of all quinolones were comparable to those 
found for strains from Intensive Care Units (figure 4.27)
Multiresistance of Klebsiella pneumoniae in Urology 
Services
Multiresistance in Urology Services increased to 9.8% in 
2010, which is much less frequent than in Intensive Care 
Units. The rate of multiresistance found in Klebsiella in 
Urology Services was lower than the rate found in E. coli 
strains (figure 4.45). 
Proteus mirabilis
Isolates tested (N): 1.104 
Trends. Amoxicillin resistance increased from 18% in 
1998 to 37% in 2004 and decreased subsequently to 
21% in 2010 (figure 4.46). The distribution of MICs was 
bimodal with a susceptible subpopulation over a small 
range in most years (MIC 0.5-1.0 mg/l) and a resistant 
one with MICs >8 mg/l (figure 4.47). Co-amoxiclav 
resistance increased from 1% in 1998 to 5% in 2010. 
The unimodal MIC distribution (figure 4.47) showed a 
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Figure 4.46. Trends in antibiotic resistance among clinical strains of 
Proteus mirabilis from Urology Services.
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Figure 4.47. MIC distributions of amoxicillin and co-amoxiclav for Proteus mirabilis from Urology Services. 
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Figure 4.48. MIC distributions of ciprofloxacin for Proteus mirabilis from 
Urology Services. 
Quinolone resistance fluctuated considerably, which was 
exclusively due to the existence of strains with MICs 
1-2 mg/l (figure 4.48), which is near the breakpoints 
of norfloxacin (1 mg/l), ciprofloxacin (1 mg/l) and 
levofloxacin (2 mg/l). The MIC distributions of the 
quinolones are similar, but the difference in breakpoints 
resulted in a 16% resistance to norfloxacin, 14% for 
ciprofloxacin and 4% for levofloxacin in 2010
Pseudomonas aeruginosa
Isolates tested (N): 610 
Trends. Piperacillin resistance was occasionally found, 
fluctuating between 0% and 7%. Meropenem resistance 
was found only once in 2003. Ceftazidime resistance was 
consistently low (0-5%) without a trend. 
Aminoglycoside resistance was found sporadically. 
Ciprofloxacin resistance levels calculated (0-25%) 
fluctuated strongly because of the existence of many strains 
with MIC around the breakpoint. From the levels calculated 
one may conclude that resistance increased since 2006, but 
no significant change in the shape of the MIC distributions 
was observed during the study period, which shows that 
resistance percentages without data from quantitative 
methods are not reliable for demonstration of trends. 
Enterococcus faecalis
Isolates tested (N): 1.656 
Trends. Amoxicillin resistance was found in 17 strains (1%) 
from eight centres between 2002 and 2007, only once per 
centre. Seven (out of 17) were co-resistant to vancomycin, 
teicoplanin, linezolid and quinupristin/dalfopristin. 
Vancomycin resistance (12 strains) was found once in three 
centres in 2003 and 2004. All but one was also teicoplanin 
resistant, which is evidence for clonal spread of a VanA gene 
positive strain. MICs for both drugs were >128 mg/l.
Table 4.10. Resistance levels (%) among Enterobacteriaceae and Pseudomonas aeruginosa in Urology Services participating in SIRIN in 2010.
Antibiotic E. coli K. pneumoniae P. mirabilis P. aeruginosa
amoxicillin 47 21
co-amoxiclav 30 20 5
piperacillin 40 4 7
piperacillin-tazobactam 2 7 0
carbapenem 0 0 0 2
cefuroxime 12 16 1
cefotaxime/ceftriaxone 6 7 0
ceftazidime 3 4 0 2
ceftibuten 4 4 1
cefixime 9 7 1
cefepime 2 2 0
gentamicin 6 6 3 3
tobramycin 6 5 3 4
amikacin 1 0 2 0
trimethoprim 38 35 39
co-trimoxazole 36 24 18
norfloxacin 26 21 16
ciprofloxacin 25 9 14 18
levofloxacin 25 9 4 24
moxifloxacin 26 11 17
nitrofurantoin 3 28 52
increasing since 2005
decreasing since 2005
stable since 2005
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4.2.6 Pulmonology Services - SIRIN
Streptococcus pneumoniae
Isolates tested (N): 1883 
Trends. Penicillin resistance among S. pneumoniae was 
less than 1% during the whole study period with 0.5% in 
2010 (figure 4.49).  
Cefaclor resistance increased further to 59% in 2010 with 
a significant shift to the right side within the susceptible 
area, beginning in 2000 (MIC90 0.25-0.5 mg/l) and 
moving many strains into the resistant area (MIC > 
1mg/l) from 2007 on, resulting in MIC90 = 2mg/l in 2010 
(figure 4.50). Cefuroxime resistance remained less than 
4% (figure 4.50). Clarithromycin resistance increased 
further to 14% (figure 4.49), clindamycin resistance 
fluctuated around 6% from 2005 onward, indicating that 
the increase in macrolide resistance is mainly due to 
efflux mechanisms. (not shown). Doxycycline resistance 
level was stable at 12% during the whole study period 
(figure 4.49). The MIC distribution was bimodal with 
one susceptible (MIC < 0.5 mg/l) and one resistant 
subpopulation (MIC > 16 mg/l). 
Co-trimoxazole resistance was 3-6% during the whole 
study period.  
Moxifloxacin resistance was 1-3%, without significant 
changes over time (figure 4.49); MIC90 was 0.12 mg/l. 
Haemophilus influenzae
Isolates tested (N): 3060
Trends. Amoxicillin resistance among H. influenzae 
increased with fluctuations from 8% in 1998 to 17% in 
2010, whereas the resistance to co-amoxiclav fluctuated 
between 4-7% during the last years (figure 4.51). 
The latter resistance mechanism is not based on beta-
lactamase production. The unimodal MIC distribution 
(figure 4.52) of amoxicillin became bimodal in 2005 and 
the susceptible subpopulation moved to the right side: 
Urology Services - Conclusion (see also table 4.10)
1. High and increasing resistance to penicillins, 
cefuroxime, trimethoprim, co-trimoxazole and 
quinolones among Enterobacteriaceae is matter of 
concern.
2. Aminoglycoside resistance remained low (max 6%)
3. Multiresistance is increasing and found in all 
centres
4. The MIC distributions over time identified 
significant “MIC creeps” for co-amoxiclav  
(P. mirabilis) and quinolones (K. pneumoniae), 
which predict upcoming resistance in the following 
years.
5. Nitrofurantoin is still the drug of 1st choice for 
uncomplicated E. coli infections
6. Empiric therapy with any of the existing oral drugs 
cannot be advised in complicated UTI, except for 
suspected infection by P. mirabilis (co-amoxiclav).
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Figure 4.50. MIC distributions of cefaclor for Streptococcus pneumoniae 
from Pulmonology Services.
Figure 4.51. Trends in antibiotic resistance among clinical strains of 
Haemophilus influenzae from patients of Pulmonology Services.
Figure 4.49. Trends in antibiotic resistance among clinical strains of 
Streptococcus pneumoniae from Pulmonology Services.
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80-90% of strains had MIC 0.5 mg/l until 2005, compared 
to 27% in 2010. The same shift to the right within the 
susceptible population was observed for co-amoxiclav. 
This may predict upcoming resistance and it is a matter of 
concern. 
Clarithromycin resistance (MIC > 32 mg/l) was (3-6%). 
The MIC distribution (figure 4.53) showed that > 90% of 
strains have MIC 4-16 mg/ l (intermediate area), whereas 
only 1-2% can be categorized as susceptible (MIC < 1 
mg/l). Doxycycline resistance was 8-10% in the first years 
of study and decreased to 6% in 2010. 
A matter of concern is the high resistance to co-
trimoxazole (19% in 2010), indicating that co-trimoxazole 
should not be used as empirical therapy for COPD 
exacerbations. 
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Figure 4.52. MIC distributions of amoxicillin and co-amoxiclav for Haemophilus influenzae from Pulmonology Services.
Table 4.11. Resistance levels (%) in respiratory pathogens in Pulmonology Services participating in SIRIN in 2010.
Antibiotic S. pneumoniae H. influenzae M. catarrhalis
penicillin 0.5
amoxicillin 17 40
co-amoxiclav 5 0
cefaclor 59 100
cefuroxime 4 0
clarithromycin 14 3 1
clindamycin 6 0
doxycycline 12 6 0
co-trimoxazole 3 19 3
ciprofloxacin 3 0
moxifloxacin 2 0
increasing since 2005
decreasing since 2005
stable since 2005
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Figure 4.53. MIC distributions of clarithromycin for Haemophilus 
influenzae from Pulmonology Services.
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Moraxella catarrhalis
Isolates tested (N): 1197 
Trends. Amoxicillin resistance among was 50-60% over 
the whole study period. This resistance was completely 
due to beta-lactamase production since resistance to co-
amoxiclav was not observed.  
Cephalosporin resistance was low in all Pulmonology 
Services. According to the new cefaclor breakpoint for 
resistance (> 0.12 mg/l) all M. catarrhalis strains were 
considered resistant. No resistance to cefuroxime (MIC90 
1 mg/l), cefotaxime (MIC90 0.5 mg/l) and ceftazidime 
(MIC90< 0.12 mg/l) was observed and no significant 
changes in MIC distributions were found. Clarithromycin 
resistance was 1-3% and did not show any changing 
trend; the same was found for clindamycin. Doxycycline 
resistance was 4-8% until 2001 and decreased thereafter 
to 1% or less. Co-trimoxazole resistance was 0-3% (not 
shown). Ciprofloxacin resistance was found once in 2005, 
moxifloxacin resistance was not found.
Pulmonology Services - Conclusion  
(see also table 11)
1. Penicillin or amoxicillin for treatment of 
respiratory tract infections by pneumococci remain 
first choice
2. The MIC creep for cefaclor among pneumococci, 
identified in 2000, resulted in progressive 
resistance since 2007.
3. Empiric therapy with amoxicillin is not advised 
when other pathogens then pneumococci may play 
a role. Co-amoxiclav or doxycycline may be useful 
alternatives.
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The resistance data of the species tested in the various 
patient populations in 2010 were compared for level 
and trend observed over the whole study period in each 
population. 
Escherichia coli
In general: the highest resistance levels of penicillins and 
cephalosporins were observed in Intensive Care Units, 
those of co-trimoxazole and ciprofloxacin in Urology 
Services; resistance levels in Nursing Homes, Outpatient 
Departments and Unselected Hospital Departments are 
roughly equal and higher than in Selected GP patients 
whereas the latter are higher than in GP patients from 
the community (figure 5.1). These findings reflect 
specific use of these antibiotics in specific settings 
and previous contact/use/exposure in all study groups 
except GP patients from the community. Co-amoxiclav 
resistance was 44% in Intensive Care Units, 30% in 
Urology Services, 20-23% in Nursing Homes, Outpatient 
Departments and Unselected Hospital Departments, 
16% in selected GP patients and 14% in GP patients in 
the community (figure 5.1). The use of co-amoxiclav 
for empirical therapy in any patient group should be 
reconsidered. Cefuroxime resistance showed the same 
pattern for the different populations: Intensive Care 
Units 20%, GP patients 6% and 10-12% for the other 
study groups (figure 5.1). Also resistance to cefotaxime 
and ceftazidime showed similar prevalence, although at 
lower level. Concern is the increasing resistance to all 
cephalosporins in all study groups, most in Intensive 
Care Units during the last three years and it might be 
interesting to investigate whether this is associated with 
change of antibiotic treatment and prophylaxis regimens. 
Carbapenem resistance is still very exceptional, but the 
emerging number of strains with MIC 1-8 mg/l is a matter 
of concern. These strains are categorized susceptible 
in routine susceptibility testing but may form a serious 
problem for the treatment of severe infections without 
dosing adjustments.
Aminoglycoside resistance is 5-6% in all study groups 
including Nursing Homes, except in the community 
(<1%). Gentamicin is not often used outside the hospital; 
this finding suggests previous use of gentamicin in all 
patients groups except those from the community or 
colonization with strains co-resistant to gentamicin 
after treatment with another antimicrobial drug. 
Aminoglycoside resistance in Intensive Care Units 
appeared mostly a local problem was, which underlines 
the importance of local surveillance. 
Co-trimoxazole resistance was 36% in Urology Services, 
32% in Intensive Care Units, 23-26% in Unselected 
Hospital Departments, Outpatient Departments and 
selected GP patients and 19% in Nursing Homes and the 
community (figure 5.1). The latter is decreasing, which 
may be the result of the change in the Dutch Standard 
for treatment of uncomplicated UTI in 2005 when 
trimethoprim was replaced by nitrofurantoin as a first 
choice. 
Ciprofloxacin resistance was 25% in Urology Services, 
16-17% in Intensive Care Units, Outpatient Departments 
and Nursing Homes, 10% in selected GP patients and 
5% in the community. Extensive use of this drug in most 
hospital- and Outpatients Departments and Nursing 
Homes may lead to further increasing resistance.  
A matter of concern is the increasing multiresistance in 
Intensive Care Units and Urology Services.
Klebsiella pneumoniae
The highest resistance levels for all antibiotics were 
observed in Intensive Care Units and Urology Services 
(figure 5.1). Further the same prevalence as for 
E. coli was observed: (1) comparable resistance levels 
in Selected GP patients, Outpatient Departments and 
Unselected Hospital Departments for co-amoxiclav, 
cefuroxime and co-trimoxazole; (2) resistance levels 
of parenteral antibiotics (cefotaxime/ceftriaxone, 
gentamicin) were somewhat lower in selected GP 
patients, Outpatient Departments compared to Unselected 
Hospital Departments. Carbapenem resistance remained 
exceptional. 
Resistance to most cephalosporins is increasing, most 
in Intensive Care Units. Attention needs the increasing 
aminoglycoside resistance in Intensive Care Units and in 
Unselected Hospital Departments. 
Increasing resistance was recorded for all quinolones in 
all study groups. A matter of concern is the increasing 
resistance to fosfomycin in selected GP patients and 
Outpatient Departments; this may reflect frequent use 
as an alternative therapy for UTI after failure of 1st 
choice drugs (nitrofurantoin and trimethoprim or co-
trimoxazole). 
Multiresistance is increasing in Intensive Care Units, 
although not in all, but needs careful attention. 
Proteus mirabilis
Amoxicillin was replaced by co-amoxiclav for 
complicated UTI in the last decade because of resistance 
to amoxicillin and this may have led to the 10-12% 
resistance for co-amoxiclav now found in selected GP 
patients, Outpatient Departments and Unselected Hospital 
Departments (figure 5.1). Co-trimoxazole resistance 
was highest in selected GP patients and Outpatient 
Departments, obviously as result of previous exposure. 
The 7-10% resistance level of ciprofloxacin in selected 
GP patients, Outpatient Departments and Unselected 
Hospital Departments confirm the assumption that these 
patients have been exposed to quinolones before since no 
resistance was found in the community. 
5 Comparison of resistance in patient populations
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Pseudomonas aeruginosa
Resistance levels to all antibiotics tested were the 
highest in Intensive Care Units (figure 5.1); this was 
most frequently due to circulation of resistant clones in 
a limited number of centres, which underlines again the 
value of local surveillance. Aminoglycoside resistance 
remained low in general in all study groups. Ciprofloxacin 
resistance was high in Intensive Care Units (25%), 
Urology Services (18%) and lower in Outpatients 
Departments (12%). Unfortunately no alternative but 
parenteral antibiotics in Pseudomonas infection can be 
advised in case of quinolone resistance. 
Staphylococcus aureus
MRSA prevalence was 2.6% in Nursing Homes, 
compared to 1.8% in Unselected Hospital Departments 
and 1.1% in Intensive Care Units. Macrolide resistance 
is increasing to 10-11% in hospitals, which is matter of 
concern since a macrolide is the alternative for patients 
with known penicillin allergy. Ciprofloxacin resistance 
is high in Nursing Homes (23%) compared to 9% in 
hospitals. Glycopeptide resistance is exceptional.
Streptococcus pneumoniae
Penicillin resistance was higher in strains from Unselected 
Hospital Departments (2%) compared to that in strains 
from Pulmonology Services (< 1%). Macrolide- and 
doxycycline resistance is higher in Pulmonology Services 
(14%) than in Unselected Hospital Departments (9%), 
indicating the preference for certain antibiotics per ward. 
Doxycycline resistance is comparable in both wards  
(10-12%).
Haemophilus influenzae
Resistance levels for amoxicillin, co-amoxiclav, 
macrolides and doxycycline among H. influenzae from 
patients from Pulmonology Services were consistently 
higher than those found in Unselected Hospital 
Departments; in contrast 21% of strains were resistant 
to co-trimoxazole in Unselected Hospital Departments, 
whereas resistance was even increasing, that in 
Pulmonology Services remained stable at 19%.  
Moraxella catarrhalis
Resistance levels of amoxicillin, macrolides, doxycycline 
and co-trimoxazole appeared higher in Unselected 
Hospital Departments than in Pulmonology Services. We 
have no explanation for this finding. 
0
10
20
30
40
50
0
10
20
30
40
50
0
10
20
30
40
50
0
10
20
30
40
50
co-amoxiclav cefuroxime cefotaxime/ceftriaxone ceftazidime gentamicin co-trimoxazole ciprofloxacin
co-amoxiclav cefuroxime cefotaxime/ceftriaxone ceftazidime gentamicin co-trimoxazole ciprofloxacin
co-amoxiclav cefuroxime cefotaxime/ceftriaxone ceftazidime gentamicin co-trimoxazole ciprofloxacin
Escherichia coli Klebsiella  pneumoniae
Community Nursing Homes Selected GP Patients Outpatient Departments Unselected Hospital Departments Intensive Care Units Urology Services
Proteus mirabilis
piperacillin carbapenem ceftazidime tobramycin ciprofloxacin
Pseudomonas aeruginosa
Re
sis
tan
ce
 (%
)
Re
sis
tan
ce
 (%
)
Resistance in various patient populations
Figure 5.1. Resistance to antibiotics among Enterobacteriaceae and Pseudomonas aeruginosa in various patient populations in 2010. 
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Daan W Notermans and Jan Muilwijk
Carbapenemase producing Enterobacteriaceae (CPE) 
are increasingly recognised as an important public 
health threat. In 2011, a large outbreak of OXA-48 
producing Klebsiella pneumoniae in a hospital in the 
city of Rotterdam became apparent, raising considerable 
professional and media attention.
The guidelines for laboratory detection and confirmation 
of carbapenemases that were available as a draft version 
since early 2010 were officially adopted by general 
assembly of the Dutch Society for Medical Microbiology 
(NVMM) in 2011. (1, 2)
The national surveillance of CPE was started during 
2010. From patient samples taken in 2011, excluding 
strains directly related to the outbreak hospital, 169 
strains from 142 patients were submitted by 40 
hospitals to the National Institute for Public Health and 
the Environment (RIVM). Thirty five different CPE 
were detected. The majority (21) concerned OXA-
48 producing K. pneumoniae. In 11 of the 35 cases, 
MICs for meropenem were within susceptible range 
(<= 2 mg/L) according to EUCAST criteria. As far as 
information was available (n=17), the origin of strains 
could either be traced back to the Rotterdam outbreak or 
to previous visits to endemic countries from North Africa 
or the Middle East, mainly including hospitalisation in 
these countries.[3]
Data from ISIS show that only for a small fraction 
of Escherichia coli and K. pneumoniae with initial 
screening MICs above the confirmation threshold, the 
advised phenotypic or genotypic confirmation results 
were available. In 2010, this was the case for only 5%. 
After an evaluation in the beginning of 2011 and more 
active feedback through ISIS, the availability of this 
information increased to approximately 15 % in 2011. (4)
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Anaerobic pathogens isolated from patients hospitalized 
at the University Medical Centre Groningen during 
2011 and from patients with severe periodontitis (oral 
strains) were included in the study. The microaerophilic 
Campylobacter ureolyticus and capnophylic 
Aggregatibacter actinomycetemcomitans were also 
included. Susceptibility was determined by E-test 
for amoxicillin, co-amoxiclav (only Gram-negative 
bacteria and oral strains), clindamycin, metronidazole, 
azithromycin (oral strains) and tetracycline (oral strains). 
Resistance was determined by EUCAST criteria. 
Gram-negative anaerobes
The majority of Bacteroides fragilis sp. and Bilophila 
sp. were resistant to amoxicillin (table 7.1); one strain 
of B. fragilis sp. also to co-amoxiclav. Oral strains of 
Prevotella  intermedia were less resistant to amoxicillin 
compared to non-oral strains of Prevotella sp. (4% 
versus 22%). Resistance to amoxicillin among other 
Gram-negative anaerobes was low or absent. The MIC 
distribution of amoxicillin for B. fragilis sp. was bimodal 
with one subpopulation with MICs 1-64 mg/l (peak at 48 
mg/l) and one with > 128 mg/l. The MIC distributions 
of Fusobacterium nucleatum, and Bilophila sp. were 
unimodal over a wide range (MIC <0.016-256 mg/l); 
that of C. ureolyticus was unimodal from MIC 0.016-
0.19 mg/l (figure 7.1). Remarkable was the difference in 
unimodal MIC distributions of amoxicillin for oral (range 
MIC < 0.015-4 mg/l) and non-oral strains (range MIC < 
0.015-256 mg/l) of Prevotella sp. (figure 7.1). 
Clindamycin resistance was encountered in a minority 
of B. fragilis sp., Prevotella sp., C. ureolyticus and 
Parvimonas micra (table 7.1) and 47% of  
A. actinomycetemcomitans. The MIC distribution of  
B. fragilis sp. was bimodal with one subpopulation with 
MIC 0.015-8 mg/l and one with MIC >256 mg/l, that 
of A. actinomycetemcomitans was unimodal and ranged 
from MIC 2-64 mg/l.
Metronidazole resistance was not encountered among the 
anaerobic bacteria tested
Gram-positive anaerobes
Amoxicillin and co-amoxiclav resistances were not 
encountered for Gram-positive anaerobes. The highest 
MIC was 1 mg/l. The MIC distributions were unimodal 
for all genera tested.
Clindamycin resistance was recorded in 14 % of 
the Gram-positive anaerobic cocci and sporadic in 
other Gram-positive bacteria tested (table 7.1). The 
MIC distributions were bimodal with one susceptible 
subpopulation (MIC 0.016-2 mg/l) and one resistant 
subpopulation (MIC 8-> 256 mg/l).
Metronidazole resistance was not found.
Susceptibility testing to azithromycin and tetracycline 
for oral strains (197) revealed unimodal MIC 
distributions over a broad range (< 0.015-4 mg/l) for both 
antibiotics; six strains had high MICs (8-256 mg/l) for 
azithromycin. EUCAST has not delivered breakpoints 
for azithromycin and tetracycline for anaerobes, so we 
cannot calculate resistance levels, although we assume 
that they might be categorized susceptible. None of 
the A. actinomycetemcomitans strains were resistant to 
azithromycin or tetracycline.
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Figure 7.1. MIC distribution of amoxicillin and clindamycin for clinical strains of anaerobic Gram-negative bacteria (N= 158).
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Anaerobic bacteria - Conclusion
1. Amoxicillin resistance was 2% in oral Gram-
negative anaerobic bacteria, 74% in non-oral 
bacteria and 0% in Gram-positive bacteria (oral 
and non-oral); co-amoxiclav resistance was not 
found, except for one B. fragilis sp. strain.
1. Clindamycin resistance was 10-12% for both 
Gram-positive and Gram-negative bacteria
2. All anaerobic bacteria were susceptible to 
metronidazole.
Table 7.1.  Resistance among anaerobic bacteria.
Antibiotic resistance N (%)
Species (N) amoxicillin co-amoxiclav clindamycin metronidazole
Gram-negative bacteria
    Bacteroides fragilis sp. (82-84)* 81 (98) 1(1) 10 (12) 0
    Fusobacterium sp. (9-10)* 2 0 0 0
    Fusobacterium nucleatum (50)** 1 (2) 0 0 0
    Prevotella sp. (23-24)* 10 (22) 0 2 (8) 0
    Prevotella intermedia (50)** 2 (4) 0 2 (4) 0
    Bilophila sp. (13) 11 (85) 0 0 0
    Campylobacter  ureolyticus (10-11)* 0 0 1 (9) 0
   Porphyromonas gingivalis (50)** 0 0 0 0
   Aggregatibacter actinomycetemcomitans (47)**^ 2 (4) 1 (2) NA NA
Gram-positive bacteria
    Gram + anaerobic cocci (57) 0 NT 8 (14) 0
    Parvimonas micra (50)** 0 0 1 (2) 0
    Propionibacterium sp. (31) 0 NT 1 (3) NA
    Actinomyces sp. (9) 0 NT 1 NA
    Clostridium sp. (21) 0 NT 4 (19) 0
* not all strains were tested for all antibiotics
** oral strains
^ Breakpoint derived from Haemophilus influenzae
NA not available
NT not tested
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8 Antifungal resistance
Dik Versteeg and Paul Verweij
Further increase of azole-resistant Aspergillus isolates 
in the Netherlands
Resistance to medical triazoles is an increasing problem 
in the opportunistic fungus Aspergillus fumigatus. This 
mold causes a spectrum of diseases in humans, including 
invasive aspergillosis in severely immunocompromised 
patients. In the Netherlands azole resistance emerged in 
1998 when the first azole resistant isolate was recovered 
from a clinical specimen (1). Since then the prevalence 
has increased and surveillance studies indicate that azole 
resistance is now wide spread (1, 2). The underlying 
resistance mechanism is a combination of 2 changes in 
the Cyp51A-gene (TR34/L98H), which is the target for 
antifungal azoles. This resistance mechanism is found in 
more than 90% of azole-resistant isolates, and there is 
increasing evidence that TR34/L98H has emerged through 
environmental exposure to azole fungicides (3). Molecule 
alignment studies have shown that that there are five 
azole fungicides that exhibit a highly similar molecule 
structure to the medical triazoles (4). These compounds 
include, tebuconazole, epoxiconazole, difenoconazole, 
bromuconazole and propiconazole, and interestingly 
these compounds were authorized for use by Dutch Board 
for the Authorization of Plant Protection Products and 
Biocides between 1990 and 1996. 
Azole resistance in the Netherlands
In the prospectively collected fungus culture collection 
of the Microbiology Department of the Radboud 
University Nijmegen Medical Centre, a continued 
increase was observed (figure 8.1) and in most recent 
years around 10% of patients with a positive culture with 
A. fumigatus azole resistance is found. This increase 
is partly due to the emergence and spread of a second 
resistance mechanism, which is believed to also be 
from environmental origin. This resistance mechanism 
involves multiple changes to the Cyp51A-gene (TR46/
Y121F/T289A) and has been found in environmental  A. 
fumigatus isolates. The phenotype of this isolate is lack of 
activity of voriconazole, which is the recommended agent 
of first choice for treatment of many Aspergillus diseases, 
including invasive aspergillosis. The proportion of azole 
resistant isolates in Nijmegen that harbour the TR46/
Y121F/T289A resistance mechanism has increased from 
10% in 2010 to 20% in 2011. Sequence analysis of 55 
azole resistant Af isolates sent to Nijmegen in 2011 from 
various primary and secondary Dutch referral hospitals 
revealed 35 (64%) isolates with TR34/L98H and 20 (36%) 
isolates with TR46/Y121F/T289A.
The Dutch Ministry of Health, Welfare and Sports 
has supported the initiation of a National Reference 
Laboratory situated at the RUNMC that will perform 
active surveillance in close collaboration with the 
National Centres for Infectious Disease Control (CIb). 
Migration of azole resistance
International surveillance indicates that TR34/L98H is 
also found in clinical isolates in other countries. TR34/
L98H was found in Belgium, France, Italy, Austria and 
Denmark. The molecular epidemiology of TR34/L98H 
isolates from the Netherlands and Europe indicates that 
these isolates are genetically less diverse than wild type 
control isolates (5). The implication of this finding is 
that TR34/L98H might have originated from a common 
ancestor and that migration of TR34/L98H has occurred 
rather than de novo development of TR34/L98H locally. 
Given the similar characteristics of isolates harboring 
TR46/Y121F/T289A, compared to TR34/L98H, one can 
anticipate that TR46/Y121F/T289A will also spread across 
borders. 
Over the past year the prevalence of azole resistance 
in A. fumigatus has increased further. Our current 
understanding of resistance development in the 
environment indicates that this trend will continue 
and that the emergence and spread of new resistance 
mechanisms can be anticipated. 
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Adam Meijer and Marcel Jonges
Introduction
Infection by influenza A(H1N1), A(H3N2) or B viruses, 
results in substantial morbidity and excess mortality 
each year. Vaccination against seasonal influenza is the 
key control measure used in the Netherlands and Europe 
to minimize morbidity and mortality, especially in the 
risk groups for development of complications upon 
influenza virus infection. However, antigenic mismatch 
between vaccine components and circulating viruses 
does occur every few years requiring the vaccine to be 
reformulated. This together with sub-optimal vaccine 
uptake in recommended patient groups, non-responders 
to vaccination and waning immunity during the season 
provides the rationale for the use of antiviral drugs in 
the prophylaxis and treatment of influenza under special 
circumstances (1, 2). In addition, preparations have been 
made for provision of antiviral treatment and prophylaxis 
in case of a pandemic and the Dutch government has 
stockpiled oseltamivir and zanamivir. These preparations 
came into effect when in 2009 the first influenza 
pandemic of the 21th century occurred, caused by a triple 
reassortant virus from swine origin, the A(H1N1)pdm09 
virus (3). 
Prescriptions	of	influenza	antivirals
Two classes of influenza antiviral drugs are available for 
treatment and prophylaxis, the M2 ion-channel blockers 
(M2Bs), amantadine (Symmetrel®) and rimantadine 
(Flumadine®, not registered in the Netherlands), and 
the neuraminidase inhibitors (NAIs), oral oseltamivir 
(Tamiflu®) and inhaled zanamivir (Relenza®). M2Bs 
have been available since 1964, but their usefulness 
have been limited because of adverse effects, rapid 
development of resistance (full cross-resistance for both 
drugs) and lack of activity against influenza B virus 
infections. M2Bs are also indicated for Parkinson disease. 
We showed previously that during influenza outbreaks 
there is no significant increase in amantadine prescriptions 
in the Netherlands, consistent with the limited usefulness 
of this type of influenza antiviral drugs (4).
The introduction in 1999 of NAIs, which are active 
against both type A and B influenza viruses, was a 
major breakthrough in treatment and prophylaxis of 
influenza using antiviral drugs. In addition, because of 
different molecular interactions of both drugs with the 
neuraminidase, a limited number of mutations result 
in full cross-resistance, and if resistance mutations 
occur these mostly adversely affect infectiveness and 
transmissibility of the mutated virus. According to 
prescription data, NAIs are not widely used in the 
Netherlands during seasonal epidemics (5). During the 
first and second wave of the A(H1N1)pdm09 pandemic 
use of oseltamivir was at the peak months 2-4 times 
higher than in October 2005 when there were concerns 
about spread of A(H5N1) avian influenza into Europe. 
However, a substantial amount of prescriptions as 
precaution cannot be excluded (6). After the pandemic, 
prescriptions dropped to levels seen before the A(H1N1) 
2009 pandemic (5). In Europe the number of prescriptions 
of NAI by country is in general low, but the Netherlands 
is among the lowest (7). 
Surveillance for resistance
Details about surveillance for influenza antiviral 
resistance has been described previously (4). Briefly, in 
the Netherlands, monitoring of antiviral susceptibility is 
since the 2005/2006 season embedded in the integrated 
clinical and virological surveillance of influenza using 
general practitioner (GP) sentinel stations, which is 
carried out by the NIVEL Netherlands Institute for Health 
Services Research and the National Influenza Centre 
location Bilthoven, Centre for Infectious Disease Control, 
National Institute for Public Health and the Environment. 
In special circumstances, like during the emergence of 
oseltamivir resistant A(H1N1) virus during the 2007/2008 
season and during the 2009 A(H1N1) pandemic, this 
system is extended to include viruses detected in hospital 
and peripheral laboratories with special attention for 
viruses detected in patients treated with antivirals who 
show prolonged shedding of influenza virus (8, 9). 
Techniques used to monitor antiviral resistance in 
influenza viruses are determination of the 50 percent 
inhibitory concentration (IC50) in cell-ELISA virus 
growth inhibition assay or plaque reduction assay and 
Sanger sequencing, pyrosequencing or site-specific 
polymerase chain reaction (PCR) assay for known 
resistance markers for both the M2Bs and NAIs (10-
13). For NAIs the IC50 can also be determined using an 
enzyme inhibition assay (14, 15). In the absence of known 
NAI resistance mutations detected by genotypic assays, 
determination of the IC50 is the only way to determine 
the drug susceptibility of a virus.
 
Resistance
Antiviral susceptibility of influenza viruses in the 
Netherlands since the 2005/2006 season is summarised 
in the table. Previously we described the emergence 
of M2B resistance in A(H3N2) viruses and A(H1N1) 
viruses, although for A(H1N1) a lineage of M2B sensitive 
viruses gradually replaced the resistant lineage (4,16). In 
addition, the emergence of oseltamivir resistant A(H1N1) 
viruses during the 2007/2008 season was described (4, 
8). During the A(H1N1) 2009 influenza pandemic in the 
Netherlands enhanced molecular influenza surveillance 
was implemented using molecular methods to screen for 
mutations in the genome related to antiviral resistance 
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directly from a clinical specimen (9). Because no virus 
isolate is needed this reduces the analysis time by 1-1 
½ week, which is of benefit for a rapid response. A 
total of 19 cases with the H275Y resistance amino acid 
substitution in the neuraminidase were detected, 18 of 
them associated with oseltamivir therapy (9). In the 
2010/2011 season no viruses resistant against the NAIs 
were detected (Table).
All the A(H1N1)pdm09 influenza viruses analysed 
since the 2008/2009 season of which the M2 gene 
was sequenced had the S31N amino acid substitution 
characteristic for resistance against the M2 blockers 
(Table). All A(H3N2) viruses analysed since the 
2007/2008 season were also resistant against the M2 
blockers with the same substitution (Table). Therefore, 
there is since 2009 no place for M2 blockers in the 
treatment or prophylaxis of influenza.
The pandemic likely caused the seasonal A(H1N1) 
viruses to disappear, and with that the natural resistance 
of this subtype influenza viruses against oseltamivir. 
Although sporadic resistance against oseltamivir is 
detected in A(H1N1)pdm09 influenza viruses, these 
viruses do not harbour the same permissive amino acid 
substitutions in the neuraminidase that allowed the 
emergence of transmissible oseltamivir resistant seasonal 
A(H1N1) viruses (17).
Influenza B viruses in general are less susceptible to 
NAI than type A influenza viruses. However, over the 
period 2005-2011 only very sporadically an influenza 
B virus that was resistant against NAIs or had a 
reduced susceptibility for NAIs has been detected in the 
Netherlands (Table) (16).
Conclusion
Emergence of oseltamivir resistance in A(H1N1)
pdm09, A(H3N2) and  B influenza viruses is since 
the replacement of seasonal A(H1N1) by A(H1N1)
pdm09 viruses sporadic. However, the emergence 
of natural resistance against oseltamivir in seasonal 
A(H1N1) viruses during the 2007/2008 season has set 
the scene. Therefore, continuous alertness using sentinel 
surveillance and close monitoring of patients under 
therapy and their contacts is needed for early warning 
and timely action to limit spread of resistant viruses.
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1. Summary
Antibiotic Usage
In the years 2009-2011 the total sales of antibiotics 
licenced for therapeutic usage in the netherlands 
decreased by nearly 32%, from 495 tonnes in 2009 to 
338 tonnes in 2011. This means that the policy objective 
for 2011, a 20% reduction in 2011, compared with 
2009, was more than reached. moreover, using 2007 as 
reference year with highest antibiotic usage the decrease 
in antibiotic usage up to 2011 was even 40%.
Antimicrobial resistance
as in previous years, S. Enteritidis and S. Typhimurium 
were the most prevalent serovars isolated from humans 
in the netherlands, represented by 29.5% and 28.1% 
of all isolates respectively, followed by the antigenic 
monophasic variant of S. Typhimurium: S. enterica 
serovar 1,4,5,12:i:-. The contribution of this variant 
increased from 6.2% in 2008/2009 to 14.2% in 2010/2011 
among human isolates, but increased also in animals. 
Other remarkable shifts in Salmonella serovars from 
animals are the strong increase for S. Derby in pigs 
(from 16.7% in 2008/2009 to 31.2 in 2010/2011), the 
replacement of S. Dublin (34.6%) as most prevalent 
serovar in cattle by S. Typhimurium (36.2%) and the 
appearance of S. Braenderup in laying hens (15.7%).
S. Typhimurium has acquired resistance against a number 
of antimicrobials. The most common resistance pattern is 
aSTSuCipnalFC. In addition, ESBL producing strains 
(cefotaxime reduced susceptible with mIC > 0.5 mg/l) 
amounted for 0.5% of the Typhimurium isolates. The 
group of fluoroquinolones is widely regarded as the 
treatment of choice for severe salmonellosis in adults. 
Using the epidemiological cut-off value of 0.06 mg/l, 
12.6% of Salmonella isolates demonstrated a non-wild 
type phenotype for ciprofloxacin, while 1.1% showed 
mICs larger that the clinical breakpoint (1 mg/l). The 
serovars of these ciprofloxacin resistant isolates were 
predominantly travel related S. Kentucky (67%) or S. 
Java (12%). The remaining 20% consisted of a diversity 
of serovars merely represented by a single strain. In 
2010/2011, the total number of cefotaxime reduced 
susceptible (mIC > 0.5 mg/l) ESBL suspected Salmonella 
isolates was 52 (1.2%), among 17 different serovars.  
a substantial part of the isolates belonged to the serovar  
S. Java (19 of 52 isolates) and S. Heidelberg (7 isolates).
In animals and poultry meat, a very high proportion 
of Campylobacter was resistant to ciprofloxacin, 
whereas lower levels were observed for erythromycin 
and gentamicin. High resistance was also recorded 
for commonly used antimicrobials such as ampicillin 
and tetracyclines. Similarly, a high proportion of 
Campylobacter in humans was resistant to ciprofloxacin, 
whereas low resistance was recorded for erythromycin.
among indicator (commensal) E. coli isolates from 
meat and animals, resistance to ampicillin, streptomycin, 
tetracyclines, sulfonamides and trimethoprim was 
commonly detected in all host species except dairy cattle. 
Reduced susceptibility to ciprofloxacin and nalidixic 
acid was highest for E. coli isolates from broilers 
(59.4% and 59.6% respectively) and turkeys (31.6% 
and 27.4% respectively). resistance to third-generation 
cephalosporins was observed in indicator E. coli isolates 
from poultry, pigs and cattle and varied from very low 
levels in dairy cattle (0.4%) to 13.2% in broiler chickens 
in 2010/2011. 
For the first time, data for enterococci from turkey were 
included. although isolates from only a limited number 
of farms (n=20) were included, resistance levels were 
high in comparison to other farm animals, notably for 
tetracycline, erythromycin, ampicillin, chloramphenicol 
and ciprofloxacin. Resistance to vancomycin continued to 
be detected at low levels in enterococci from animals.
ESBL/ampC-genes are detected in high prevalences 
in all food-producing animals, pets and wild-birds. 
This demonstrates that the Dutch ecosystem is heavily 
contaminated. However in broiler chickens the occurrence 
of ESBL producing E. coli in broilers is shows a tendency 
to decrease from 2010 onwards, the moment when the use 
of ceftiofur at Dutch hatcheries was banned.
It can be concluded that antibiotic sales data show a steady 
and substantial decrease since the top year 2007. In 2008 
measures to limit antibiotic usage were initiated. Its effect 
on the occurrence of resistance is not yet noticeable except 
for the occurrence of cefotaxime resistance in broilers, 
which show a tendency to decrease after the ban of 
ceftiofur in poultry hatcheries in 2010.
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2.1 Total sales of veterinary antibiotics in 
the Netherlands 2011
2.1.1 Analysis of sales data
FIDIn, the federation of the Dutch veterinary 
pharmaceutical industry, reports the total number of 
kilograms of antibiotics (active ingredient) sold in the 
netherlands in 2011 at the level of pharmacotherapeutic 
groups. The data about use of active substances are based 
on sales data of members of FIDIn and are estimated to 
cover about 98% of all sales in the netherlands. actual 
use can be different from the amounts sold as a result of 
stock piling and cross border use.
The European medicines agency (Ema) collects 
harmonised antibiotic usage data based on overall 
sales of veterinary antimicrobial agents, as well as per 
animal species. The European Surveillance of Veterinary 
antimicrobial Consumption (ESVaC) project was 
launched by Ema in September 2009. To ensure that 
the data provided by the member States are harmonised, 
an ESVaC Data Collection Protocol (ESVaC template) 
has been developed and a call for data has been sent 
to most EU member states. To fully implement the 
ESVaC protocol FIDIn had to adjust the levels of active 
ingredients for several products, taking into account 
the salt and ester formulations and calculation factors 
of active ingredients expressed in international units. 
These corrections led to a reduction of the calculated 
total amount of active substance by approximately 4%. 
The sales figures of 2009, 2010 and 2011 were based on 
the ESVAC template; the figures of 1999 to 2008 were 
re-calculated and corrected accordingly. The sales data 
in this report give information about the total sales for 
all animals, not per individual animal species. Detailed 
information about antibiotic usage per animal species can 
be found on the maran website www.maran.wur.nl.
To adjust for trends in the size of the animal population 
the sales of antibiotics were also expressed as grams  
of active ingredient per kilogram live animal weight 
(Figure aBuse01). For this purpose the annual total sales 
data published by FIDIn were related to the total live 
weight of the average number of animals present in the 
Dutch livestock farming sector (pigs, poultry, veal calves, 
other cattle and sheep). For this analysis the following 
average weights were used: veal calves 172 kg (i.e. the 
weighted average of white veal calf 164 kg and rosé 
veal calf 192 kg), other cattle 500 kg, turkeys 6 kg, other 
poultry 1 kg, fattening pigs 70 kg, sows 220 kg, piglets 
(<20 kg) 10 kg, sheep 60 kg. This yields information 
about the trend in the sales of antibiotics in grams per 
kilogram of live animal weight present in the netherlands 
over the years, thus taking into account yearly fluctuations 
in the size of the animal population. The yearly average 
numbers of animals and its conversion into live weight 
are given in Table aBuse01 and Table aBuse02.
2.1.2 Trends in total sales
Figure aBuse01 shows the trends in the total sales of 
antibiotics licenced for therapeutic use in animals in the 
netherlands, also expressed in grams of active substance 
per kg of live weight present. It reveals that in the years 
2009-2011 the total sales decreased by nearly 32%, to a 
total of 338 tonnes in 2011. This means that the policy 
objective for 2011, a 20% reduction in 2011, compared 
with 2009, was more than reached. moreover, using 2007 
as reference year with the highest antibiotic usage, the 
decrease in usage up to 2011 was even 40%.
Discussion
The total sales volume amounted to 338 tonnes in 2011, 
which is below the level of the year 2000. However, at 
that time an additional 205 tonnes of antimicrobial growth 
promoters were used (see Table aBuse03). almost all 
classes of antibiotics showed a decrease.
Tetracyclines
The sales data show a decrease of tetracyclines from 251 
tonnes in 2009 to 157 tonnes in 2011 (-37%), of which 
102 tonnes of oxytetracycline (-41%) and 54 tonnes of 
doxycycline (-31%). The true exposure to tetracyclines 
decreased by an estimated 35%, roughly assuming a 
constant livestock population and an average dosage of 30 
mg per kg of animal for oxytetracycline and 10 mg per kg 
for doxycycline.
Fluoroquinolones
In 2011 the fluoroquinolones represented 1.52% of the total 
veterinary antibiotic sales in the netherlands, of which 
0.43% ‘newer’ fluoroquinolones (danofloxacin, difloxacin, 
2. Usage of antibiotics in animal husbandry in the Netherlands
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Figure ABuse01. Veterinary therapeutic sales from 1999-2011 (FIDIN, 
2012; vertical bars). The line presents the the trends in grams of active 
ingredients used per kg live weight.
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enrofloxacin and marbofloxacin). In the years 2009-2011 
the sales of fluoroquinolones decreased substantially, by 
34%. The sales of the newer fluoroquinolones showed a 
slight increase of 6%.
Cephalosporins
The cephalosporins represented 0.23% of the total sales, of 
which 0.17% third and fourth generation cephalosporins 
(cefoperazon, cefovecin, cefquinome, ceftiofur). In 
2009-2011 the sales of third and fourth generation 
cephalosporins decreased by 37%.
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Table ABuse01. Trends in livestock in the Netherlands in numbers (thousands).
Number of animals * 1.000 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Piglets (less than 20 kg) 4791 4935 4422 4225 3896 4300 4170 4470 4680 4555 4809 4649 4797
Sows 1320 1272 1161 1140 1052 1125 1100 1050 1060 1025 1100 1098 1106
Fattening pigs 7028 6615 5931 5789 5818 5715 5730 5700 5970 6155 6199 6459 6200
Turkeys 1544 1544 1523 1451 1112 1238 1245 1140 1232 1222 1246 1167 1167
Other poultry 53,453 53,453 58,475 62,066 42,991 43,854 45,525 42,529 44,487 50,270 52,323 54,367 57,811
Veal calves 800 756 676 692 748 775 813 824 860 913 886 921 919
Cattle (excl. veal calves) 3297 3134 3166 3088 2986 2984 2933 2849 2960 3083 3112 3039 2993
Sheep 1152 1250 1250 1300 1476 1700 1725 1755 1715 1545 1091 1211 1113
Sources: Eurostat (pigs, cattle, sheep, laying hens before 2008), FAO (other poultry), CBS (laying hens 2008-2011); For poultry, FAO Poultry figures 2011 
were not yet available; and 2010 data were used.
Table ABuse03. Antibiotic sales from 1999-2011 in tonnes (FIDIN, 2012).
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Penicillins /cephalosporins 35 36 38 38 36 43 51 57 61 70 73 71 66
Tetracyclines 162 194 200 214 216 256 292 301 321 257 251 217 157
Macrolides 10 15 17 19 17 23 28 42 55 52 46 39 34
Aminoglycosides 13 12 11 10 9 9 11 11 12 11 10 9 7
Fluoroquinolones 7 7 6 6 5 7 8 7 9 8 8 7 5
Trimethoprim/Sulfonamides 71.5 80.4 92.1 92.1 88.2 91.1 91.1 93.1 99 100 92 78 58
Others 11 12 11 11 7 6 6 8 8 7 15 13 10
Total therapeutic sales 310 356 376 390 378 434 487 519 565 506 495 433 338
Antimicrobial growth promoters (AGP) 250 205 180 140 120 80 40 0 0 0 0 0 0
Total sales including AGP 560 561 556 530 498 514 527 519 565 506 495 433 338
Table Abuse02. Trends in livestock in the Netherlands in live weight (tonnes).
Live weight 
*1.000 kg
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
pigs 831,676 793,563 715,996 699,438 678,789 691,693 685,946 675,840 699,094 703,131 725,260 741,472 726,530
Poultry 62,717 62,717 67,613 70,772 49,663 51,282 52,995 49,369 51,879 57,602 59,799 61,369 64,813
Veal calves 137,920 130,334 116,542 119,301 129,024 133,610 140,161 142,058 148,264 157,401 152,746 158,780 158,436
Cattle (excl.  
veal calves)
1,648,500 1,567,000 1,583,000 1,544,000 1,493,150 1,492,000 1,466,500 1,424,500 1,480,000 1,541,500 1,556,000 1,519,500 1,496,500
Sheep 69,120 75,000 75,000 78,000 88,560 102,000 103,500 105,300 102,900 92,700 65,460 72,660 66,780
Total 2,749,933 2,628,614 2,558,152 2,511,511 2,439,186 2,470,585 2,449,102 2,397,067 2,482,137 2,552,334 2,559,265 2,553,781 2,513,059 
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3.  Resistance data
In this chapter susceptibility test results are presented 
as determined in 2010 and 2011 for the food-borne 
pathogens Salmonella enterica, Campylobacter spp. 
and Escherichia coli O157, the food-borne commensal 
organisms E. coli, Enterococcus faecium and E. faecalis.
3.1 Food-borne pathogens
3.1.1 Salmonella
Salmonella is an important zoonotic pathogen, which 
can be isolated from the intestinal content of a broad 
range of animal host species. more than 2500 serovars 
of zoonotic Salmonella have been recognised, and the 
prevalence of these different serovars differs among host 
species and can change over time. The present convention 
is to capitalize the serovar designation and indicate it 
(without italics) after the genus name. as an example, 
Salmonella enterica subsp. enterica serovar Typhimurium 
is described as S. Typhimurium.
resistance percentages are presented on Salmonella 
isolated from humans suffering from clinical infections, 
food-producing animals and food products from animals 
as potential sources for distribution to humans via the 
food chain, and animal feeds as potential source for food-
producing animals.
3.1.1.1 Salmonella serovar prevalence
In the netherlands, an extensive monitoring of Salmonella 
is carried out by the Dutch national Institute of Public 
Health and the Environment (rIVm), the EU reference 
laboratory (EU-rL) for Salmonella (EC) 882/2004). 
a summary of the sero- and phage typing results is 
presented in Table S01, concerning Salmonella isolates 
recovered from humans and farm animals (swine, cattle 
and poultry).
Human isolates (n=2708 in 2010/2011) concerned a 
selection from first isolates sent to the RIVM by regional 
public health laboratories. All strains were the first 
isolates recovered from patients with salmonellosis. The 
majority of the isolates from pigs (n=159) and cattle 
(n=109), including calves were sent to the rIVm by the 
animal Health Service from a diversity of surveillance 
programs and clinical Salmonella infections. Those from 
chickens (broilers, including poultry products, n= 146; 
layers, reproduction animals and eggs, n=110) concerned 
mainly nonclinical Salmonella isolations derived 
from a diversity of monitoring programs on farms, 
slaughterhouses and at retail. Isolates from a diversity of 
other sources have been analysed as well (animal feed 
and human food products; other animals from animal 
husbandry and pets, samples from the environment, etc.). 
as in previous years, S. Enteritidis and S. Typhimurium 
were the most prevalent serovars isolated from humans 
in the netherlands, represented by 29.5% and 28.1% 
Highlights
1. as in previous years, S. Enteritidis and S. 
Typhimurium were the most prevalent serovars 
isolated from humans in the netherlands, 
represented by 29.5% and 28.1% of all isolates 
respectively, followed by the antigenic monophasic 
variant of S. Typhimurium: S. enterica serovar 
1,4,5,12:i:-. The contribution of this variant 
increased from 6.2% in 2008/2009 to 14.2% 
in 2010/2011 among human isolates, but also 
increased in animals. Other remarkable shifts in 
Salmonella serovars from animals are the strong 
increase for S. Derby in pigs (from 16.7% in 
2008/2009 to 31.2 in 2010/2011), the replacement 
of S. Dublin (34.6%) as most prevalent serovar 
in cattle by S. Typhimurium (36.2%) and the 
appearance of S. Braenderup in laying hens 
(15.7%).
2. S. Typhimurium has acquired resistance against 
a number of antimicrobials, most commonly 
resistance pattern is aSTSuCipnalFC. In addition, 
ESBL producing strains (cefotaxime reduced 
susceptible with mIC > 0.5 mg/l) amounted for 
0.5% of the Typhimurium isolates. 
3. In S. Java characteristic findings are high 
level resistance against trimethoprim which is 
characteristic of the clone predominating in the 
netherlands in poultry, in combination with 
acquired resistance against the quinolones and 
third generation cephalosporins cefotaxime and 
ceftazidime. 
4. The group of fluoroquinolones is widely regarded 
as the treatment of choice for salmonellosis in 
adults. Using the epidemiological cut off value 
of 0.06 mg/l, 12.6% of Salmonella isolates 
demonstrated a non-wild type phenotype for 
ciprofloxacin, while 1.1% showed MICs larger 
that the clinical breakpoint (1 mg/l). The serovars 
of these ciprofloxacin resistant isolates were 
predominantly travel-related S. Kentucky (67%) 
or S. Java (12%). The remaining 20% consists of 
a diversity of serovars merely represented by a 
single strain. 
5. In 2010/2011, the total number of cefotaxime 
reduced susceptible (mIC > 0.5 mg/l) ESBL 
suspected Salmonella isolates was 52 (1.2%), 
among 17 different serovars. a substantial part of 
the isolates belonged to the serovar S. Java (19 of 
52 isolates) and S. Heidelberg (7 isolates).
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Table S01. Most prevalent Salmonella sero- and phage types isolated in 2010/2011 and 2008/2009 from humans, pigs, poultry, broilers and 
layers and the % travel related human infections from 2008 – 2011.
 N Travel Humans Pigs Cattle Poultry Broiler Layer
’08/11 ‘08/09 ’10/11 ‘08/09 ’10/11 ‘08/09 ’10/11 ‘08/09 ’10/11 ‘08/09 ’10/11 ‘08/09 ’10/11
N total 10% 3130 3096 1137 279 179 127 1004 459 641 198 109 134
N tested 2502 2708 386 159 149 109 639 352 400 146 75 110
Typhimurium 1797 3% 34.6 28.1 14.2 19.4 20.1 36.2 2.6 4.8 1.6 3.0 6.4 6.0
SI 1,4,5,12:i:2- 623 3% 6.2 14.4 4.6 15.4 3.9 10.2 1.6 2.4 1.2 3.0 3.0
Enteritidis 1822 13% 31.8 29.5 1.4 0.4 0.6 0.8 11.3 12.9 7.8 8.6 33.9 31.3
 Pt 1 218 15% 3.0 4.4 0.3 0.2 0.3 0.9 1.5
 Pt 21 255 9% 4.8 2.4 0.8 2.3 1.7 1.9 1.5 7.3 3.0
 Pt 4 530 7% 7.2 9.9 0.1 3.0 3.1 1.6 1.5 11.0 6.7
 Pt 6 131 33% 2.7 1.6 0.1 0.3 1.3 0.3 1.0 3.0
 Pt 7 32 29% 0.2 0.4 0.6 0.7 3.7 2.2
 Pt 8 370 7% 7.1 5.0 0.7 0.6 1.9 1.5 1.6 0.5 3.7 7.5
 Pt 14b 91 18% 1.8 1.1 0.7 2.2
Anatum 41 17% 0.2 0.3 2.8 0.4 0.6 0.6 0.7 0.9 1.5
Bareilly 27 14% 0.2 0.3 0.2 0.4 1.8 4.5
Bovismorbificans 31 0% 0.4 0.4 3.2 1.7
Braenderup 59 15% 0.2 0.5 0.1 0.8 0.1 4.6 0.2 15.7
Brandenburg 87 0% 0.4 0.5 5.6 10.0 0.6 0.8 0.3 0.7 0.5 0.9 1.5
Bredeney 14 --- 0.1 1.5 2.5 0.2 0.9 0.2
Corvallis 69 29% 0.9 1.0 0.2 2.0 0.2 1.5 3.0
Cubana 7 --- 0.1 2.2 0.2 0.4 0.3 1.5
Derby 169 7% 0.5 0.6 16.7 31.2 0.6 1.6 0.3 1.1 0.2 2.0 1.8
Dublin 169 0% 0.5 0.6 0.2 62.6 34.6
Hadar 54 18% 0.4 0.3 0.3 1.8 0.2 2.5 0.5
Havana 9 --- 0.03 0.1 0.3 1.8
Heidelberg 62 5% 0.6 0.4 0.9 1.2 1.7 1.1 2.5 1.8
Indiana 47 0% 0.1 0.1 0.1 1.6 1.9 4.4 2.0 7.1 0.7
Infantis 221 15% 1.5 1.2 4.1 1.4 7.3 5.4 6.4 8.6 3.7 1.5
Paratyphi B. var. Java 705 0% 0.6 0.9 0.1 1.1 46.6 32.7 57.3 40.4 0.9 6.7
Kottbus 21 13% 0.3 0.2 0.2 0.8 0.8 0.2 1.8
Livingstone 77 20% 0.2 0.1 6.1 1.4 1.5 2.4 0.8 2.0 4.6 3.7
London 60 0% 0.4 0.4 10.9 1.4
Mbandaka 82 17% 0.2 0.4 0.7 0.6 0.8 4.1 2.4 6.1 4.5 0.9
Minnesota 54 --- 0.1 1.9 3.5 1.6 6.1
Molade 6 --- 0.1 0.2 0.2 0.5 1.8
Montevideo 30 38% 0.3 0.3 0.3 2.8 2.4 0.2 0.2 0.3 0.5
Newport 104 21% 1.3 2.0 0.3 1.2 0.9 0.8 0.5
Oranienburg 33 13% 0.5 0.5 0.1 2.8
Poona 24 33% 0.3 0.4 0.1 1.8
Rissen 31 33% 0.1 0.4 0.9 1.1 0.3 0.9 0.2 0.9 2.2
Senftenberg 22 10% 0.3 0.03 0.4 0.6 0.9 0.6 1.8
Tennessee 24 0% 0.2 0.1 0.1 2.4 0.7 0.7 0.5 1.0 3.7 0.7
Goldcoast 42 0% 0.2 0.3 6.2 11.1 3.9 0.2 0.7
(Para)Typhi (A B C) 68 32% 1.2 1.1
SI 9,12:NM 6 33% 0.1 0.3 1.1 0.8 0.2 1.8
SI 4,5,12:d:2- 10 --- 0.03 0.03 2.6 0.7 0.2 0.4 0.3 0.5
Other 1029 18% 15.4 14.0 15.7 3.6 1.1 2.4 11.1 13.1 7.0 6.6 24.7 15.7
Typing results of the Dutch Salmonella Reference Laboratory (RIVM, Bilthoven). Isolates are from different sources and programs. 
Poultry: all chicken categories together; Broilers: including chicken products; Layers: including reproduction animals and eggs.
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sulfamethoxazole, ampicillin, streptomycin and to a lesser 
extend trimethoprim, ciprofloxacin, and nalidixic acid.
Quinolone resistance
The class of fluoroquinolones is widely regarded as the 
treatment of choice for severe salmonellosis in adults. 
Using the epidemiological cut off value of 0.06 mg/l, 
12.6% of Salmonella isolates demonstrated a non-wild 
type phenotype for ciprofloxacin, while 1.1% showed 
mICs larger than the clinical breakpoint (1 mg/l). The 
serovars of these ciprofloxacin resistant isolates were 
predominantly travel related S. Kentucky (67%) or  
S. Java (12%) in poultry. The remaining 20% consists of a 
diversity of serovars merely represented by a single strain.
 
ESBL
The emergence of multidrug resistant Salmonella strains 
with resistance to fluoroquinolones and third-generation 
cephalosporins is a serious development, which results 
in severe limitation of the possibilities for effective 
treatment of human infections (WHO, factsheet 139, 
2005). In 2010/2011, the total number of cefotaxime 
reduced susceptible (mIC > 0.5 mg/l) ESBL suspected 
Salmonella isolates was 52 (1.2%), among 17 different 
serovars. a substantial part of the isolates belonged to the 
serovar S. Java (19 of 52 isolates). Of the S. Java isolates 
for which information on the origin was available, all but 
one were recovered from poultry. a single isolate was 
recovered from a human sample, with a resistance profile 
distinctive from the multiresistant poultry type. In total, 
11% of S. Java isolates were suspected ESBL producers. 
remarkably, among S. Heidelberg this percentage was 
even higher as seven of the 21 isolates (33%) that were 
tested were cefotaxime resistant, all from poultry origin. 
Of all the ESBL producing Salmonella isolates, 25% were 
recovered from human samples, 52% from poultry or 
poultry products, 6% from meat or meat products (other 
than poultry), and 6% were from other food samples. 
For 10% the source was unknown. resistance against 
cefotaxime in isolates from poultry is associated with 
transfer of ESBLs between E. coli and Salmonella in the 
GI-tract of Dutch poultry (see appendix 1).
Resistance profiles vary considerably among serovars 
as shown in Table S03. This table presents resistance 
percentages for the thirteen most prevalent serovars 
isolated in the netherlands in 2010/2011. Highest 
resistance levels are observed in S. Typhimurium, the 
monophasic S. enterica serovar 1,4,[5],12:i:-, S. Java,  
and to a lesser extend in S. infantis.
Generally, S. Typhimurium has acquired resistance 
against a number of antimicrobials. The most common 
resistance pattern was aSTSuCipnalFC. In addition, 
ESBL producing strains (cefotaxime reduced susceptible 
with mIC > 0.5 mg/l) amounted for 0.5% of the isolates. 
The monophasic S. Typhimurium 1,4,5,12:i:- typically 
has a multidrug resistance phenotype, with resistance 
of all isolates respectively, followed by the antigenic 
monophasic variant of S. Typhimurium: S. enterica 
serovar 1,4,5,12:i:-. The contribution of this variant 
increased from 6.2% in 2008/2009 to 14.4% in 
2010/2011.
major shifts in the occurrence of Salmonella serotypes 
in food animal and humans are regularly seen. Currently 
the global spread of a multidrug-resistant antigenic 
monophasic variant of S. Typhimurium: S. enterica 
serovar 1,4,5,12:i:-, both in animals and humans is a cause 
of concern. In the netherlands, this serotype has shown a 
sudden, dramatic increase in humans since 2008. also in 
animals, mostly pigs and cattle, the relative contribution 
seems to be increasing although the absolute numbers are 
much smaller (Table S01)
In pigs, an evident increase in S. Derby was apparent 
(from 16.7% in 2008/2009 to 31.2 in 2010/2011), while 
traditionally S. Typhimurium used to be the most common 
serotype. also the monophasic variant of  
S. Typhimurium was considerably more common 
compared to previous years (increasing from 4.6% of all 
porcine isolates in 2008/2009 to 15.4% in 2010/2011).
In cattle, S. Dublin has for years been the most recovered 
serovar, but has been surmounted by S. Typhimurium 
(34.6% and 36.2 respectively 2010/2011). also the rise 
of the monophasic variant of S. Typhimurium should be 
noted, which covered 10.2% of the bovine isolates as 
opposed to 3.9% in 2008/2009. Another finding is the 
presence of S. Goldcoast in the top four most prevalent 
types (3.9%), which was not found in previous years in 
cattle.
In poultry S. Paratyphi B var. Java (S. Java) was again the 
most predominant serovar in broilers, in which species 
it represented 40.4% of all isolates. The most common 
serovar in laying hens was S. Enteritidis (31.3%).  
A notable finding in laying hens was the appearance of 
S. Braenderup in 2010/2011, consisting of 15.7% of the 
isolates. This serovar was also frequently detected in 
poultry in 1998 to 2000, but has not been recovered in the 
period in-between for no apparent reason.
Depending on the sero/phagetype, travel contributed up 
to 38% of the cases of human salmonellosis from 2008 
onwards. This substantial contribution was noted for S. 
montevideo, but also for a number of other serovars about 
one third of the cases was travel related (S. Enteritidis 
Pt6; S. Poona; S. rissen; S. SI 9,12:nm; and typhoidal 
Salmonella cases). It should be noted that the contribution 
of travel as depicted in Table S01 is only indicative of the 
true contribution, because travel is underreported by about 
a factor two.
3.1.1.2 Resistance levels
antimicrobial susceptibility testing was performed on 
4404 isolates. Table S02 presents mIC-distributions 
and resistance percentages of all Salmonella’s tested 
for susceptibility in 2010/2011 (n = 4404). Highest 
levels of resistance were observed for tetracycline, 
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against amoxicillin, streptomycin, sulfamethoxazole, and 
tetracycline, referred to as resistance type aSSuT.
In S. Java characteristic findings are high level resistance 
against trimethoprim which is characteristic of the 
clone, in combination with acquired resistance against 
the quinolones and third generation cephalosporins 
cefotaxime and ceftazidime.
S. Typhimurium
as shown in Table S01, S. Typhimurium represented 
28.1% of all human Salmonella isolates as characterized 
by the rIVm in 2010/2011. also in animals S. 
Typhimurium is a common serotype. If the monophasic 
SI 1,4,5,12:i:- variant is included, S. Typhimurium may 
be regarded as the most dominant serotype in humans 
and food animals like pigs and cattle. It is also present in 
poultry, although to a lesser extent.
resistance in S. Typhimurium was very high for 
ampicillin, tetracycline and sulphonamides and high for 
streptomycin (Table S02), which is also related to the 
frequent occurrence of the monophasic S. Typhimurium 
variant. Resistance to the fluoroquinolones and third 
generation cephalosporins, regarded as clinically 
important drugs in human medicine, was moderate 
(ciprofloxacin and nalidixic acid) or low (ceftazidime). 
Resistance to chloramphenicol and florfenicol was 
common. 
In previous years, resistance patterns for different phage 
types were presented. However, at the rIVm phage 
typing has in 2010 been replaced by mLVa typing as the 
routine typing system. For this reason, in this report data 
on the different subtypes of S. Typhimurium are no longer 
presented. 
Generally, the typical resistance patterns for S. 
Typhimurium (aSTSuCipnalFC) is irrespective of 
phage type and also evident when isolates are classified 
according to host species. nevertheless, some variation is 
evident for the different antimicrobials tested as shown in 
Table S04. In addition, ESBL resistance is occasionally 
present in isolates recovered from human samples and in 
samples from poultry origin, but has not been detected in 
cattle and swine. 
With regard to trends, resistance levels in S. Typhimurium 
isolates from human samples appear to increase over the 
years. This is probably influenced by the emergence and 
spread of multidrug resistant clones like DT104 (2008, 
concerning a foodborne outbreak of which the origin was 
suspected to be abroad) and the recent upswing of the 
monophasic SI 1,4,5,12:i:- variant.
With regard to animal strains, resistance levels vary 
considerably over the years and interpretation should 
be done with caution because of the relatively small 
number of the isolates per year. The trend analysis is 
further affected by the differences in proportion of multi 
drug resistant phage types per category and per year. In 
this respect, especially the results in poultry isolates (i.e. 
the apparent decrease in resistance levels for a number 
of antimicrobials in 2011 compared to 2010) should be 
interpreted with caution.
S. enterica serovar 1,4,5,12:i:- (monophasic S. 
Typhimurium 1,4,[5],12:i:-)
The number of S. enterica serovar 4,[5],12:i:- isolates has 
increased dramatically over the last years, not only in the 
netherlands, but also in other EU member states (EFSa, 
EU summary report on antimicrobial resistance, 2010).  
S. enterica serovar 4,[5],12:i:- is considered a monophasic 
variant of serovar Typhimurium (4,[5],12:i:1,2) due to 
antigenic and genotypic similarities between the two 
serovars. Pigs have been suggested as a likely source 
of infection as cases of infection have been particularly 
linked to pigs and pork products. Interestingly, the 
antibiotic susceptibility profiles of the Salmonella 
4,5,12:i:– isolates recovered around the world show 
considerable variation. In general, isolates from Europe 
appear to harbour more resistance traits as opposed to 
isolates from north and South america and asia. Dutch 
strains also show a multidrug resistance phenotype, with 
typically resistance against ampicillin, streptomycin, 
sulfamethoxazole, and tetracycline, referred to as 
resistance type aSSuT. (Table S03).
S. Enteritidis
In the netherlands, human infections caused by S. 
Enteritidis are predominantly related to the consumption 
of raw shell eggs. However, the difference in phage 
types isolated from Dutch broilers and humans and the 
moderate resistance of strains from human infections 
compared to the lack of resistance in Dutch layers 
indicates that other sources of infection exist. These are 
considered to be consumption of imported eggs and travel 
abroad (Table S01).
In Dutch poultry the prevalence of S. Enteritidis is 
substantially lower than S. Java (12.9% and 32.7% 
respectively of all galline Salmonella isolates) as shown 
in Table S01. although S. Enteritidis prevalence varies 
over the years, it is traditionally higher in layers than in 
broiler chickens. In 2010/2011, S. Enteritidis was by far 
the most common serotype, consisting of 31.3% of all 
Salmonella isolates recovered from layers. In broilers,  
S. Enteritidis covered 8.6% of all Salmonella isolates and 
was, together with S. Infantis, the second most prevalent 
serotype.
In Table S05, resistance percentages for S. Enteritidis 
are specified according to host and most prevalent phage 
types. as in previous years, Pt4 was the most frequently 
recovered S. Enteritidis phage type among human isolates 
(9.9%). Other common phage types were Pt8 (5.0 %), 
Pt1 (4.4%), Pt21 (2.4%), Pt6 (1.6%), and Pt14b (1.1%), 
together representing 87.5% of all S. Enteritidis isolates 
examined. among S. Enteritidis isolated from Dutch 
poultry, the most commonly found phage types were Pt4, 
Pt8 and Pt 21, with slightly different relative prevalences 
in layers as opposed to broilers.
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Compared to other Salmonella serovars, resistance in 
S. Enteritidis are generally low. Highest levels are seen 
for the quinolones, showing some variation between 
phage types as shown in Table S05. most extensive 
levels are observed in Pt1 and Pt14b (31.3% and 23.5% 
respectively), both of which are travel related in humans. 
The trends in resistance levels over the years are 
summarized in Figure S02. It should be noted that the 
variation in quinolone resistance levels over the years is 
also reflected by the relative proportion of certain phage 
types. apart from this, similar to the situation for S. 
Typhimurium, resistance levels vary considerably over 
the years because of the relatively small number of animal 
isolates per year and interpretation should be done with 
great caution.
Table S03. Resistance (%) of the thirteen most prevalent Salmonella serovars isolated in the Netherlands in 2010 and 2011.
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Ampicillin 3.7 59.2 91.7 51.2 6.1 0 8.8 4.0 2.8 4.3 15.9 1.9 1.9
Cefotaxime 0.1 0 0.9 11.4 0 0 2.2 0 1.4 2.9 1.4 0 0
Ceftazidime 0.1 0.4 0.9 10.8 0 0 2.2 0 1.4 2.9 1.4 0 0
Gentamicin 0.1 0.6 1.5 3.6 0 1.1 0 0 0 0 5.8 1.9 0
Kanamycin 0.2 1.0 1.7 10.2 1.0 1.1 6.6 0 0 0 5.8 0 0
Streptomycin 0.5 42.5 91.7 27.1 5.1 0 6.6 6.7 1.4 2.9 7.2 9.3 3.8
Tetracycline 1.6 62.5 92.4 19.9 8.1 1.1 23.1 4.0 1.4 0 14.5 3.7 11.5
Sulfamethoxazole 1.3 59.5 92.0 53.0 6.1 0 25.3 2.7 1.4 0 11.6 5.6 5.8
Trimethoprim 0.7 23.6 6.1 81.3 4.0 0 14.3 0 1.4 0 7.2 0 3.8
Ciprofloxacin 9.2 16.0 2.4 50.6 2.0 0 23.1 4.0 1.4 0 14.5 1.9 0
Nalidixic acid 9.3 15.3 1.7 49.4 0 0 23.1 4.0 0 0 13.0 1.9 0
Chloramphenicol 0.2 26.1 4.1 1.8 0 0 5.5 1.3 2.8 0 5.8 1.9 0
Florfenicol 0 24.2 1.3 0 0 0 1.1 0 1.4 0 5.8 0 0
Table S02. MIC distribution (in %) and resistance percentages (R%) for all Salmonella’s (N = 4404) tested for antibiotic susceptibility 
during 2010 and 2011.
Salmonella 
N = 4404
MIC (%) distribution mg/L
R% 95% CI
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 1.0 35.1 31.5 2.9 0.2 0 0 29.2 29.5 28.1 - 30.8
Cefotaxime 31.5 55.9 10.3 1.1 0 0 0 1.1 1.2 0.8 - 1.5
Ceftazidime 63.5 32.1 3.0 0.2 0.2 0.1 0.2 0.6 1.1 0.8 - 1.4
Gentamicin 31.7 55.7 9.5 1.5 0.1 0.2 0.7 0.3 0.2 1.5 1.1 - 1.9
Kanamycin 95.7 2.6 0.3 0.1 0 0 1.2 1.7 1.3 - 2.1
Streptomycin 5.5 20.3 26.6 16.6 7.7 4.3 3.5 15.4 23.3 21.9 - 24.5
Tetracycline 4.5 59.0 5.9 0.7 0.2 2.4 3.5 23.9 30.0 28.5 - 31.3
Sulfamethoxazole 49.7 16.8 3.0 0.3 0.1 0 0 0.1 29.9 30.0 28.6 - 31.3
Trimethoprim 87.1 1.4 0 0 0 0 0 11.4 11.5 10.5 - 12.4
Ciprofloxacin 27.5 57.8 2.0 1.5 6.0 2.5 1.4 0.3 0 0.2 0.5 12.6 11.5 - 13.5
Nalidixic acid 81.3 5.8 1.2 0.4 0.1 11.1 11.6 10.6 - 12.5
Chloramphenicol 0.1 7.1 77.7 7.7 0.2 0.2 6.9 7.4 6.5 - 8.1
Florfenicol 0.6 43.1 47.2 3.0 3.0 2.1 1.0 6.1 5.3 - 6.8
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate MIC values > the 
highest concentration in the range. Values at the lowest concentration tested indicate MIC-values ≤ the lowest concentration in the 
range. The vertical bars indicate the epidemiological cut-off values we used to calculate the resistance percentages, the dashed 
bars indicate clinical breakpoints.
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Figure S01. Trends in resistance (%) of S. Typhimurium isolated from humans and food-animals from 1999 – 2011.
Table S04. Resistance percentages of S. Typhimurium isolated 
from different sources in 2010/2011.
S. Typhimurium
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Ampicillin 71.9 52.1 78.3 53.1
Cefotaxime 0.6 0 0 3.1
Ceftazidime 0.6 0 0 3.1
Gentamicin 0.8 0 0 3.1
Tetracycline 73.3 72.9 69.6 46.9
Sulfamethoxazole 70.7 81.3 78.3 53.1
Trimethoprim 18.3 14.6 30.4 3.1
Ciprofloxacin 12.7 2.1 0 3.1
Nalidixic acid 11.9 2.1 0 0
Chloramphenicol 18.9 27.1 17.4 9.4
Florfenicol 17.2 18.8 8.7 9.4
Streptomycin 58.2 81.3 65.2 46.9
Kanamycin 1.4 0 0 0
S. Paratyphi B var. Java (S. Java)
as in previous years, in 2010/1011 S. Java was the most 
predominant serovar isolated in broiler production. 
roughly one third of all Salmonella strains isolated 
from poultry were identified as such (Table S01, Figure 
S03). From poultry 138 S. Java strains were isolated. 
With the exception of five isolates, all harboured the 
phenotype typical for the clone, which is characterized 
by high level resistance against trimethoprim. This 
occurs frequently in combination with acquired 
resistance against the quinolones and third generation 
cephalosporins cefotaxime and ceftazidime. The majority 
of S. Java isolates from poultry expressed non-wild type 
susceptibility to ciprofloxacin (59.4%) and nalidixic acid 
(58.0%); resistance to cefotaxime (ESBL-producers) 
was detected in 13.0% of the isolates from poultry, which 
is slightly less than in previous years (22.9% in 2009 
and 20.9 in 2008). a number of S. Java strains were 
isolated from human infections in 2010 (10) and 2011 
(18). all but two strains were trimethoprim susceptible 
and therefore not related to the clone spreading in Dutch 
poultry and probably travel related.
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Table S05. Resistance (%) of S. Enteritidis isolated from different sources and phage types 4, 8, 1, 21, 6, and 14b in 2010/2011.
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Ampicillin 3.7 3.8 0 4.5 1.0 0.6 6.7 9.2 3.7 0
Cefotaxime 0.1 0.1 0 0 0 0 0 0 0 0
Ceftazidime 0.1 0.1 0 0 0 0 0 0 0 0
Gentamicin 0.1 0.1 0 0 0 0 0 1.1 0 0
Kanamycin 0.2 0.2 0 0 0 0 0 0 0 0
Streptomycin 0.5 0.4 0 4.5 0.7 0 0.7 1.1 0 0
Tetracycline 1.6 1.8 0 0 0 0 0.7 0 3.7 0
Sulfamethoxazole 1.3 1.1 0 9.1 1.4 0 0.7 1.1 1.9 0
Trimethoprim 0.7 0.7 0 0 0 0 0.7 1.1 0 0
Ciprofloxacin 9.2 9.7 2.9 13.6 3.1 3.7 31.3 6.9 11.1 23.5
Nalidixic acid 9.3 9.9 2.9 13.6 3.1 3.7 31.3 6.9 11.1 23.5
Chloramphenicol 0.2 0.2 0 0 0.3 0 0 0 1.9 0
Florfenicol 0 0 0 0 0 0 0 0 0 0
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Figure S02. Trends in resistance (%) of S. Enteritidis isolated from humans, layers and other poultry sources from 1999 – 2011.
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3.1.1.3 Salmonella in raw meats at retail
resistance data are presented for poultry meat only, 
because in beef and pork the numbers of isolates 
examined are too small to provide an accurate estimate 
(Table S06). as expected, in poultry meat samples S. Java 
was the most prevalent Salmonella serovar encountered 
(49%). Other serovars regularly included were S. 
Infantis (9%), S. minnesota (8%), S. Heidelberg (5%), S. 
Enteritidis (5%) and S. Typhimurium (3%). as expected, 
resistance profiles of S. Java isolates were similar to 
those from life animals. noteworthy in poultry meat 
isolates other than S. Java is the high level of resistance 
against cefotaxime and ceftazidime, associated with the 
presence of S. Heidelberg, S. minnesota, S. Infantis and 
S. mbandaka. also resistance to the quinolones was 
relatively high, which mainly can be attributed to the 
presence of S. Heidelberg and S. Infantis, the relatively 
high level of kanamycin resistance to S. minnesota.
From “exotic meat”, 19 Salmonella serovars were isolated 
which are infrequently seen. Only two serovars isolated 
from crocodile meat show resistance, to streptomycin, 
sulfamethoxazole, tetracycline and trimethoprim. all 
other isolates, mainly from kangaroo meat were fully 
susceptible for the antibiotics tested. Figure S04 shows 
the overall resistance levels of Salmonella from poultry 
products over the years. It should be noted that this not 
necessarily reflects the exposure of humans to resistant 
salmonellae. For instance S. Java, with a substantial 
contribution to the resistance levels, is hardly infective for 
humans.
Table S06. Resistance (%) of Salmonella enterica isolated from raw meats from poultry, and other raw meat sources in 2010/2011.
poultry meat S. Java
N = 76
poultry meat other serovars
N = 79
other raw meat sources
N = 116
Ampicillin 59.2 32.9 34.5
Cefotaxime 18.4 16.5 3.4
Ceftazidime 18.4 16.5 2.6
Gentamicin 5.3 1.3 2.6
Kanamycin 10.5 15.2 4.3
Streptomycin 38.2 15.2 28.4
Tetracycline 28.9 49.4 40.5
Sulfamethoxazole 64.5 54.4 40.0
Trimethoprim 100 7.6 14.7
Ciprofloxacin 68.4 26.6 18.1
Nalidixic acid 65.8 27.8 18.1
Chloramphenicol 2.6 8.9 16.4
Florfenicol 2.6 2.5 13.8
Salmonella Java
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Figure S03. Trends in resistance (%) of S. Paratyphi B var. Java isolated 
from poultry from 1999 – 2011 and humans (Separate data on the right 
indicate all human S. Java isolates from 1999 – 2011).
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3.1.1.4 Salmonella in other European countries 
The annual report on trends and sources of zoonoses, 
issued by the European Food Safety authority and 
the European Centre for Disease prevention and 
Control summarizing data from 27 EU member states, 
presents data on the occurrence of zoonoses and 
foodborne outbreaks as well as on antibiotic resistance 
in these agents. Data from 2010 show that 99,020 
salmonellosis cases in humans with a decreasing trend 
in case numbers over the years (assumed to be due to 
successful Salmonella control programmes in poultry, 
in particular vaccination against S. Enteritidis). In 
foodstuffs, Salmonella was most often detected in fresh 
broiler and turkey meat (The European Union Summary 
report on Trends and Sources of Zoonoses, Zoonotic 
agents and Food-borne Outbreaks in 2010, EFSa 
Journal 2012;10(3):2597; http://www.efsa.europa.eu/en/
efsajournal/pub/2597.htm).
as in previous years, S. Enteritidis (45.0%) and S. 
Typhimurium (22.4%) were the two most commonly 
reported Salmonella serovars of all reported confirmed 
human cases in 2010 in reporting member states. 
monophasic S. Typhimurium 1,4,5,12:i:- entered the 
top 10 group as the fourth most commonly reported 
serovar. monophasic S. Typhimurium was the second 
most commonly reported serovar in pigs and third most 
commonly reported serovar in cattle as well as in pig and 
bovine meat, following S. Typhimurium and S. Derby 
in pigs and S. Typhimurium and S. Dublin in cattle. 
EFSa data suggest that monophasic S. Typhimurium are 
increasing in poultry and poultry products and that the 
current tetracycline-resistant epidemic strain has spread 
beyond his initial porcine source in many countries since 
its emergence in 2006.
It should be noted that the methods and breakpoints 
used for Salmonella antimicrobial susceptibility testing 
differed somewhat between member states. most 
countries used clinical breakpoints as provided by the 
Clinical and Laboratory Standards Institute (CLSI) for 
the interpretation of test results, whereas in this report 
mostly epidemiological cut-off values provided by the 
European Committee on antimicrobial Susceptibility 
Testing (EUCaST) have been used. For chloramphenicol, 
nalidixic acid, sulfonamides and tetracycline, the CLSI 
and EUCaST breakpoints/cut-offs are equivalent, 
whereas for the remaining antimicrobials they might differ 
markedly, hampering comparison between countries.
although disparities in resistance were frequently 
observed between different member states, in general high 
resistance levels were recorded to ampicillin, tetracyclines 
and sulfonamides in Salmonella isolates from humans, 
whereas resistance to third-generation cephalosporins and 
fluoroquinolones remained low. In Salmonella isolates 
from fowl, pigs, cattle and meat thereof, resistance 
to tetracyclines, ampicillin and sulfonamides was 
also commonly detected, whereas resistance to third-
generation cephalosporins was low. 
Moderate to high levels of ciprofloxacin resistance were 
observed in Salmonella isolates from turkeys, fowl and 
broiler meat (The European Union Summary report 
on antimicrobial resistance in zoonotic and indicator 
bacteria from humans, animals and food in 2010. EFSa 
Journal 2012;10(3):2598; http://www.efsa.europa.eu/en/
efsajournal/pub/2598.htm)
Compared to the reported data from other EU member 
states, resistance percentages of Dutch Salmonella isolates 
showed no exceptional differences.
3.1.2 Campylobacter
This chapter describes the resistance in Campylobacter 
jejuni and C. coli isolated from food animals and from 
humans suffering from diarrhoea. Samples from food 
animals (broiler chickens, slaughter pigs, veal calves 
and dairy cows), as well as meat samples have been 
collected by the Dutch Food and Consumer Product 
Safety authority (nVWa). mICs have been determined 
by the Central Veterinary Institute (CVI) for the isolates 
from live animals, isolates from meat were tested at 
the nVWa. Data on human isolates were provided by 
the Dutch national Institute for Public Health and the 
Environment (rIVm).
Highlights
1. In veal calves and poultry meat, a very high 
proportion of Campylobacter is resistant to 
ciprofloxacin (ranging from 58.7% in C. jejuni to 
up to 80.6% in C. coli). 
2. Low levels were observed for erythromycin and 
gentamicin, with the exception of erythromycin 
resistance in C. coli (25%). 
3. High resistance was also recorded for commonly 
used antimicrobials such as ampicillin and 
tetracyclines.
4. Similarly, a high proportion of Campylobacter 
in humans is resistant to the critically important 
antimicrobial ciprofloxacin whereas low resistance 
was recorded for another critically important 
antimicrobial, erythromycin. 
3.1.2.1 Resistance levels
In Table C01 the mIC-distributions and resistance 
percentages are summarized for all Campylobacter jejuni 
and C. coli strains isolated from broilers, pigs, veal calves 
and dairy cows in 2010 and 2011. Table C02 shows the 
more detailed resistance profiles of C. jejuni and C. coli 
according to the different sources (meat as well as from 
fecal samples from different animal species). Figure C01 
and C02 present trends over the last decade in resistance 
of C. jejuni and C. coli from the different sampling 
categories. 
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national surveillance data from 2002 onwards for 
Campylobacter spp. isolated from humans are shown 
in Figure C03, and Tables C03 and C04. It should be 
noted that data on antimicrobial resistance in isolates 
from human cases were mainly interpreted using 
clinical breakpoints, while the quantitative data on 
antimicrobial resistance in isolates from food and animals 
were interpreted using epidemiological cut-off values 
defining the microbiologically resistant isolates. The 
epidemiological cut-off values discriminate between 
the wild-type (susceptible) bacterial population and 
the non-wild type populations which have a decreased 
susceptibility towards a given antimicrobial. This enables 
the early detection of developing resistance. However, 
the use of different thresholds, clinical breakpoints and 
epidemiological cut-off values, means that resistance 
data in isolates from humans and in isolates from animals 
and food may not be fully comparable and interpretation 
should be done with caution. 
In 2010/2011 high resistance levels in C. jejuni from 
animals are seen for tetracycline (56.5%), the quinolones 
ciprofloxacin and nalidixic acid (49.1% and 48.2% 
respectively), and ampicillin (41.7%). resistance levels 
in C. coli are traditionally higher compared to C. jejuni, 
with very high levels of resistance for tetracycline 
(86.4%) and streptomycin (70.7%). However resistance 
is also commonly seen for sulfamethoxazole (46.8%), 
ciprofloxacin and nalidixic acid (41.2% and 41.4% 
respectively), ampicillin (30.2%), as well as for the 
macrolides (erythromycin, tulathromycin, clarithromycin).
Quinolones
For years, there is an increasing trend in the percentage 
of isolates resistant to the quinolones, both in strains 
Table C01. MIC distribution (in %) for all Campylobacter jejuni (N = 448, of which 201 from broilers, 132 from veal calves, 77 from dairy cows, 
and 38 from other sources) and C. coli (N = 454, of which 262 from pigs, 150 from veal calves, 39 from broilers, and 13 from other sources).
C. jejuni 
(N = 448)
MIC (%) distribution mg/L
R% 95% CI
0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 0.2 0.7 4.9 29.0 23.4 5.8 4.9 31.0 41.7 37.3-46.4
Gentamicin 90.0 6.5 3.1 0.2 0.2 0.4 0-1.1
Neomycin 88.4 4.2 1.1 1.1 1.6 2.2 0.7 0.7 7.4 5.1-9.8
Streptomycin 92.4 2.5 0.9 0.9 1.6 0.4 0.2 1.1 5.1 3.1-7.4
Tetracycline 35.0 4.9 3.6 0.9 0.4 0.9 2.2 9.2 42.9 56.5 51.8-60.9
Sulfamethoxazole 1.1 9.2 20.1 36.4 24.8 5.4 1.6 1.1 0.4 3.1 1.6-4.9
Ciprofloxacin 42.9 5.4 1.8 0.9 0.9 0.7 17.9 17.9 11.8 49.1 44.4-53.8
Nalidixic acid 6.3 29.9 12.9 2.7 0.7 0.7 13.8 33.0 48.2 43.5-52.9
Erythromycin 25.2 48.0 19.2 6.7 0.7 0.2 0.9 0.2-1.8
Clarithromycin 17.9 38.8 29.7 10.7 2.7 0.2 0.2 0-0.7
Tulathromycin 83.5 12.5 2.2 0.7 0.2 0.4 0.2 0.2 0.4 0-1.1
Chloramphenicol 37.1 44.0 12.7 5.6 0.4 0.2 0.7 0-1.6
C. coli
(N = 454)
MIC (%) distribution mg/L
R% 95% CI
0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 0.4 0.4 0.2 2.8 10.6 29.3 26.1 10.3 19.8 30.2 26.1-34.5
Gentamicin 35.8 58.0 3.9 1.1 0.4 0.9 1.3 0.4-2.4
Neomycin 53.2 33.0 2.8 1.3 0.6 0.2 0.4 0.9 7.5 11.0 8.2-14
Streptomycin 23.7 3.7 1.9 1.3 24.6 31.0 6.3 1.1 6.5 70.7 66.6-74.8
Tetracycline 8.4 3.4 1.7 0.4 0.6 0.4 1.5 3.9 79.5 86.4 83.2-89.4
Sulfamethoxazole 9.7 15.7 12.7 9.1 2.4 3.7 23.5 17.2 6.0 46.8 42.2-51.3
Ciprofloxacin 39.4 17.2 1.9 0.2 2.6 11.4 17.7 9.5 41.2 36.6-45.7
Nalidixic acid 0.2 0.2 20.7 31.9 5.4 0.2 0.4 17.5 23.5 41.4 36.9-45.9
Erythromycin 3.4 13.6 30.6 21.3 5.2 0.9 0.4 1.1 23.5 25.0 21.1-29.1
Clarithromycin 5.2 8.6 29.5 23.7 6.7 1.3 1.3 0.4 23.3 23.7 19.8-27.6
Tulathromycin 47.4 21.6 4.1 1.3 0.4 0.2 3.2 6.9 14.9 25.0 21.1-29.1
Chloramphenicol 4.7 36.4 47.4 9.5 1.7 0.2 1.9 0.9-3.2
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate MIC values > the 
highest concentration in the range. Values at the lowest concentration tested indicate MIC-values ≤ the lowest concentration in the 
range. Vertical bars indicate the epidemiological cut-off values, used as breakpoints.
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Table C02. Resistance percentages of Campylobacter jejuni and C. coli isolated from raw meat from poultry and from faecal samples of 
broilers, veal calves, dairy cows (only C. jejuni) and pigs (only C. coli) in 2010/2011.
C. jejuni C. coli
N
poultry 
products
254
broilers
201
veal 
calves
132
dairy cows
77
poultry 
products
103
broilers 
39
veal 
calves
150
pigs
262
Ampicillin 53.5 59.2 30.3 7.8 42.7 30.8 41.3 23.3
Gentamicin 0 0.5 0.8 0 1.0 0 4.0 0
Neomycin 2.4 1.0 19.7 3.9 8.7 2.6 27.3 3.4
Streptomycin 3.1 2.5 10.6 0 13.6 15.4 72.7 79.8
Tetracycline 47.6 48.8 84.8 15.6 76.7 48.7 96.7 87.4
Sulfamethoxazole 2.8 4.5 1.5 0 18.4 20.5 43.3 54.2
Ciprofloxacin 58.7 60.7 50.8 15.6 80.6 66.7 86.7 9.5
Nalidixic acid 58.7 58.7 51.5 16.9 80.6 66.7 86.7 9.9
Erythromycin 1.6 1.0 1.5 0 32.0 7.7 30.0 24.0
Tulathromycin 1.6 0 1.5 0 32.0 7.7 30.0 24.0
Clarithromycin 1.6 0.5 0 0 31.1 2.6 30.0 22.9
Chloramphenicol 1.2 0 0.8 0 1.0 0 4.7 0
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Figure C01. Trends in resistance (%) of Campylobacter jejuni isolated from broilers, poultry meat, veal calves and dairy cattle in recent years in the 
Netherlands.
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Figure C02. Trends in resistance (%) of Campylobacter coli isolated from broilers, poultry meat, slaughter pigs and veal calves in recent years in the 
Netherlands.
Table C03. Percentage Campylobacter jejuni and C. coli isolates from humans resistant against fluoroquinolones, tetracycline and 
erythromycin from 2002 to 2011.
percentage of resistant Campylobacter isolates
2002/05 2007 2008 2009 2010 2011
Fluoroquinolones 35.2 45.2 50.5 51.4 53.3 57.0
Tetracycline 20.2 23.9 17.2 20.3 22.1 24.8
Erythromycin 1.5 2.9 2.4 2.6 2.7 3.7
Table C04. Domestically acquired and travel related resistance in C. jejuni and C. coli isolated from humans from 2002 - 2011 from all 16 PHLS 
covering >50% of the Dutch population.
2009-2011 2002-2005
C. jejuni C. coli C. jejuni C. coli
Domestically 
acquired
Travel 
related
Domestically 
acquired
Travel 
related
Domestically 
acquired
Travel 
related
Domestically 
acquired
Travel 
related
R% (n) R% (n) R% (n) R% (n) R% (n) R% (n) R% (n) R% (n)
Fluoroquinolones 53.1 (8673) 67.2 (454) 51.1 (630) 56 (50) 32.7 (6792) 53.5 (600) 36.3 (386) 50 (56)
Tetracycline 20.5 (5164) 34.4 (90) 34.7 (398) 40 (10) 18.5 (5028) 27.1 (425) 22.7 (353) 20.4 (49)
Erythromycin 2.4 (7339) 4.4 (338) 8.1 (540) 14.3 (35) 1.2 (5735) 1.6 (511) 3.0 (372) 0 (52)
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from animal origin (Figure C01) as in those from human 
patients (Figure C02). This is a worrisome development 
as ciprofloxacin is the second-choice drug for treatment 
of campylobacteriosis and resistance evolves rapidly, 
not only in the netherlands, but worldwide. In 2010 and 
2011, 60.7% of C. jejuni and 66.7% of C. coli isolates 
from broilers were resistant, and 57% of the human 
Campylobacter isolates.
Macrolides
Erythromycin or other suitable macrolides, are the first-
choice drugs for the treatment of campylobacteriosis 
in humans. The level of resistance for erythromycin 
reported in animals and humans is low for C. jejuni, on 
average 0.9% in strains from animal origin in 2010 and 
2011(n=448) and 2.4% in human isolates from 2009-2011 
(n=7339). It should be noted that  for human isolates more 
sensitive breakpoints for resistance have been applied (≥ 
1.5-2.0), for animal isolates the EUCaST epidemiological 
cut-off values were used (≥4 for C. jejuni, and ≥8 for C. 
coli). In contrast, in C. coli levels are much higher and 
importantly, seem to be steadily increasing in recent years 
(Figure C01) in isolates from animals. In veal calves, 
levels as high as 30% and 24% in pigs (Table C02) are 
noted.
3.1.2.1.1 Broiler chickens and poultry meat
In Campylobacter from poultry, resistance profiles for 
isolates recovered from animals as well as from meat 
samples are available. Campylobacter is seldom isolated 
from other animal meat, except turkey. as shown in 
Table C02, high levels of resistance are observed for the 
quinolones, tetracycline and ampicillin, while resistance 
to the other antimicrobial drugs is (very) low. In general, 
resistance levels in isolates from both sample categories 
are comparable. One exception is the higher level 
of macrolide resistance in C. coli from poultry meat 
(31.1% for clarithromycin, 32.0% for erythromycin and 
tulathromycin) compared to the percentages observed 
in caecal samples from poultry taken at abattoirs 
(2.6% for clarithromycin, 7.7% for erythromycin and 
tulathromycin). This might be due to the relatively low 
numbers of isolates tested or to possible bias in sampling.
3.1.2.1.2 Pigs
In C. coli from pigs, highest resistance levels were 
observed for tetracycline (87.4%), followed by 
streptomycin (79.8%), and sulfamethoxazole (54.2%). 
Resistance to nalidixic acid and ciprofloxacin was 
relatively low (9.9% and 9.5% respectively) compared 
to levels in broilers (66.7%) and veal calves (86.7%), 
probably reflecting the low use of quinolones in swine. 
resistance to macrolides occurred fairly common with 
22.9-24% of the isolates resistant. Over the last 5-10 
years, levels have remained relatively stable.
3.1.2.1.3 Veal calves
Data for both C. jejuni and C. coli isolated from veal 
calves are included in this report. C. coli isolates were 
more resistant than C. jejuni for all antimicrobial drugs 
included in the test panel. In both species highest levels 
were observed for tetracycline (84.8% in C. jejuni and 
96.7% in C. coli) and ciprofloxacin and nalidixic acid 
(50.8% and 51.5% respectively in C. jejuni and 86.7% in 
C. coli). The high level of macrolide resistance (30%) is 
comparable to that observed in pigs. There is also a strong 
tendency to increase over the last six years.
3.1.2.1.4 Dairy cows
In C. jejuni form dairy cattle the highest levels of 
resistance were observed for the quinolones (15.6% 
for ciprofloxacin and 16.9% for nalidixic acid) and 
tetracycline (15.6%). a lower level of resistance was 
recorded for ampicillin (7.8%) and neomycin (3.9%) 
while for the other antimicrobials tested no resistance was 
found.
Due to the relative low number of isolates, the levels over 
the years show some variation. nevertheless, no obvious 
changes have been observed.
3.1.2.2 Campylobacter in humans 
Data on resistance levels are available for ciprofloxacin, 
erythromycin and tetracycline and are summarized in 
Table C03 and Figure C03. High levels of resistance are 
observed in 2010 and 2011 for the critically important 
antimicrobial ciprofloxacin (53.3% and 57.0%) and 
also resistance to tetracycline was commonly detected 
(22.1% and 24.8% respectively). Erythromycin resistance, 
another critically important antimicrobial, was low in both 
years, although the percentage in 2011 (3.7%) tended to 
be somewhat higher than in previous years.
The trends as shown in Figure C03 indicate that resistance 
levels for ciprofloxacin and tetracycline show a constant 
tendency to increase, most outspokenly for ciprofloxacin. 
In Table C04 resistance levels have been specified 
0
10
20
30
40
50
60
'92 '93 '94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11
Re
sis
tan
ce
 (%
)
tetracycline ciprofloxacin erythromycin
  Campylobacter spp.
Figure C03. Trends in resistance (%) of Campylobacter spp. isolated 
from humans between 1992 and 2011 at the regional Public Health 
Laboratories (PHLS) of Arnhem and Heerlen covering 990.000 inhabitants 
(400-700 isolates per year). The continuous line represents national 
surveillance data from 2002 onwards; the average number of strains 
tested per year was approximately 2400, ranging from 1900 – 2900.
m a r a n  2 0 1 2
22
according to the most probable infection route, i.e. 
whether the infection was either acquired domestically or 
abroad. In C. jejuni, resistance levels were higher for all 
three antimicrobials in travel related infections compared 
to domestically acquired campylobacteriosis. For C. 
coli this difference is less straightforward, based on the 
relatively low number of isolates. 
3.1.2.3 Campylobacter in other European countries
The EU notification rate of campylobacteriosis has 
followed an increasing trend since 2006, making it by 
far the most frequently reported zoonosis in humans in 
the EU with over 200,000 reported cases in 2010 in 27 
countries (The European Union Summary report on 
Trends and Sources of Zoonoses, Zoonotic agents and 
Food-borne Outbreaks in 2010, EFSa Journal 2012; 
10(3):2597; http://www.efsa.europa.eu/en/efsajournal/
pub/2597.htm). In the EU member states, the high 
occurrence of resistance against ciprofloxacin is of 
concern, commonly observed in Campylobacter isolates 
from poultry, as well as from pigs and cattle, at levels 
ranging from 37% to 84%.
resistance to erythromycin was detected in 
Campylobacter isolates from poultry, poultry meat 
and pigs at levels of 0.5% to 25%. among isolates 
of Campylobacter from meat and animals, resistance 
against ciprofloxacin, nalidixic acid and tetracyclines was 
commonly detected at levels of 21% to 84%, whereas 
in general much lower levels of resistance against 
erythromycin and gentamicin were reported.
3.1.3 Shiga- toxin producing E. coli (STEC)
Highlights
1. In the last five years, resistance levels in Shiga- 
toxin producing E. coli (STEC) from human 
patients and from cattle have seen in increase, 
although there seems to be a time lag in trends 
from human isolates compared to bovine isolates.
2. resistance levels in cattle are generally higher 
for streptomycin, tetracycline, sulfamethoxazole, 
trimethoprim and chloramphenicol. nevertheless, 
the similarity in mIC data of STEC from cattle and 
humans isolated in 2010 has led to the suggestion 
that cattle, via the food chain, might be a likely 
source of at least some human infections.
3. Based on MIC profiles, one extended spectrum 
beta-lactamases (ESBL) suspected isolate was 
found in humans, but not in cattle.antimicrobial, 
erythromycin. 
In 2010 and 2011, 234 Shiga-toxin producing E. coli 
O157 (STEC) isolates were tested for susceptibility. 
Isolates were obtained from human patients in 2010 
(n=58) and 2011 (n=76), from cattle isolates were 
available only for 2010 (n=100). mIC results are shown 
in Table STEC01. Of the bovine isolates, 65 were 
recovered from veal calves and 35 from dairy cattle. 
3.1.3.1 Trends in resistance
Over the last ten years, MIC profiles seem to have 
a tendency to increase as shown in Figure STEC01. 
Traditionally, resistance levels in E. coli O157 have 
been very low, both in human as in bovine strains. From 
2004 onwards, resistance in cattle strains occurred more 
commonly. most striking increases have been noted for 
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Figure STEC01 Trends in resistance percentages of E. coli O157 (STEC) isolated in The Netherlands from 1999 – 2011.
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tetracycline, sulfamethoxazole and trimethoprim and 
to a lesser extend for ampicillin, chloramphenicol and 
florfenicol. Resistance to the aminoglycosides kanamycin 
and streptomycin is also commonly found.
Likewise a moderate increase can be noted in human 
isolates from 2006/2007, although in general resistance 
levels are lower. The similarity in mIC data of Shiga- 
toxin producing E. coli (STEC) from cattle and humans 
isolated in 2010 has been interpreted as confirmatory 
data for cattle, via the food chain, being a likely source 
of at least some human infections (The European Union 
Summary report on antimicrobial resistance in zoonotic 
and indicator bacteria from humans, animals and food 
in 2010, EFSa Journal 2012;10(3):2598).  although 
resistance data may provide a powerful tool to investigate 
and speculate on likely epidemiology of infection, for 
the confirmation of epidemiological relationships such 
data should preferably be used in combination with other 
typing methods. 
Beta-lactamases (ESBLs)
In 2010, for the first time resistance to third generation 
cephalosporins (cefotaxime or ceftazidime) was 
encountered in one human strain, which is considered to 
be an indication for the presence of extended spectrum 
beta-lactamases (ESBLs). In this particular isolate an mIC 
level of >4 mg/l and >16 was observed for cefotaxime 
and ceftazidime respectively. no ESBL suspected isolates 
have been recovered from bovine samples in this period, 
although a cefotaxime and ceftazidime resistance has been 
recorded in 2006/2007 (among 142 isolates tested). 
Table STEC01. MIC distribution (in %) and resistance percentages (R%) for E. coli O157 isolated from humans (N=134) and cattle (N=100) 
in The Netherlands in 2010 and 2011.
Humans
N = 134
MIC (%) distribution mg/L R% 95% CI
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 17.2 76.1 7.5 7.5 2.9 - 12
Cefotaxime 91.8 7.5 0.7 0.7 0 - 2.2
Ceftazidime 98.5 0.7 0.7 0.7 0 - 2.2
Gentamicin 20.1 58.2 19.4 2.2 0.7 0.7 0 - 2.2
Kanamycin 93.3 3.0 0.7 3.0 3.7 0.4 - 7.0
Streptomycin 3.0 47.8 36.6 0.7 0.7 3.0 1.5 7.5 12.7 6.9 - 18.4
Tetracycline 66.4 24.6 0.7 0.7 8.2 9.0 4 - 13.8
Sulfamethoxazole 85.1 1.5 13.4 13.4 7.5 - 19.3
Trimethoprim 94.0 0.7 5.2 5.2 1.3 - 9.0
Ciprofloxacin 67.2 33.6 0 0 - 0.03
Nalidixic acid 100.0 0 0 - 0.03
Chloramphenicol 3.7 85.1 10.4 1.5 1.5 0 - 3.5
Florfenicol 17.2 78.4 3.7 1.5 1.5 0 - 3.5
Cattle
N = 100
MIC (%) distribution mg/L R% 95% CI
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 92.0 1.0 7.0 7.0 1.8 - 12.1
Cefotaxime 100.0 0 0 - 0.04
Ceftazidime 99.0 1.0 0 0 - 0.04
Gentamicin 18.0 75.0 6.0 1.0 0 0 - 0.04
Kanamycin 92.0 2.0 6.0 6.0 1.2 - 10.7
Streptomycin 64.0 19.0 2.0 3.0 5.0 3.0 4.0 15.0 7.8 - 22.1
Tetracycline 19.0 67.0 2.0 12.0 14.0 7.0 - 20.9
Sulfamethoxazole 36.0 32.0 17.0 15.0 15.0 7.8 - 22.1
Trimethoprim 92.0 2.0 6.0 6.0 1.2 - 10.7
Ciprofloxacin 46.0 54.0 0 0 - 0.04
Nalidixic acid 96.0 4.0 0 0 - 0.04
Chloramphenicol 94.0 1.0 5.0 5.0 0.6 - 9.3
Florfenicol 28.0 72.0 0 0 - 0.04
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate MIC values > the highest 
concentration in the range. Values at the lowest concentration tested indicate MIC-values ≤ the lowest concentration in the range. Vertical bars 
indicate the cut-off values used as breakpoints. Dashed bars indicate the clinical breakpoints.
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3.2 Commensal indicator organisms
This chapter describes the susceptibility profiles of 
commensal micro-organisms of the gastro-intestinal tract. 
The level of antimicrobial resistance in bacteria inhabiting 
the intestinal tract directly reflects the selection pressure 
as a result of the use of antibiotics in animals, especially 
over time. For this purpose, E. coli and Enterococcus 
species (E. faecium and E. faecalis) are included as 
indicator organisms for the Gram-negative and the Gram-
positive flora, respectively. 
Isolation of bacteria from the intestine of randomly picked 
animals (broiler chickens and pigs) at slaughter aims 
to detect the development of resistance at the bacterial 
population level in food animals as prescribed by EFSa1. 
This monitoring is conducted since 1998 in slaughter pigs 
and broilers and from 2005 onwards, resistance in isolates 
from both dairy cattle and veal calves have been included 
in the monitoring, using the same samples that were 
taken at farms to determine the prevalence of Salmonella, 
E. coli O157 and Campylobacter. From 2010 onwards, 
samples of dairy cattle were obtained at slaughter houses. 
In 2011, for the first time samples of turkeys (taken at 
farms), turkey meat, herbs, vegetables and fruits were 
included in the surveillance.
It should be noted however, that the sampling strategy 
implies that this method is inherently insensitive for 
detecting resistance as only one randomly selected isolate 
is tested from a single sample taken from one animal 
per epidemiological unit (herd or flock). The total set of 
selected isolates is intended to represent the E. coli, or 
Enterococcus species population of each animal species 
of the entire country. One per cent resistance in e.g. E. 
coli indicates that in all animals 1% of the E. coli bacteria 
are resistant. Because each animal harbours about 106 
cfu/g faeces E. coli in its gut, 1% would be approximately 
104 cfu/g faeces. This means that the absence of resistance 
in these datasets does not exclude the possibility that 
resistance is present in relatively small numbers in 
individual animals.
3.2.1 Escherichia coli
In this chapter information is presented on resistance in 
E. coli from food-producing animals in the netherlands 
as indicator organisms for the occurrence and trends in 
resistance in Gram-negative bacteria present in the gastro-
intestinal tract of food-producing animals. It should 
be noted that resistant isolates were defined by using 
epidemiological cut-off values for the interpretation of 
minimum inhibitory concentrations (mIC) values. 
Epidemiological cut-off values are in most cases lower 
than clinical breakpoints, and this can result in more 
non-wild type susceptible isolates being classified as 
resistant, depending on the mIC distribution. If available, 
the epidemiological cut-off values as well as the clinical 
breakpoints are shown in Table Eco01.
Highlights
1. among indicator (commensal) E. coli isolates 
from meat and animals, resistance to ampicillin, 
streptomycin, tetracyclines, sulfonamides and 
trimethoprim was commonly detected in all 
host species except dairy cattle. resistance to 
antimicrobials recognised as critically important in 
human medicine, such as the fluoroquinolones and 
third- and fourth generation cephalosporins, was 
also observed in the indicator E. coli isolates. 
2. Reduced susceptibility to ciprofloxacin and 
nalidixic acid was highest for E. coli isolates 
from broilers (59.4% and 59.6% respectively) and 
turkeys (31.6% and 27.4% respectively). These 
high proportions of isolates exhibiting resistance to 
ciprofloxacin are of concern. 
3. resistance to third-generation cephalosporins was 
observed in indicator E. coli isolates from poultry, 
pigs and cattle and varied from very low levels in 
dairy cattle (0.4%) to 13.2% in broiler chickens. 
more extensive information on ESBL producing 
E. coli in broilers is presented in appendix I, which 
shows that cefotaxime resistance shows a tendency 
to decrease from 2009 onwards.
3.2.1.1 Resistance levels
mIC distributions concerning a total of 2098 isolates 
selected from chicken, pig, cattle, and turkey are 
summarized in Table Eco01. Trends in resistance levels 
over time according to host animal species are shown in 
Figure Eco01 and information on multidrug resistance is 
shown in Figure Eco02. additionally, data are presented 
on 1091 isolates collected and tested by the Dutch Food 
and Consumer Product Safety authority. These consist of 
mIC distributions of E. coli isolates from beef, veal, pork, 
poultry and turkey meat. This year for the first time data 
are included on E. coli isolated from vegetables, fruits 
and herbs in 2011 (Table Eco02). Trends in resistance 
of E. coli isolated from poultry meat products, beef and 
pork in the netherlands from the period 1998 to 2011 
are presented in Figure Eco03. Finally, results for the 
netherlands are related to the situation in other EU 
member states.
Table Eco01 presents the mIC distributions and 
percentages for E. coli strains expressing reduced 
susceptibility from farm animals in 2010 and 2011and 
specified for broiler chickens, slaughter pigs, veal calves 
1 report from the Task Force on Zoonoses Data Collection including guidance for harmonized monitoring and reporting of antimicrobial resistance 
in commensal Escherichia coli and Enterococcus spp. from food animals. http://www.efsa.europa.eu/en/efsajournal/pub/141r.htm.
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Table Eco01 MIC distribution (in %) and resistance percentages (R%) for E. coli isolated as indicator organism from intestines of broiler 
chicken (N = 567), slaughter pigs (N=569), veal calves (N=338), dairy cattle (N=529) in The Netherlands in 2010 and 2011 and turkey (N=95) in 
2011.
Broilers
N = 567
MIC (%) distribution mg/L
R% 95% CI
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 0.5 10.6 16.2 1.4 0.2 71.1 71.3 67.4 - 75
Cefotaxime 66.8 17.6 2.3 0.2 0.7 0.4 0.5 11.5 13.2 10.3 - 16
Ceftazidime 80.6 6.5 2.3 2.1 2.6 2.6 2.3 0.9 12.9 10 - 15.6
Gentamicin 2.6 51.3 32.6 5.1 1.1 1.6 3.2 1.4 1.1 8.3 5.9 - 10.6
Kanamycin 77.8 7.6 1.6 0.2 12.9 14.6 11.6 - 17.6
Streptomycin 0.2 7.1 23.3 4.9 6.2 8.6 8.8 40.9 64.6 60.5 - 68.5
Tetracycline 4.9 23.1 15.3 0.9 0.2 0.5 7.2 47.8 55.7 51.5 - 59.9
Sulfamethoxazole 32.6 0.2 0.9 0.2 66.1 67.2 63.2 - 71.1
Trimethoprim 40.6 1.1 0.4 58.0 58.4 54.2 - 62.5
Ciprofloxacin 30.9 8.8 0.9 3.7 32.8 11.8 3.9 0.5 0.4 3.9 2.5 59.4 55.3 - 63.5
Nalidixic acid 39.9 0.2 0.4 1.1 4.2 54.3 59.6 55.4 - 63.7
Chloramphenicol 0.4 6.3 58.6 11.5 3.0 7.1 13.2 23.3 19.7 - 26.8
Florfenicol 0.4 10.6 65.6 19.9 3.2 0.4 3.5 1.9 - 5
Slaughter pigs
N = 569
MIC (%) distribution mg/L
R% 95% CI
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 2,5 23,2 36,4 3,5 0,2 34,3 34,4 30.4 - 38.4
Cefotaxime 84,4 14,2 0,2 0,4 0,2 0,7 1,2 0.3 - 2.1
Ceftazidime 94,0 4,4 0,9 0,2 0,2 0,4 1,6 0.5 - 2.6
Gentamicin 7,6 51,1 33,4 6,2 1,4 0,4 1,8 0.6 - 2.8
Kanamycin 88,0 8,1 1,6 0,5 1,8 3,9 2.2 - 5.4
Streptomycin 0,2 9,3 24,4 9,5 10,7 10,0 10,2 25,7 56,6 52.4 - 60.7
Tetracycline 4,2 21,1 9,0 0,5 1,2 1,4 12,8 49,7 65,2 61.2 - 69.1
Sulfamethoxazole 45,2 0,2 0,2 54,5 54,7 50.4 - 58.8
Trimethoprim 51,0 0,5 0,4 0,2 0,2 47,8 48,2 43.9 - 52.3
Ciprofloxacin 81,2 17,6 0,2 0,2 0,4 0,4 0,2 1,1 0.1 - 1.9
Nalidixic acid 97,4 1,8 0,2 0,7 0,7 0 - 1.4
Chloramphenicol 0,2 10,0 67,7 10,2 4,2 2,1 5,6 12,0 9.2 - 14.6
Florfenicol 1,2 14,6 71,0 12,1 0,9 0,2 1,1 0.1 - 1.9
Veal calves
N = 338
MIC (%) distribution mg/L
R% 95% CI
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 1,8 16,9 34,0 1,8 0,3 45,3 45,6 40.1 - 50.9
Cefotaxime 75,1 18,3 4,1 0,9 0,3 1,2 2,4 0.7 - 4
Ceftazidime 91,4 6,5 1,2 0,9 2,1 0.5 - 3.6
Gentamicin 4,1 45,0 32,5 7,4 1,2 0,6 3,0 3,3 3,0 10,9 7.5 - 14.3
Kanamycin 68,9 7,4 0,9 0,6 0,6 21,6 23,7 19 - 28.2
Streptomycin 0,3 13,3 25,1 6,2 4,1 4,7 9,2 37,0 55,0 49.6 - 60.4
Tetracycline 3,8 9,5 13,3 0,3 0,6 10,1 62,4 73,1 68.2 - 77.9
Sulfamethoxazole 45,6 54,4 54,4 49 - 59.8
Trimethoprim 54,4 1,2 44,4 44,4 38.9 - 49.7
Ciprofloxacin 63,0 15,1 0,6 1,8 7,4 3,3 1,2 0,3 0,9 6,5 21,3 16.8 - 25.7
Nalidixic acid 77,2 2,4 0,6 19,8 19,8 15.4 - 24.1
Chloramphenicol 6,8 53,6 11,8 0,6 4,1 23,1 27,8 22.9 - 32.6
Florfenicol 0,3 10,4 58,3 11,5 3,8 0,6 15,1 19,5 15.2 - 23.8
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Table Eco01 (continued).
Dairy cattle
N = 529
MIC (%) distribution mg/L R% 95% CI
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 3,2 22,5 65,8 7,0 1,5 1,5 0.4 - 2.5
Cefotaxime 79,8 18,9 0,9 0,2 0,2 0,4 0 - 0.9
Ceftazidime 96,2 3,6 0,0 0,2 0,2 0 - 0.5
Gentamicin 6,6 61,6 25,3 5,7 0,6 0,2 0,8 0 - 1.5
Kanamycin 93,0 5,9 0,8 1,1 0.2 - 2
Streptomycin 0,9 32,9 58,6 4,9 0,4 0,6 0,9 0,8 2,6 1.2 - 4
Tetracycline 6,8 52,9 36,5 0,8 0,4 2,6 3,0 1.5 - 4.5
Sulfamethoxazole 97,4 0,4 0,4 1,9 1,9 0.7 - 3
Trimethoprim 98,1 1,1 0,2 0,6 0,6 0 - 1.2
Ciprofloxacin 79,0 20,2 0,4 0,2 0,2 0,4 0 - 0.9
Nalidixic acid 97,4 2,3 0,4 0,4 0 - 0.9
Chloramphenicol 0,2 5,3 77,9 15,7 0,2 0,2 0,6 0,9 0.1 - 1.7
Florfenicol 0,2 7,2 80,9 11,0 0,4 0,4 0,8 0 - 1.5
Turkey
N = 95
MIC (%) distribution mg/L R% 95% CI
0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 1,1 7,4 11,6 80,0 80,0 71.7 - 88.2
Cefotaxime 62,1 29,5 2,1 1,1 2,1 2,1 1,1 6,3 1.3 - 11.3
Ceftazidime 89,5 4,2 3,2 2,1 1,1 6,3 1.3 - 11.3
Gentamicin 43,2 35,8 12,6 1,1 1,1 2,1 3,2 1,1 8,4 2.7 - 14.1
Kanamycin 75,8 10,5 1,1 2,1 10,5 13,7 6.6 - 20.7
Streptomycin 1,1 36,8 6,3 14,7 12,6 10,5 17,9 55,8 45.5 - 65.9
Tetracycline 4,2 7,4 8,4 2,1 1,1 15,8 61,1 80,0 71.7 - 88.2
Sulfamethoxazole 32,6 1,1 66,3 66,3 56.6 - 76
Trimethoprim 60,0 1,1 38,9 38,9 28.9 - 48.9
Ciprofloxacin 55,8 12,6 2,1 8,4 8,4 2,1 1,1 9,5 31,6 22 - 41.1
Nalidixic acid 69,5 1,1 2,1 1,1 26,3 27,4 18.2 - 36.5
Chloramphenicol 6,3 45,3 5,3 16,8 12,6 13,7 43,2 32.9 - 53.3
Florfenicol 10,5 54,7 29,5 5,3 5,3 0.6 - 9.8
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate MIC values > the highest 
concentration in the range. Values at the lowest concentration tested indicate MIC-values ≤ the lowest concentration in the range. Vertical bars 
indicate the epidemiological cut-off values used as breakpoints as defined by EUCAST. The dashed bars indicate the clinical breakpoints.
and dairy cows. For most drugs or drug classes there 
are notable variations in resistance levels between the 
different animal species, most strikingly for ampicillin 
ranging from 1.5% in dairy cattle to 80% in turkey 
isolates.
In general, highest resistance is seen for ampicillin, 
tetracycline, streptomycin, trimethoprim and 
sulfamethoxazole. These include the drug classes that are 
most frequently used in veterinary medicine.
Quinolones
reduced susceptibility to quinolones is most commonly 
encountered in E. coli isolated from broiler chickens; 
59% of all isolates that were tested showed non-wild 
type susceptibility2 to nalidixic acid and ciprofloxacin. 
In 2010/2011 high level resistance (mIC >1 mg/l) to 
ciprofloxacin in broiler chickens was detected in 7.2%, 
compared to 5.4% in 2009 and 6.3% of the isolates in 
2008.
The percentage of E. coli with acquired resistance 
mechanisms to ciprofloxacin was also high among turkey 
(31.6%) and veal calves (21.3%) compared to 1.1% in 
pigs and 0.4% in dairy cattle. This likely reflects the use 
of quinolones in various animal husbandry systems.
2 A micro-organism is defined as wild type (WT) for a species by the absence of acquired and mutational resistance mechanisms to the drug in 
question. Wild type micro-organisms may or may not respond clinically to antimicrobial treatment (http://www.eucast.org).
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Figure Eco01. Trends in resistance (%) of E. coli isolated from broilers, slaughter pigs, veal calves, and dairy cattle in the Netherlands from 1998 – 2011.
For dairy cows changes in sampling strategy have been implemented between 2009 and 2010; Until 2009 samples were collected at farm level, in  2010 and 
2011  individual animals were randomly sampled at slaughterhouses.
Table Eco02. Resistance (in %) of E. coli isolated from raw meat products at retail in the Netherlands in 2010/2011
Poultry meat
N = 468
Pork
N = 186
Veal*
N = 31
Beef
N = 262
Turkey meat*
N = 46
Herbs* 
N = 33
Vegetables 
and fruits
N = 65
Ampicillin 65.4 22.6 32.3 11.1 76.1 33.3 1.5
Cefotaxime 20.3 1.6 3.2 1.5 2.2 0 0
Ceftazidime 19.0 2.2 0 1.5 2.2 3.0 1.5
Gentamicin 10.3 4.8 0 0.4 13.0 6.1 0
Kanamycin 14.7 5.4 6.5 5.3 21.7 3.0 0
Streptomycin 54.1 25.8 35.5 14.1 50.0 36.4 1.5
Tetracycline 54.9 31.2 45.2 14.1 69.6 42.4 3.1
Sulfamethoxazole 60.5 33.3 32.3 20.6 56.5 33.3 1.5
Trimethoprim 44.2 24.2 29.0 12.6 34.8 33.3 1.5
Ciprofloxacin 48.1 2.7 6.5 3.8 39.1 33.3 1.5
Naladixic acid 45.7 2.2 6.5 3.8 37.0 21.2 1.5
Chloramphenicol 17.7 5.9 12.9 3.1 23.9 24.2 0
Florfenicol 2.1 2.2 9.7 1.1 0 18.2 0
*Data only from 2011
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Beta-lactamases (ESBL)
resistance to third generation cephalosporins, indicative 
of ESBL producing E. coli, was detected in all animal host 
species included in this survey. reduced susceptibility 
levels for cefotaxime ranged from 0.4% in samples from 
dairy cattle to 13.2% in broiler samples from 2010/ 2011 
(Table Eco01). among E. coli isolated from meat, levels 
were as high as 20.3% (n=468) in poultry meat as shown 
in Table Eco02. more extensive information on ESBL 
producing E. coli in broilers is presented in appendix I, 
which shows that cefotaxime resistance shows a tendency 
to decrease from 2009 onwards.
3.2.1.1.1 Broilers 
In commensal E. coli isolated from caecal samples from 
broiler chickens resistance to all antimicrobials tested was 
common as summarized in Table Eco01. Very high levels 
of reduced susceptibility were observed for ampicillin 
(71.3%), sulfamethoxazole (67.2%), streptomycin (64.6%), 
trimethoprim (58.4%), the quinolones nalidixic acid (59.6%) 
and ciprofloxacin (59.4%) and tetracycline (55.7%). Also 
resistance to chloramphenicol, cefotaxime and ceftazidime, 
kanamycin and gentamicin was commonly found. 
Overall, the resistance levels in 2011 were generally 
slightly lower than those in previous years for all of the 
antimicrobials tested (Figure Eco01)
3.2.1.1.2 Slaughter pigs
Highest levels of resistance in swine isolates in 2010/2011 
were recorded for tetracycline (65.2%), streptomycin 
(56.6%), sulfamethoxazole (54.7%) and trimethoprim 
(48.2%). 
E. coli isolated from slaughter pigs has shown an on-going 
increasing trend in resistance for most antibiotics since 
approximately the turn of the century. Especially with 
regard to beta-lactam antibiotics (ampicillin, cefotaxime 
and ceftazidime), fluoroquinolones (nalidixic acid and 
ciprofloxacin), trimethoprim and sulphamethoxazole an 
increase was noted as shown in Figure Eco01. However, 
levels from recent years appear to stabilize or even show a 
slight tendency to decrease. resistance to the beta-lactam 
antibiotics was observed; 34.4% of the isolates resistant to 
ampicillin, 1.2% and 1.6% of the isolates being resistant to 
cefotaxime and ceftazidime respectively. The prevalence 
of suspected ESBL-producers was somewhat lower in 
2010/2011 compared to 2009 when 3.7% of the isolates 
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Figure Eco02. Resistance (%) to 0-9 antimicrobial classes among E. coli strains from broiler chickens, slaughter pigs and veal calves in the Netherlands 
from 1998 - 2011.
For dairy cows changes in sampling strategy have been implemented between 2009 and 2010; Until 2009 samples were collected at farm level, in  2010 and 
2011  individual animals were randomly sampled at slaughterhouses.
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were cefotaxime resistant. resistance is variable for the 
aminoglycoside class antibiotics. Streptomycin resistance 
is common (56.6% in 2010/2011), while 1.8% of the 
E. coli strains were resistant to gentamicin and 3.9% to 
kanamycin. 
Resistance to chloramphenicol and florfenicol has 
remained stable over the years, with an average rate 
around 10% for chloramphenicol and below 1% for 
florfenicol.
3.2.1.1.3 Veal calves
Figure Eco01 illustrates the trends in resistance in E. 
coli isolated from veal calves. resistance levels have 
been relatively stable over time, although there is a 
tendency to increase in the last two years. For instance 
for tetracycline, after a decrease from 82.4% in 2005 
to 59.1% in 2009, levels in 2010 and 2011 had again 
increased to 72.7 and 73.5% respectively.
For beta-lactam antibiotics, resistance to ampicillin is 
commonly seen (45.6% in 2010/2011), while, resistance 
to 3rd generation of cephalosporins like cefotaxime and 
ceftazidime remains relatively low (2.4% and 2.1% 
respectively).
With regard to fluoroquinolone resistance, about 21.3% 
of E. coli from veal calves showed reduced susceptibility 
to ciprofloxacin, 7.7% were considered clinically resistant 
with mIC values >1 mg/l. 
Resistance to both chloramphenicol and florfenicol 
is common, data from 2010/2011 show resistance 
percentages of 27.8% for chloramphenicol and 19.5% for 
florfenicol.
3.2.1.1.4 Dairy cattle
In general, resistance in E. coli isolated from dairy 
cattle is low compared to resistance levels seen in pigs, 
broilers and veal calves. Highest level of resistance was 
recorded for tetracycline (3.0% of the isolates). although 
only 1.5% of the isolates were resistant to ampicillin, 
still cefotaxime resistance was expressed by 0.4% of the 
isolates. 
The trends in resistance as illustrated in Figure Eco01 
have shown a gradual increase for a number of 
antimicrobials since 2005 with highest levels in 2009. 
Data from the last two years show a sharp decrease with 
very low levels again. Changes in sampling strategy 
have been implemented in 2010 (from collection of 
faecal samples at farm level to randomly sampling of 
individual animals at slaughterhouses) which will have 
affected the detection level of resistance determinants 
in E. coli. Therefore, these trends have to be interpreted 
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with caution, knowing the frequent occurrence of ESBL-
producing E. coli in individual animals at slaughter 
(appendix 1). From 2012 onwards, sampling is again 
conducted at farm level.
3.2.1.1.5 Turkey
In 2011, for the first time data on turkey are included. In 
the netherlands in 2010, 56 turkey farms were registered 
with a total of one million animals. Data in this report 
are based on a total of 100 samples collected from 20 
individual farms (five samples per farm).
Similar to the situation in broiler chickens, resistance 
levels are extensive, with highest levels for ampicillin and 
tetracycline (80% of the isolates). The level of suspected 
ESBL producing isolates in 2011 was 6.3%, which is 
slightly lower than E. coli from broilers in 2011 (8.1 % of 
the isolates resistant to cefotaxime). 
With 31.6% of the turkey E. coli isolates showing 
decreased susceptibility to ciprofloxacin this, together 
with broilers, represents the animal sectors with the most 
extensive level of resistance to quinolones.
Another remarkable finding is the high level of resistance 
to chloramphenicol (43.2%). Chloramphenicol has not 
been used for many years in veterinary medicine other 
than for topical use and the high level of resistance 
probably reflects either use of drugs conferring cross 
resistance or persistence of chloramphenicol resistance 
genes in the bacterial population.
Multidrug resistance
The overall increase in resistance is also reflected in de 
multidrug resistance data as shown in Figure Eco02. The 
highest level of multidrug resistance was present among 
E. coli originating from broilers. In 2010, 82.7% of the 
commensal E. coli strains from broiler chickens were 
resistant to two or more classes of antimicrobials included 
in the survey, which represents the highest level recorded 
in the past thirteen years. In 2011, this percentage was 
72.8%. also among E. coli from veal calves and pigs, 
multidrug resistance was widespread; in veal calves, 
58.1% and 60.2% of commensal E. coli isolates was 
resistant to at least two classes of antibiotics in 2010 and 
2011 respectively. among E. coli from swine this was the 
case for 59.6% of the isolates, in both years. 
For E. coli from dairy cattle multidrug resistance was only 
incidentally seen in 2010 and 2011, with 3.4% and 1.1% 
respectively resistant to two or more antibiotics. after 
an apparent increase in percentage multiresistant isolates 
up to 2009, the level has shown a tendency to decrease 
again in the last two years. In both 2010 and 2011, 
1% of all randomly selected E. coli isolates from veal 
calves showed reduced susceptibility to all nine tested 
antimicrobials or classes (represented by ampicillin, 
cefotaxime, gentamicin, tetracycline, sulfamethoxazole, 
trimethoprim, nalidixic acid, chloramphenicol, and 
kanamycin). In broiler chickens, only one such 
multiresistant strain was detected in 2010, but not in 2011. 
3.2.1.2 E. coli in raw meat products of food-animals
Table Eco02 shows resistance percentages of E. coli 
strains isolated from raw meat products sampled at retail 
in the netherlands by the Dutch Food and Consumer 
Product Safety authority (VWa), as well as strains 
isolated from vegetables, fruits and herbs. 
Overall, resistance percentages of E. coli strains as 
indicator organisms isolated from poultry products 
had a tendency to be slightly lower compared to those 
isolated from faecal samples of Dutch broiler chickens 
(Table Eco01 and TableEco02). One exception was the 
percentage of E. coli showing resistance to the cefotaxime 
and ceftazidime, which seem to be somewhat higher in 
isolates from meat products than in isolates from live 
animals for poultry.
For the first time, MIC data on E. coli isolated from 
herbs, vegetables and fruits are included in this report. 
resistance levels in isolates from vegetables and fruits 
are generally very low. Highest level is observed for 
tetracycline with 3.1% of the isolates showing resistance. 
In contrast, levels in herbs are much higher. resistance 
has been observed for all but one of the antimicrobials 
included in the test panel. although no resistance to 
cefotaxime was found, resistance to ceftazidime was 
present in one of the 33 isolates.
Interpretation of data from both pork and veal is 
complicated by the sometimes low number of isolates 
from meat products that are tested. This is reflected in 
the variability in resistance rates over the years as shown 
in Figure Eco03. Trends in resistance percentages from 
E. coli isolated from poultry meat show a tendency to 
increase, similar to resistance percentages from indicator 
bacteria isolated from faecal samples. resistance rates of 
E. coli from beef samples are stable over the years. 
3.2.1.3 E. coli in other European countries
In 2010, information on antimicrobial resistance in 
indicator E. coli isolates from animals and food was 
reported by seven to ten countries related to broilers, pigs 
and cattle. Data were analysed by the European Food 
Safety authority together with the European Centre for 
Disease Prevention and Control. The information in this 
heading has been adopted from The European Union 
Summary report on antimicrobial resistance in zoonotic 
and indicator bacteria from humans, animals and food in 
2010 (EFSa Journal 2012;10(3):2598).
microbiological resistance to antimicrobials was regularly 
observed in isolates of indicator (commensal) E. coli 
and enterococci from animals and food in the EU. In 
the case of many of the antimicrobials, there were large 
differences in the level of resistance in different member 
states. The netherlands tended to have comparatively high 
levels of resistance for most antimicrobials, compared 
to other countries. no major changes in resistance 
in E. coli were observed compared with previous 
years. However, gradual but continuous increases in 
resistance for antimicrobials typically used in animals, 
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such as ampicillin, streptomycin, sulphonamides and 
tetracyclines, have been observed in some EU member 
states in the last five years or more. 
3.2.1.3.1 Poultry
In E. coli isolates from broilers, the occurrence of 
resistance to tetracyclines, ampicillin and sulfonamides 
for all reporting member states was 31%, 35% and 
34%, respectively. Similarly, the level of resistance to 
ciprofloxacin was 29%, to nalidixic acid 26% and to 
cefotaxime 5%. There were wide variations in the level 
of resistance to these antimicrobials among different 
countries. mostly relatively stable situations in the 
resistance levels were observed in E. coli isolates from 
broilers over the years 2005–2010, although statistically 
significant national trends have been reported (mostly 
increasing).
Compared to other EU member states, the Dutch data on 
poultry isolates with respect to resistance to cefotaxime, 
but also for chloramphenicol, sulphonamides, and 
streptomycin were exceptionally high.
3.2.1.3.2 Pigs
among E. coli isolates from pigs, resistance levels 
in the reporting group of member states were 48% 
for tetracyclines, 21% for ampicillin and 37% for 
sulphonamides and 44% for streptomycin. The level of 
resistance to both ciprofloxacin and nalidixic acid was 
2%. Cefotaxime resistance was 1% and varied from 
0% to 5%. as in broilers, there were differences in the 
occurrence of resistance to each of these antimicrobials 
in different countries, with the exception of cefotaxime 
resistance, which was recorded by all reporting member 
states as low, very low or not detectable. Over the years 
2005–2010 mostly stable resistance was observed in  
E. coli isolates from pigs, with only minor fluctuations 
and no apparent general trends.
Compared to other EU member states, the Dutch data on 
swine isolates were moderate to high.
3.2.1.3.3 Cattle
In indicator E. coli isolates from cattle, resistance 
levels in the reporting group of member states were 
38% for tetracyclines, 28% for ampicillin and 34% for 
sulfonamides. Resistance to ciprofloxacin and nalidixic 
acid was 15% and 13% respectively, while the level of 
resistance to cefotaxime was 3%. again, the occurrence 
of resistance was variable among the different member 
states for all antimicrobials except cefotaxime, the level 
of resistance to which was generally low. 
Some countries showed statistically significant decreasing 
national trends in resistance to some antimicrobials (i.e. 
streptomycin and sulphonamides) in the 2005–2010 
period.
Compared to other EU member states, the Dutch data on 
cattle isolates were moderate to high.
3.2.2 Enterococcus faecalis and E. faecium
This chapter presents information on resistance in 
Enterococcus species from food-producing animals in 
the netherlands as indicator organisms for the occurrence 
and trends in resistance in Gram-positive bacteria. 
Enterococcus faecalis and E. faecium isolates were 
selected from fecal samples of chickens, pigs, cattle and 
turkey. Supplementary to isolates from live animals, 
susceptibility profiles of E. faecalis and E. faecium 
isolated from raw meat are presented as well as from 
vegetables, fruits and herbs. 
Highlights
1. as in former years, high rates of resistance were 
observed for tetracycline, erythromycin and also 
for streptomycin in both E. faecalis and E. faecium 
isolates. Streptomycin resistance was highest 
in broilers, in which also a very high level of 
resistance was noted for salinomycin in E. faecium 
(80.8%). In contrast, salinomycin resistance in E. 
faecium from pigs has shown a strong and steady 
decrease to a low level in 2011 (5.4%). 
2. For the first time, data for enterococci from turkey 
were included. although isolates from only a 
limited number of farms (n=20) were included 
and results should be interpreted with caution, 
resistance levels were high in comparison to 
other farm animals, notably for tetracycline, 
erythromycin, ampicillin, chloramphenicol and 
ciprofloxacin.
3. resistance levels in enterococci from dairy cows 
were generally low, with the exception of quinu/
dalfopristin in E. faecium (58.3%). Similar levels 
were observed in E. faecium from veal calves 
(65.5%) as well as from beef (57.8%).
4. Overall, in enterococci from meat samples, 
resistance levels were lower than in isolates from 
life animals. Similar as for broiler chickens, 
salinomycin resistance levels in meat was high 
(29.1% in E. faecalis, 57.0% in E. faecium), with a 
strong tendency to increase in the last decade. also 
ciprofloxacin and erythromycin resistance levels in 
E. faecium showed a tendency to increase in 2011.
5. resistance to vancomycin continued to be detected 
at low levels in enterococci from animals.
In 2010/2011 mIC values have been determined for 
477 E. faecalis and 952 E. faecium strains isolated from 
fecal samples of animals at abattoirs as well as for 1368 
E. faecalis and 552 E. faecium isolates from different 
meat samples. In Table Ent01 mIC distributions are 
summarized for all E. faecalis and E. faecium strains 
isolated from live animals. Table Ent02 presents 
information on resistance rates in different animal species, 
specified for broiler chickens, slaughter pigs,  
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veal calves, dairy cows and turkeys. Trends over the years 
are depicted in Figure Ent01. 
Data for 2010 and 2011 on E. faecalis and E. faecium 
from different meats and from vegetables, fruits and herbs 
are presented in Table Ent03, trends over the years for 
enterococci from the various raw meat sources in Figure 
Ent02.
3.2.2.1 Resistance levels
Compared to other EU member states, resistance levels 
in enterococci from food producing animals in the 
netherlands are among the highest reported in Europe, 
similar as the situation for E. coli.
Tetracyclines
In 2010 and 2011 highest resistance levels among the 
Enterococcus species from animals were detected for 
tetracyclines, against which 74.2% of all E. faecalis  
(n = 477) and 64.5% of E. faecium isolates (n = 952) were 
resistant (Table Ent01). These levels are lower than those 
recorded in 2009 (92.8%, n = 194 and 71.1%,  
n = 298 respectively). resistance levels for tetracyclines 
varied among the different animal species. Highest levels 
were observed in turkey, for which 100% of E. faecalis 
and 89.8% of E. faecium tested resistant. Lowest levels 
in cattle with 19.4% resistance for E. faecalis and 1.9% 
for E. faecium in dairy cows and 56.7% (E. faecalis) and 
55.2% (E. faecium) in veal calves.
Erythromycin
also resistance to erythromycin was high (65.2% for  
E. faecalis, 55.9% for E. faecium), although, similar as for 
Table Ent01. MIC distributions (in %) for Enterococcus faecalis (N = 477) and E. faecium (N =952) isolated in food producing animals in the 
Netherlands in 2010 and 2011.
E. faecalis 
(n=477)
MIC (%) distribution mg/L R% 95% CI
0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 86.4 13.4 0.2 0.0 0 - 0
Linezolid 1.9 34.8 63.1 0.2 0.2 0 - 0.6
Tetracyline 19.5 6.1 0.2 0.2 0.4 15.9 26.0 31.7 74.2 70.2 - 78.2
Erythromycin 17.8 12.8 4.2 2.3 2.3 2.5 0.8 57.2 65.2 60.8 - 69.5
Vancomycin 54.9 40.9 4.0 0.2 0.2 0 - 0.6
Ciprofloxacin 19.9 71.9 4.6 0.4 0.4 2.7 3.1 1.5 - 4.7
Quinu/dalfopristin 0.2 0.4 0.6 1.9 38.2 54.9 3.4 0.4 0.4 0 - 1.0
Salinomycin 10.1 40.7 13.4 31.2 4.6 4.6 2.6 - 6.5
Streptomycin 0.4 4.8 44.7 7.3 0.4 0.2 42.1 42.3 37.8 - 46.8
Gentamicin 1.3 22.0 71.3 2.5 2.9 2.9 1.3 - 4.4
Chloramphenicol 7.1 81.6 2.1 6.5 2.7 9.2 6.5 - 11.8
Florfenicol 0.6 28.3 70.9 0.2 0.2 0 - 0.6
E. faecium 
(n=952)
MIC (%) distribution mg/L
R% 95% CI
0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024 2048
Ampicillin 17,5 30,4 25,4 17,2 1,3 0,7 2,1 3,9 1,5 26,7 23,8 - 29,5
Linezolid 0,2 8,1 84,0 7,4 0,3 0,3 0 - 0,6
Tetracyline 34,7 0,3 0,1 0,4 0,3 0,6 1,4 18,7 43,5 64,5 61,3 - 67,5
Erythromycin 17,1 19,3 7,7 2,5 0,7 0,4 0,2 0,3 51,7 55,9 52,6 - 59,1
Vancomycin 57,4 35,7 5,8 0,8 0,3 0,3 0 - 0,6
Ciprofloxacin 5,3 22,0 21,4 42,3 8,6 0,4 9,0 7,1 - 10,8
Quinu/dalfopristin 0,1 10,4 10,5 14,3 48,8 14,1 0,9 0,8 79,0 76,3 - 81,6
Salinomycin 0,2 27,7 26,1 14,4 31,6 31,6 28,6 - 34,6
Streptomycin 0,2 3,0 43,5 18,2 0,7 0,2 2,2 31,9 35,1 31,9 - 38,1
Gentamicin 6,8 43,0 38,9 8,9 0,2 0,6 0,2 0,3 1,1 2,4 1,4 - 3,4
Chloramphenicol 0,7 9,1 65,7 11,2 12,1 1,2 1,2 0,4 - 1,8
Florfenicol 0,1 7,7 89,9 0,9 0,1 0,9 0,3 1,4 0,6 - 2,1
The white areas indicate the dilution range tested for each antimicrobial agent. Values above this range indicate MIC values > the 
highest concentration in the range. Values at the lowest concentration tested indicate MIC-values ≤ the lowest concentration in the 
range. Vertical bars indicate the epidemiological cut-off values used as breakpoints. The dashed bars indicate clinical breakpoints.
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tetracycline, considerable variation in the resistance levels 
was observed in the different animal species or categories 
(Table Ent02). again, highest levels were observed in 
broiler chickens and turkey (76.1% - 79%), lowest levels 
were seen in dairy cows (8.3% and 9.3% for E. faecalis 
and E. faecium respectively).
Streptomycin
Streptomycin resistance was high in both E. faecalis 
(42.3%) and E. faecium (35.1%), ranging from 0% in 
dairy cattle to 56.2% in broiler chickens for E. faecalis 
and from 1.9% in dairy cattle to 56.0% in broiler 
chickens.
Vancomycin and linezolid
The overall resistance to vancomycin and linezolid was 
very low (0.2% in E. faecalis and 0.3% in E. faecium 
for both antimicrobials). With respect to vancomycin, in 
2010 and 2011 three highly resistant E. faecium strains 
were isolated, two from broiler chickens and one from a 
pig. In 2010 a vancomycin resistant E. faecalis strain was 
isolated from a calf. Four linezolid resistant isolates were 
all isolated from calves.
Quinu/dalfopristin
acquired resistance to the streptogramin combination of 
quinupristin and dalfopristin (synercid®) was much more 
common in E. faecium than in E. faecalis (79.0% and 
0.4% respectively). This combination is a last resort drug 
for the treatment of infections caused by staphylococci 
and vancomycin-resistant E. faecium (VrE). Based on the 
clinical breakpoint value of >4, 15.9% of the E. faecium 
isolates were resistant. With respect to E. faecium strains 
recovered from meat samples, resistance rates have 
increased over the years to similar rates as seen in  
E. faecium isolated from live animals.
Table Ent02. Resistance percentages (%) of Enterococcus faecalis and E. faecium isolated from faeces from dairy cows, veal calves, 
slaughter pigs, broilers and turkey in The Netherlands in 2010 and 2011.
E. faecalis Slaughter pigs
N = 74
Broiler chickens
N = 276
Veal calves
N = 60
Dairy cows
N = 36
Turkey
N = 31
Ampicillin 0 0 0 0 0
Linezolid 0 0 1.7 0 0
Tetracyline 86.5 79.0 56.7 19.4 100
Erythromycin 54.1 79.0 43.3 8.3 77.4
Vancomycin 0 0 1.7 0 0
Ciprofloxacin 2.7 3.6 3.3 2.8 0
Quinu/dalfopristin 0 0 0 0 6.5
Salinomycin 0 7.2 0 0 6.5
Streptomycin 23.0 56.2 35.0 0 29.0
Gentamicin 6.8 1.8 3.3 0 6.5
Chloramphenicol 12.2 3.3 31.7 0 22.6
Florfenicol 0 0 1.7 0 0
E. faecium Slaughter pigs
N = 184
Broiler chickens
N = 427
Veal calves
N = 145
Dairy cows
N = 108
Turkey
N = 88
Ampicillin 23.4 36.1 12.4 0 44.3
Linezolid 0 0 2.1 0 0
Tetracyline 77.2 72.8 55.2 1.9 89.8
Erythromycin 28.3 78.5 46.9 9.3 76.1
Vancomycin 0.5 0.5 0 0 0
Ciprofloxacin 3.3 10.5 4.1 15.7 13.6
Quinu/dalfopristin 91.8 80.8 65.5 58.3 90.9
Salinomycin 12.0 61.1 0 0 20.5
Streptomycin 13.6 56.0 35.2 1.9 19.3
Gentamicin 0 3.5 4.8 0 1.1
Chloramphenicol 0 0.5 6.2 0 0
Florfenicol 0 0 9.0 0 0
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Figure Ent01. Trends in resistance percentages of Enterococcus faecium and E. faecalis isolated from slaughter pigs, broilers and veal calves in the 
Netherlands from 1996 – 2011.
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3.2.2.1.1 Pigs
as in previous years, very high resistance levels were 
recorded for tetracycline in 2010/2011 in both E. faecalis 
(86.5%) and E. faecium (77.2%). remarkably, resistance 
levels in pork were much lower (21.2% and 14.5% 
respectively). Other antimicrobials for which resistance 
was commonly detected in slaughter pigs included 
erythromycin in E. faecalis (54.1%) and E. faecium 
(28.3%), quinu/dalfopristin in E. faecium (91.8%) and 
streptomycin (23% in E. faecalis and 13.6% in  
E. faecium). Streptomycin resistance showed a tendency 
to decrease from 2008 when it was first included in 
the test panel to 14.1% in E. faecium and 33.3% in E. 
faecalis in 2011.
no vancomycin resistant isolates were present among  
E. faecalis, however a single E. faecium isolate with high 
level resistance was observed in 2010.
In 2009 a remarkable increase (41.9%) to 
chloramphenicol was reported in E. faecalis. However, 
levels in 2010 (10.5%) and 2011 (13.9%), were again 
comparable to those in 2008 and before. also for other 
antimicrobials fluctuations over subsequent years were 
noticeable probably due to the limited number of isolates 
for which mIC information is available.
a strong tendency to decrease was noted for salinomycin 
resistance levels in E. faecium in the previous decade 
from 59.1% in 2003 to 5.4% in 2011, which is probably 
associated to the ban on salinomycin as a feed additive in 
2006.
3.2.2.1.2 Broilers
also in broilers, highest resistance levels were observed 
for tetracycline (79.0% in E. faecalis and 72.8% in  
E. faecium), erythromycin (79.0% in E. faecalis and 
Table Ent03. Resistance % of Enterococcus faecalis and E. faecium strains isolated from raw meat products from pork, poultry, beef, veal, 
and lamb in the Netherlands in 2010/2011.
E. faecalis Pork
N = 410
Poultry
N = 330
Beef
N = 365
Veal
N = 52
Lamb
N = 52
Turkey
N = 38
Herbs*
N = 25
Vegetables 
and fruits*
N = 96
Ampicillin 0 1.5 0 0 0 0 0 0
Linezolid 0 0 0 0 0 0 0 0
Tetracyline 21.2 70.9 19.7 46.2 38.5 81.6 24.0 16.7
Erythromycin 7.3 62.0 4.7 15.4 17.3 57.9 4.0 6.3
Vancomycin 0 0.6 0.3 0 0 0 0 1.0
Ciprofloxacin 0.7 3.6 0 0 0 7.9 0 0
Salinomycin 1.0 29.1 0 0 1.9 21.1 0 0
Quinu/dalfopristin 0 1.8 0 0 0 2.6 0 0
Gentamicin 0.2 1.8 0.8 1.9 3.8 10.5 4.0 0
Streptomycin 4.4 46.4 5.5 19.2 23.1 21.1 8.0 2.1
Chloramphenicol 1.5 4.8 1.6 7.7 5.8 2.6 0 2.1
Florfenicol 0 0 0 0 0 0 4.0 0
E. faecium Pork
N = 152
Poultry
N = 86
Beef
N = 180
Veal
N = 33
Lamb
N = 11
Turkey
N = 13
Herbs*
N = 11
Vegetables 
and fruits*
N = 66
Ampicillin 3.3 9.3 1.7 0 0 38.5 0 0
Linezolid 0 1.2 0 3.0 0 0 0 0
Tetracyline 14.5 51.2 9.4 27.3 9.1 84.6 27.3 7.6
Erythromycin 19.1 48.8 15.6 45.5 9.1 53.8 18.2 25.8
Vancomycin 0 0 0 0 0 0 0 0
Ciprofloxacin 2.6 20.9 5.6 0 0 0 0 1.5
Salinomycin 4.6 57.0 2.8 0 9.1 46.2 0 0
Quinu/dalfopristin 73.0 76.7 57.8 63.6 54.5 84.6 100 71.2
Gentamicin 0 0 0 3.0 0 0 0 0
Streptomycin 4.6 29.1 4.4 12.1 0 61.5 0 3.0
Chloramphenicol 0 0 0 3.0 0 0 0 0
Florfenicol 0 0 0.6 3.0 0 0 0 0
*Data only from 2011
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78.5% in E. faecium), and streptomycin (56.2% in 
E. faecalis and 56.0% in E. faecium). In E. faecalis, 
additional high levels of resistance were observed for 
quinu/dalfopristin (80.8%), salinomycin (61.1%) and to a 
lesser extent to ampicillin (36.1%).
Over the years, resistance to the tested antimicrobials 
appears to have remained relatively stable in E. faecalis, 
while in E. faecium, more pronounced fluctuations were 
observed.
3.2.2.1.3 Veal calves
In veal calves, highest resistance levels were observed  
for tetracycline (56.7% in E. faecalis; 55.2% in  
E. faecium), erythromycin (43.3% in E. faecalis and 
46.9% in E. faecium); streptomycin (35.0% in E. 
faecalis and 35.2% in E. faecium) and the combination 
of quinupristin and dalfopristin in E. faecium (65.5%). 
notably, veal calves were the host species in which 
florfenicol and chloramphenicol resistance was highest 
in comparison with other food animals, reflecting the use 
of florfenicol for respiratory infections. Low levels or 
no resistance were observed for the other antimicrobials 
tested. Although for some antimicrobials fluctuations 
are apparent in resistance levels over the years due to 
the limited number of isolates, there seems to be a slight 
decreasing tendency for resistance to tetracycline and 
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Figure Ent02. Trends in resistance percentages in Enterococcus faecalis and E. faecium isolated from raw meat products from pork, poultry, and beef in the 
Netherlands from 2003 to 2011.
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streptomycin in E. faecium.
a single high level vancomycin resistant E. faecalis 
isolate was recorded in a calf in 2010. also linezolid 
resistant isolates have been recovered from veal calves, 
both E. faecalis (n = 1) and E. faecium (n = 3).
3.2.2.1.4 Dairy cattle
Overall, resistance levels are low in E. faecalis and  
E. faecium in dairy cows. In 2010/2011 highest resistance 
levels in E. faecalis were recorded for tetracycline 
(19.4%) and erythromycin (8.3%). In E. faecium, 
highest level was observed for quinu/dalfopristin 
(58.3%), ciprofloxacin (15.7%) and to a lesser extent 
to erythromycin (9.3%). Compared to ciprofloxacin 
resistance levels in other animals, the relatively high 
percentage is remarkable, as quinolones are not readily 
used in dairy cows. Similar to the situation in veal calves, 
levels show some fluctuations over the years. It should 
be noted that in dairy cattle a change in sampling strategy 
was implemented in 2009/2010 as already mentioned for 
E. coli as indicator organism. This might have caused 
a bias in mIC results and therefore trends should be 
interpreted with caution.
3.2.2.1.5 Turkey 
In 2011, for the first time data on turkey are included. 
resistance levels in both E. faecalis and E. faecium were 
very high for tetracycline (100% and 89.8% respectively) 
and for erythromycin (77.4% and 76.1% respectively). 
additionally, resistance was frequently observed for 
quinu/dalfopristin (90.9%) and ampicillin (44.3%) in  
E. faecium and for streptomycin (29% in E. faecalis, 
19.3% in E. faecium) and chloramphenicol (22.6%) in  
E. faecalis. 
Compared to other food animal species, E. faecium 
from turkeys show relatively high resistance levels 
for salinomycin (20.5%) and ciprofloxacin (13.6%). 
However, interpretation must be done with caution, as 
data are based on a limited number samples collected 
from 20 individual farms.
no resistance has been detected for vancomycin or 
linezolid in turkeys.
3.2.2.2 Enterococcus faecalis and E. faecium in raw 
meat products of food-animals
Table Ent03 shows resistance percentages of E. faecalis 
and E. faecium strains isolated from raw meat products 
sampled at retail in the netherlands by the Dutch Food 
and Consumer Product Safety authority (nVWa), as well 
as strains isolated from vegetables, fruits and herbs. 
as in previous years, resistance in E. faecalis and  
E. faecium isolated from fresh meat was in general lower 
compared to isolates recovered from fecal samples. 
Variable resistance levels were observed among  
E. faecalis and E. faecium isolated from meat from 
different host species as shown in Table Ent03. For 
tetracycline, levels ranged from 19.7% to 81.6% among 
E. faecalis and from 9.1 to 84.6% in E. faecium; for 
erythromycin, levels ranged from 4.7% to 62.0% in E. 
faecalis and from 9.1% to 53.8% in E. faecium. For 
streptomycin, levels ranged from 4.4% to 46.4% in E. 
faecalis and from 0% to 61.5% in E. faecium.
no resistance for linezolid was detected in E. faecalis, 
however two resistant E. faecium strains are reported, 
one from poultry meat and one from veal. Vancomycin 
resistance was observed in E. faecalis, isolated from pork 
(n=1), poultry meat (n=2) and beef (n=1). noticeably, 
vancomycin resistance was also observed in an E. faecalis 
strain isolated from vegetables.
Resistance to ampicillin and ciprofloxacin was either 
low or not detected in enterococci species from meat, 
with the exception of poultry and turkey meat. Of the 13 
E. faecium isolates from turkey included in the survey, 
five expressed MICs ≥8 mg/l for ampicillin (38.5%). 
For E. faecalis, 3.6% of poultry isolates and 7.9% of 
turkey isolates were resistant to ciprofloxacin. Also for 
salinomycin, resistance levels in poultry and turkey meat 
was higher than in other meats, both in E. faecalis and  
E. faecium.
Quinu/dalfopristin resistance was high in E. faecium, but 
low in E. faecalis in all sample categories. Gentamicin 
resistance was low in E. faecalis, and absent among  
E. faecium except for a single E. faecium strain from veal. 
Also resistance to chloramphenicol and florfenicol was 
low or absent in enterococci isolates from the various 
sample sources.
Trends over time are fairly stable. noticeable are the 
increasing tendencies for salinomycin levels in pork, 
poultry meat and beef as shown in Figure Ent02. With 
respect to quinu/dalfopristin, after an increase from 2004 
onwards, levels seem to have reached a relatively stable, 
although high, level in all three categories in recent 
years. In poultry meat, ciprofloxacin and erythromycin 
resistance levels in E. faecium in 2011 show a tendency to 
increase.
These reported tendencies are not reflected in the 
temporal resistance data in animals. Together with the 
overall differences between resistance levels in animals 
and meat, this might suggest that certain selection 
pressures could favor the election of certain biotypes in 
meat. also imported meat might have biased the results.
For the first time, MIC data on E. faecalis and E. faecium 
isolated from herbs, vegetables and fruits are included in 
this report. resistance levels are generally low. In  
E. faecalis, highest levels were observed for tetracycline 
with 24.0% in herbs and 16.7% of the isolates from 
vegetables and fruits showing resistance. In E. faecium, 
highest levels were observed for the quinu/dalfopristin 
combination (100% and 71.2% in herbs and vegetables/
fruits respectively). In addition relatively high levels of 
resistance were recorded for erythromycin (up to 27.3%, 
in herbs) and tetracycline (up to 25.8%, in vegetables and 
fruit).
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3.2.2.3 Enterococci in other European countries
In 2010, seven member states and one non-member state 
submitted information on the occurrence of antimicrobial 
resistance in enterococci isolates from animals and 
food to the European Commission, the European Food 
Safety authority and the European Centre for Disease 
Prevention and Control. The results are published in the 
EU Summary report (The European Union Summary 
report on antimicrobial resistance in zoonotic and 
indicator bacteria from humans, animals and food in 
2010 (EFSa Journal 2012; 10(3):2598). most of the 
data related to isolates from broilers, pigs and cattle. 
In general, wide variation in the level of resistance in 
different countries was observed. among the indicator 
enterococci isolates from animals and food, resistance 
against tetracyclines and erythromycin was commonly 
detected in isolates from poultry, pigs and cattle at levels 
of 13 % to 71 %, the level of resistance being lowest 
for isolates from cattle. To the same extend as in E. coli, 
the resistance percentages in enterococci from food 
producing animals in the netherlands are among the 
highest reported in Europe. 
Since there is cross-resistance between avoparcin and the 
human antimicrobial vancomycin, the use of avoparcin 
as an antimicrobial growth promoter was banned in the 
EU in 1997. resistance to vancomycin continued to be 
detected, albeit at low to very low levels, at 0.3 % to 0.9 
%, in enterococci isolates from animals.
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Surveillance of resistance to extended spectrum 
cephalosporins in the netherlands is routinely done by 
random isolation of a minimum of 170 isolated E. coli, 
each representing one epidemiological unit, from faecal 
samples of food producing animals as prescribed by EFSa 
guidelines3. These isolates are tested for susceptibility to 
cefotaxime and proportions of non-wild type isolates are 
determined based on EUCaST epidemiological cut-off 
values (non-wild type mIC > 0.25 mg/l). 
Figure ESBL01 shows that since 1998 cefotaxime 
resistance was observed at low levels in all animal species. 
In broilers after 2001 an apparent increase was observed up 
to levels that varied from 15 – 20%, followed by a decrease 
in 2010 which may be attributed to the total ban on the 
usage of ceftiofur at Dutch hatcheries in march 2010. a 
prevalence study conducted in 2009 at broiler farms showed 
that using selective isolation methods, all conventional 
Dutch broiler farms were positive and within these farms ≥ 
80% of the animals shed ESBL-producing E. coli in their 
faeces (maran-2009). although the quantity of ESBL-
producing E. coli shed by broilers may have been reduced, 
the ban of ceftiofur has not yet resulted in a reduction 
of the number of farms positive for ESBL-producing E. 
coli. In 2011, prevalence studies of ESBL-producing E. 
coli were initiated in all Dutch food-producing animals in 
close collaboration between the Dutch Food and Consumer 
Product Safety authority (nVWa) and the Central 
Veterinary Institute (CVI). at Dutch slaughterhouses a 
4.  Appendix I. ESBL and AmpC-producing E. coli in food producing animals 
 in the Netherlands
3 report from the Task Force on Zoonoses Data Collection including guidance for harmonized monitoring and reporting of antimicrobial resistance 
in commensal Escherichia coli and Enterococcus spp. from food animals. http://www.efsa.europa.eu/en/efsajournal/pub/141r.htm.
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Figure ESBL01. Trends in cefotaxime non-wild type susceptibility in E. coli 
from food –producing animals from 1998 – 2011. The arrow indicates the 
year 2010, when usage of ceftiofur at broiler hatcheries was stopped.
Table ESBL01. Beta-lactamases detected in E. coli  from Dutch food-producing animals.
Beta-Lactamase family Enzyme Slaughter pigs Veal calves Broilers Dairy cows
N
CTX-M-1gr CTX-M-1 26 25 11 6
CTX-M-3 2
CTX-M-15 1 10
CTX-M-32 1 4 2
CTX-M-2gr CTX-M-2 1 3
CTX-M-9gr CTX-M-14 1 9
TEM TEM-1a 3 2
TEM-1b 4 2
TEM-1c 1
TEM-20 1   
TEM-52c 9 4 3
SHV SHV-12 3  2 1
pAmpC CMY-2 1 1 12 1
ampC-promoter mutant type-3 13 6 4
type-11 1 1
type-18 3
type-40 1
% flocks positive 68% 70% 100% 14%*
* individual animals
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faecal sample was taken from ten (apparently healthy) 
animals per flock of animals. In total samples were taken 
from 100 flocks of slaughter pigs, 100 flocks of veal calves 
and 29 flocks of broiler chickens. Moreover, 100 individual 
dairy cows were sampled, each representing a different 
farm.
Each sample was analysed for the presence of ESBL/
ampC-producing E. coli using selective pre-enrichment 
in Luria Bertani broth with 1 mg/l cefotaxime, followed 
by selective isolation on macConkey agar with 1 mg/l 
cefotaxime by the nVWa. all isolates were sent as pure 
cultures to CVI for molecular analysis of the ESBL/
AmpC-genes. One isolate per flock was screened for 
beta-lactamase gene families using the aTr0503 alere 
miniaturised micro-array. Subsequently the genes were 
identified by dedicated PCR and sequence analysis. 
all isolates with a negative array result for ESBL or 
ampC genes were examined for promoter mutants in the 
chromosomal ampC-genes.
Table ESBL01 shows the ESBL/ampC genes detected in 
the different animal species. The highest prevalence was 
found in broilers, but also in veal calves and slaughter 
pigs a high proportion of flocks were found to be positive. 
A wide variation in beta-lactamase genes was identified. 
BlaCTX-m-1, was the dominant variant throughout Dutch 
food-producing animals. The predominance of other 
variants varied by animal species. In pigs blaTEm-52c was 
frequently detected next to individual other variants. In 
veal calves a surprisingly high proportion of blaCTX-m14 
and blaCTX-m-15, which are considered to be typical ‘human’ 
ESBLs, were detected. Promotor mutants of chromosomal 
ampC-genes were detected in all animal species. Because 
these ampC-genes are not horizontally transferable they 
are not considered to be a source for potential transfer to 
human bacteria. also blaTEm-1 variants were found as single 
genes in ESBL-suspected isolates, which may be associated 
with over-expression resulting in a cephalosporin-resistant 
phenotype, or a combination with undetected resistance 
mechanisms since these genes are considered not to be 
ESBLs. 
as part of a continuous surveillance programme of 
infectious organisms in wild birds in the netherlands, 
165 dead birds (mostly ducks, swans, gulls and waders) 
were collected from summer 2010 until February 2012 at 
different locations throughout the netherlands. all animals 
were examined for ESBL/ampC producing E. coli in their 
faeces as described above. Twenty-two (13%) of the birds 
were positive (Table ESBL02). The beta-lactamase genes 
found mimic those found in food-producing animals, with 
blaCTX-m-1 being the predominant gene variant detected. 
However also human associated blaCTX-m-14 and blaCTX-m-15 
were detected. In the latter isolate also blaOXa-1 and the 
Table ESBL02. Beta-lactamases detected in E. coli  from wild bird of different species sampled from July 2010 to February 2012.
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Beta-Lactamase family Enzyme N
CTX-M-1gr CTX-M-1 2 1 1 4
CTX-M-1; TEM-1b 1 1
CTX-M-1; TEM-1c 1 1
CTX-M-1; TEM-33' 1 1
CTX-M-3 1 1
CTX-M-15 1 1
CTX-M-15; OXA-1; aac6'-Ib-cr 1 1
CTX-M-15; TEM-1 1 1
CTX-M-32 1 1 2
CTX-M-32; TEM-1b 1 1
CTX-M-9gr CTX-M-14 2 2
CTX-M-14;TEM-1b 1 1
TEM TEM52c + ampC type 3 1 1
pAmpC CMY-2 1 1 2
CMY-2; TEM-1c 1 1
CMY-2; TEM-33 1 1
Total 1 5 1 1 2 1 1 1 1 1 1 1 5 22
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plasmid mediated quinolone resistance variant aac(6’)-
Ib-cr was detected. This combination of genes is highly 
typical for the human uropathogenic E. coli ST131 with 
IncF-plasmids harbouring these genes. However, this was 
not yet confirmed for this isolate. The most frequent bird in 
which ESBLs were found were anas platyrhynchos (Wild 
Duck) and Tringa totanus (Common redshank). Both birds 
feed in surface water or meadows, wetlands and mud flats 
that may be polluted by contaminated manure or faeces of 
animal or human origin.
It can be concluded that the occurrence of ESBL/ampC-
producing E. coli is widespread in Dutch food-producing 
animals. The potential attribution to infections in humans 
warrants strict measures to control antibiotic usage 
and possibilities of transmission of these organisms in 
animal production chains. The frequent finding of ESBL/
ampCs in E. coli from wild birds indicates a widespread 
contamination of the environment in the netherlands that 
may contribute to dissemination of these genes.
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Detailed information on microbiological methods used is 
available on the website www.maran.wur.nl
5 Appendix II. Materials and Methods

